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 Chapter 1 
 
Introduction 
 
 
To most of the modern pharmacologists the receptor is like a beutiful but remote lady. He 
has written her many a letter and quite often she has answered the letters. From these 
answers the pharmacologists has built himself an image of this fair lady. He cannot, 
however, truly claim ever to have seen her, although one day he may do so. 
                                                                                                              D. K. de Jongh (1964) 
 
1.1 Histamine and its receptors 
Histamine1 (1, Fig. 1.1), 2-(1H-imidazol-4-yl)ethylamine, is a biogenic amine formed by 
enzymatic decarboxylation of the amino acid L-histidine. It is found in many plants and 
present in nearly all animal tissues where it is detected in many cell types, e.g., mast cells, 
basophils, platelets, endothelial and neuronal cells.2 Histamine plays a role as a chemical 
messenger, i.e., it transfers signals from one cell to another. As such, it is able to induce 
numerous (patho)physiological effects, like smooth muscle contraction, stimulation of 
hormone release, modulation of immune responses, gastric acid secretion, induction of 
sleep and modulation of cognitive processes. Histamine release from mast cells and 
basophils is notorious for the pathophysiological effects of the biogenic amine in allergic 
diseases and inflammation, for instance, the well known symptoms of irritation in skin and 
airways, bronchospams and vasodilation.3,4 In 1937, Bovet and Staub discovered 
compounds that antagonised several of these effects of histamine.5 Subsequently, many 
other chemicals that have similar actions have been identified. Some of these compounds 
(e.g., mepyramine, diphenhydramine) were introduced to clinical use in allergic conditions 
like hay fever. As these classical “antihistamines” were not able to block certain effects of 
histamine such as the stimulation of gastric acid secretion, in the sixties, Ash and Schild 
suggested that histamine acts via two distinct receptor subtypes.6 This prediction was 
confirmed when Black and co-workers developed burimamide, the first compound 
described to antagonize the histamine-stimulated gastric acid secretion or the histamine-
induced relaxation of the electrically stimulated rat uterus.7 This led to the classification of 
two subtypes of histamine receptors termed H1, blocked by classical antihistamines, and H2 
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receptors, blocked by burimamide. As the structural requirement for compounds having H1 
or H2 receptor affinity are different, selective H2 receptor ligands could be developed and 
H2 antagonists became blockbuster drugs for the treatment of gastric and duodenal ulcers 
(e.g., cimetidine, ranitidine). 
 
Histamine is widely distributed within the mammalian central nervous system (CNS). 
Mapping of the histaminergic pathways in the rat and guinea-pig revealed that the 
arrangement of the histaminergic fibres were similar to, e.g., the noradenaline and 5-
hydroxytryptamine pathways.8,9 The role of histamine as a neurotransmitter became 
apparent in 1983 when Jean-Charles Schwartz and co-workers discovered that histamine 
inhibits its own release from depolarized slices of rat cortex.10 Such feedback mechanisms 
mediated through presynaptic receptors are crucial to neurotransmission. These effects were 
found not to be mediated by H1 or H2 receptors since neither H1 nor H2 activity of the 
histaminergic ligands correlated with the inhibitory effect. Hence the results indicated a 
third histamine receptor subtype. In 1987, the existence of this H3-receptor was validated by 
the development of the potent and selective H3 antagonist thioperamide.11 Subsequent 
pharmacological characterization of the receptor using selective histamine H3 receptor 
ligands, confirmed the H3 receptor as being located presynaptically on the histaminergic 
(autoreceptors) and other nerve endings (heteroreceptors). Histamine H3 receptors are 
predominantly involved in the function of central nervous system (CNS). Various 
biological responses (e.g., arousal, circadian rhythm) are supposed to be associated with 
histamine acting in the CNS. Besides H3-receptor, H1 and H2-receptors are also widely 
expressed in the mammalian brain.  
H1, H2, and H3-receptors were initially characterized by pharmacological means and the 
cloning of their respective genes12 has been performed later. By using cloning approaches, 
most recently, a new histamine receptor subtype was discovered.13 Several groups 
independently identified a DNA sequence with homology to the H3 histamine (37-43%), 
that was cloned and later termed the histamine H4-receptor. The functions of this receptor 
are not yet known in detail, but its detection in the bone marrow, in spleen and leukocytes 
(particularly eosinophils and neurophils) may allude to a possible involvement in 
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immunological processes and the regulation of hematopoiesis14. A summary of the most 
important characteristics of histamine receptors is presented in Table 1.1. 
 
Table 1.1: Histamine receptors and some biological effects 
H1 - contraction of smooth muscles (e. g., gut, bronchi) 
- increase in the permeability of the capillaries 
- vasoconstriction (via receptors at vascular smooth muscles) 
- vasodilatation (via EDRF release from endothelial cells) 
H2 - stimulation of gastric acid secretion 
- Positiv inotropic and chronotropic effect on the heart 
- vasodilatation 
H3 - inhibition of neuronal synthesis and release of histamine (presynaptic autoreceptor) 
- modulation of various neurotransmitters (e. g. acetylcholine, serotonin, noradrenaline,  
  dopamine) via presynaptic heteroreceptors 
H4   - biological function? (H4 receptors were found, e. g., in leukocytes, spleen, thymus, 
colon)  
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Fig. 1.1. Schematic representation of the histamine H2 receptor. Interactions of amino acids 
Asp 98, Tyr 182 and Asp 186 in transmembrane domains TM3 and TM5, respectively, are 
considered to be involved in receptor activation.  
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All histamine receptors belong to the G-protein coupled receptor (GPCR) superfamily that 
possesses seven transmembrane domains, three extracellular and three intracellular loops. 
The transmembrane domains contain stretches of 20-25 hydrophobic amino acids that are 
predicted to form α-helices that span the cell membrane. The third (TM-III) and fifth (TM-
V) transmembrane domains of heptahelical receptors appear to be especially important for 
ligand-binding as schematically shown for the histamine H2 receptor in Fig. 1.1. H1 
receptors are coupling to Gq/11 (IP3 ?, Ca2+?), H2 to Gs (cAMP ?), H3 and H4 receptors to 
Gi/o proteins (cAMP ?).15  
 
1.2 Histamine H2 receptors and their ligands 
As mentioned, the histamine H2 receptors was pharmacologically characterized by Black et 
al. in 1972.7 With the high affinity (KD=0.3 nM) radioligand [125I]iodoaminopotentidine16-19 
the H2 receptor was found to be widely distributed in the brain, with highest densities in the 
basal ganglia, hippocampus, amygdala, and cerebral cortex.19 Lowest densities were 
detected in cerebellum and hypothalamus.19 In the periphery the H2 receptor was found, for 
example, in gastric cells, cardiac tissue, airway, uterine, and vascular smooth muscle.15 H2 
receptors have a potent stimulatory effect on gastric acid secretion, and the inhibition of this 
secretory process by H2 receptor antagonists has provided evidence for an important 
physiological role of histamine in the regulation of gastric acid secretion.7 The cloned rat, 
human, guinea pig, mouse and canine H2 receptor include 358 or 359 amino acids.  
 
1.2.1 Histamine H2 receptor antagonists 
After the characterization of the histamine H2-receptor by Black et al7, there was a great 
effort to search for H2 receptor selective antagonists for the treatment of peptic ulcer. The 
histamine derivative 5-methylhistamine, the first compound described to exhibit some 
selectivity for the histamine H2 receptor7,20,21. The extension of the side chain and 
replacement of the basic amino group with polar, planar groups (e.g. thiourea or 
cyanoguanidine) that are uncharged at physiological pH led to discovery of burimamide and 
the more active H2 antagonsts which are therapeutically used as antiulcer drugs. After the 
discovery of the histamine H3 receptor the weak H2 antagonist burimamide was found to be 
a more potent antagonist at the H3 receptor.10 Cimetidine and metiamide were developed 
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directly from burimamide.22-24 Cimetidine was the first H2 blocker launched onto the 
market for the treatment of gastric and duodenal ulcer. Since then a large number of H2-
receptor antagonist such as ranitidine, tiotidine, famotidine, nizatidine, roxatidine acetate 
and mifentidine have been developed as antiulcer drugs.15 Most H2-receptor antagonists are 
polar compounds and penetrate poorly into the central nervous system (CNS). On one hand 
this property is useful to obtain peripherally acting drugs (e.g. gastric secretion inhibitors), 
on the other hand the lack of penetration into the brain is limiting the use of H2 antagonists 
for in vivo pharmacological investigations of the role of H2 receptors in the CNS. 
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Fig. 1.2: Structures of histamine, the selective H2 receptor agonist 5-methylhistamine and 
the H2 receptor antagonists burimamide, metiamide, cimetidine and ranitidine.  
 
1.2.2 Histamine H2 receptor agonists 
From the therapeutic point of view the interest in drugs acting on histamine receptors is 
focused on antagonists. Nevertheless, there has been increasing evidence that histamine 
receptor stimulation might be an interesting aspect for the development of future drugs as 
well. 
5-Methylhistamine was the first histamine H2 receptor agonist described in literature.7 
Another H2 receptor selective ligand devoid of an imidazole ring is dimaprit (2)25 which is 
about as potent as histamine. Cyclization of the isothiourea partial structure of dimaprit led 
to the development of amthamine (3).26 Most interesting thing was this kind of ligand is 
devoid of H1 and H3-receptor activity. Further replacement of the sulphur atom by a 
selenium atom (amselamine) was found to result in similar activity. All these small 
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molecules are similar to histamine concerning both structural criteria and H2 receptor 
agonistic potency, but are selective for the H2-receptor.  
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H2N S
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CH3
CH3
 2  Dimaprit  3  Amthamine
N
S
CH3
H2N
NH2
N
HN
NH2
N
HN
NH2
H3C
5-Methylhistamine
 
Fig. 1.3: Examples of amines with histamine H2 receptor agonistic activity 
 
In addition to the synthesis and pharmacological characterization of histamine analogues 
and related small molecules, theoretical investigations were performed to identify the 
putative active species of the H2-receptor agonists (i.e., protonation sites(s) at physiological 
pH, the conformeric and tautomeric form) and its possible interaction with the receptor 
protein.27,28 The histamine binding site of the H2 receptor was identified by in vitro 
mutagenesis studies and molecular modeling approaches based on the 3D structure of 
bacteriorhodopsin and bovine rhodopsin, respectively. Investigations of H2 receptor 
mutants supported an ionic interaction of the protonated amino group with Asp98 (TM3).29 
The second and the third site of the widely accepted three-point model for biogenic 
amine/GPCR interaction could principally be formed by the couples Asp186/Thr190 or 
Tyr182/Asp186 in TM5.30-32 (Fig. 1.4) Based on a pure alpha helical TM5, the proposed 
two hydrogen bonds of the imidazole ring with the H2-receptor are only possible with 
Tyr182 and Asp186. This assumption is also in agreement with pH-dependant model of H2-
receptor activation that suggests tautomerisation of the imidazole into the Nπ-H form caused 
by neutralization of histamine upon binding and accompanied by proton transfers from 
Tyr182 to Nπ and Nτ to Asp186, respectively.33 
 
The first highly potent H2 receptor agonist impromidine (4, Fig. 1.5) resulted from 
histamine, by extending the chain length by one additional methylene group, replacing the 
amine functionality by the strongly basic guanidine group and combining the structure with 
the 2-[(5-methyl-1H-imidazole-4-yl)methylthio]ethyl moiety known from the H2 receptor 
antagonist cimetidine.34 
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Fig. 1.4: Interaction model for the binding of histamine to the human histamine H2 receptor  
This prototypical guanidine-type H2 receptor agonist is nearly 50 times more potent than 
histamine on the isolated spontaneously beating guinea-pig right atrium (positive 
chronotropic effect), a standard model used for the pharmacological characterization of H2 
receptor ligands. Impromidine is a full agonist on the atrium but, depending on species and 
the tissue studied, its intrinsic activity may be lower.15,35-40 
 
N
HN
N
H
N
H
S
NH N
NH
CH3
CH3
(R)
 Sopromidine
N
HN
N
H
N
H
S
NH N
NH
CH3
4  Impromidine1  Histamine
N
HN
NH2
Cimetidine-like
moiety
Homohistamine moiety
 
Fig. 1.5: Examples of H2-receptor agonists: Impromidine. 
 
Numerous impromidine analogues have been synthesized and analysed for agonistic 
activity at H2-receptor41,42 Highest potency is observed for compounds with a three- instead 
of a two- carbon chain as in histamine connecting the imidazole ring and the basic 
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guanidine group, although the corresponding partial structures of impromidine and 
histamine are considered as functionally equivalent groups that are important for the 
receptor activation. The lower homologue of impromidine is considerably less potent than 
impromidine. However, an unique stereochemical differentiation was found for the (R)-
configured methyl branched imidazolylethylguanidine, sopromidine, which proved to be an 
H2 receptor agonist achieving nearly 7 times the potency of histamine in gunea-pig atrium, 
whereas the (S)-enantiomer has weak H2 receptor antagonistic properties.43 Baumann and 
co-workers demonstrated that H2 receptor agonists may be useful as positive inotropic 
drugs for the treatment of catecholamine insensitive congestive heart failure, by intravenous 
administration of impromidine to severely ill patients.44 Unfortunately, the compound is 
also a powerful stimulant of gastric acid secretion, it is inactive after oral administration, 
and it produces pronounced disrhythmias, even in very low concentrations. Thus, for 
general therapeutic application H2 agonists with a more beneficial profile of action, e.g., 
less pronounced induction of rhythm disturbances, lower positive chronotropic effect, and 
more favorable heart/stomach activity ratio than that of impromidine as well as activity 
after oral dosage, are required.  
Therefore, at the beginning of an extensive research programme impromidine (4) was 
considered the chemical lead. The imidazolylpropylguanidine moiety appears to be 
essential for the agonistic activity.45 Several attempts to replace the homohistamine part by 
other groups resulted in a decrease in activity. However, variations of the other partial 
structures were tolerated in a wide range. The molecule was mainly modified in two ways: 
(I) The “cimetidine-like” part, which is considered to confer the high receptor affinity on 
impromidine, was replaced by alternative groups which are known from antagonists to 
contribute H2 receptor affinity, such as imidazoles, thiazoles, piperidinomethylphenoxy 
groups, etc.42,46,47 
(II) The “cimetidine-like” part was replaced by lipophilic H2 nonspecific structures. 
Although potent H2 receptor selective agonists were obtained in both ways, the most 
interesting compounds were found in the latter group. Replacement of 5-methyl-4-
imidazolylmethylthio moiety in impromidine with aryl, and arylmethyl ethers and 
thioethers resulted H2 agonists with up to 5 times higher potency than that of histamine in 
the guinea-pig atrium. Additionally, these compounds proved to be weak H1 receptor 
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antagonists in the guinea-pig ileum. The H2 agonistic potency could be retained and the H1 
receptor antagonistic activity further increased by replacement of the monoaryl with diaryl- 
or aryl(heteroaryl)methylthio groups. The guanidine 5a was found to be about 4 times more 
potent than histamine on H2 receptors and, additionally, to be a moderately active H1 
antagonist, achieving about 10 % of the potency of diphenhydramine or pheniramine.48  
N
HN
N
H
N
H
S
NH N
NH
CH3
N
HN
N
H
N
H
NH
4  Impromidine
S
N
5a
 
Fig. 1.6: Structure of impromidine (4) and compound 5a: replacement of the cimetidine-
like moiety in 4 with a pheniramine-like phenyl(pyridyl)methyl group. 
Table 1.2: Structures and histamine H2 receptor agonistic activities of the arpromidine-like 
imidazolylpropylguanidines 5a-i49  
 
N
HN
N
H
N
H
A
NH
X
Y
5a-k  
No. A X Y PEC50 Rel. potency 
Histamine (1)    6.00 1.0 
Impromidine (4)    7.70 50.1 
  5a CH2CH2S 2-pyridyl Ph 6.60 4.0 
  5b (CH2)3 2-pyridyl Ph 6.61 4.1 
  5c (CH2)2 2-pyridyl Ph 7.39 25.5 
Arpromidine (5d) (CH2)2 2-pyridyl 4-FC6H4 8.01 102.3 
  5e (CH2)2 2-pyridyl 3,4-F2C6H3 8.12 131.8 
  5f (CH2)2 2-pyridyl 3,5-F2C6H3 8.05 112.2 
  5g (CH2)2 2-pyridyl 3,4-Cl2C6H3 8.19 154.9 
  5h (CH2)2 2-pyridyl 3,5-Cl2C6H3 7.37 23.4 
  5i (CH2)2 3-pyridyl 4-FC6H4 8.01 123.0 
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Bioisosteric replacement of ‘S’ by ‘CH2’ and optimization of the chain led to 5b, the parent 
molecule of H2 agonists with pheniramine-like moieties. This compound is about 25 times 
more potent than histamine and is an H1 receptor antagonist with about 16 % of the activity 
of pheniramine, additionally.48,49 
In a series of ring substituted analogues the p-fluoro compound (5d, arpromidine) was 
found to be the optimum at both histamine receptors.49 Arpromidine (5d) is composed of 
the weakly active partial H2 receptor agonist imidazolylpropylguanidine (X, Fig. 1.7) 
(SK&F 91486)50 and the pheniramine-like guanidine (Y), which is a weak H1 antagonist.49 
The hybrid molecule possesses about 100 times histamine’s potency on the guinea-pig 
atrium and H1-antagonistic activity comparable to pheniramine on the guinea-pig ileum. 
Thus the pheniramine part provides additional binding to the H2 receptor and the 
homohistamine group increases the H1 receptor affinity of the fragment X. Eventually, 
Arpromidine became a promising new chemical lead for the development of 
‘cardiohistaminergics’.51 
N
HN
N
H
N
H
NH
N
F
H2N NH
NH
N
F
N
HN
N
H
NH2
NH
X  Weak partial H2-agaonist
(0.04 x histamine, i.a. = 0.3;
pD2 = 4.65)
Y  Weak H1-antagonist
(pA2 ca. 6.6; noncompetitive)
5d   H1-antagonist:pA2 = 7.65
Potent H2-agonist, 100 x histamine  
Fig. 1.7: Symbiotic approach for the design of arpromidine49 
 
Table 1.2 shows the results for arpromidine analogues substituted at the phenyl nucleus. 
Ortho halogenation does not affect the agonistic activity. By contrast, meta or para 
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substitution with Cl or F results in up to a 4-fold increase in potency, arpromidine being 
most potent in the monosubstituted series. Further increase in agonistic activity is achieved 
with the 3,4-difluoro, 3,5-difluoro and 3,4-dichloro analogues (5e-h), which are 100-160 
times as potent as histamine. An exception is the 3,5-dichloro compound 5h, which is 
considerably less active than its isomer 5g. The 3-pyridyl isomer (5i) of arpromidine is 
about equipotent on the atrium, but 10 times less active as H1 antagonist on the ileum. 
These arpromidine analogues, so-called ‘cardiohistaminergics’, were developed as positive 
inotropic vasodilators for the treatment of severe congestive heart failure.47,51-55 The 3,4- 
and 3,5-difluorinated compounds 5e and 5f proved to be superior to impromidine in 
potency, hemodynamic profile and side effects when tested in the guinea-pig under 
physiological conditions and in a pathophysological model of severe congestive heart 
failure (vasopression-induced acute heart failure).55,56 Moreover, arpromidine-like 
compounds having both H2 receptor agonistic and H1 receptor antagonistic properties 
significantly increased the survival time in rat endotoxic shock.57 Independent from H2 
agonism, such compounds were described as first competitive non-peptidic neuropeptide Y 
(NPY) Y1 receptor antagonists.58-60 These compounds exhibited only low moderate Y1 
receptor affinity (pKi up to 6.5), however, they proved to be useful as chemical leads for the 
development of more potent non-peptidic NPY receptor antagonists.61 
O
O
H
H
O (or Thr 190 ?)
-
O
O
-
transmembrane 
domain III
transmembrane 
domain V
H-bonds
HN
NH
N
N
H2N N
F
+
phenyl(pyridyl)alkyl moiety
providing additional binding
ionic
interaction
A
B
C
D
Asp- 186
Tyr- 182
Asp- 98
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.8: Possible interactions of arpromidine with the guinea-pig H2 receptor49  
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The interaction of guanidine-type agonists with the histamine H2 receptor may be 
interpreted by analogy with the model proposed for histamine by Weistein et al.27,62  
 
II
III
IV
V
VI
VII
I
Tyr11Asp271
Glu270
Arg257
Asp98
Tyr182
Asp186
 
 
Fig. 1.9: Molecular modeling representation of the binding of arpromidine (C-atoms green) 
at the guinea-pig histamine H2 receptor. Side chains and α-C atoms are drawn only for the 
putative binding site and residues of the upper parts of TM1 and TM7, wich are different 
from the human H2-receptor.42  
 
The imidazole ring may be involved in a proton transfer mechanism by interacting with 
hydrogen bonding regions (A, B) (Fig. 1.8). A shift in the tautomeric system could be 
induced by interaction of the guanidinium cation with a negatively charged group (e. g., a 
carboxylate group) (C). Since imidazolylpropylguanidine (X) is only a weakly active partial 
H2 agonists, the phenyl(pyridyl)propyl substituent of arpromidine (or a corresponding class 
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of potent compounds) appears to increase the receptor binding to a site D. On the basis of 
molecular modeling investigations (Fig. 1.8) some amino acids of transmembrane domains 
6 and 7 were suggested to be involved in this interaction.63 
 
The diphenylpropylguanidine (6a) analogues of arpromidine are known to produce a 
similar dual mode of action but at a lower level of potency. Two aromatic rings are not 
required. For example, one or both of the aryl rings may be replaced by a cyclohexyl (6f-h) 
and a methyl group (6e) resulting in H2 agonists which are more potent than histamine.64 
 
Table 1.3: Structures and histamine H2 receptor agonistic activities of diphenylalkyl-, 
phenylalkyl- and cyclohexylalkyl-substituted imidazolylpropylguanidines64 
N
HN
N
H
N
H
A
NH
X
Y
6a-h  
No. A X Y pEC50 rel. potency 
Histamine (1)    6.00 1.0 
Impromidine (4)    7.70 50.1 
Arpromidine (3d) (CH2)2 2-pyridyl 4-FC6H4 8.01 102.3 
6a (CH2)2 Ph Ph 7.15 14.1 
6b CH2 Ph Ph 6.20 1.6 
6c (CH2)2 Ph 4-FC6H4 7.75 56.2 
6d (CH2)2 4-FC6H4 4-FC6H4 7.75 56.2 
6e (CH2)2 Ph Me 7.50 31.6 
6f (CH2)2 c-Hex H 6.80 6.3 
6g (CH2)3 c-Hex H 6.40 2.5 
6h (CH2)2 c-Hex Me 7.50 31.6 
 
Very recently, the stereoisomers of the 3,4-difluorinated and the 3,4-dichlorinated 
arpromidine analogues (5e, 5g) were isolated and tested on the gunea pig right atrium. The 
(S)-enantiomers were found to be the eutomers with eudismic ratios of up to 40.65,66 These 
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compounds are up to 400 times more potent than histamine on the guinea-pig right atrium 
and are the most potent H2-receptor agonists known so far.  
However, in addition to their agonistic activity at the H2 receptor and weak to moderate 
antagonistic activity at H1 receptor, the impromidine and arpromidine-like compounds have 
also remarkable H3 antagonistic properties (in a low nanomolar range) as examplified for 
some representative derivatives. Eriks et al. have found that the imidazole ring of the 
arpromidine-like molecule is not essential for H2 agonism, but can be replaced with an 
amthamine-like 2-amino-4-methylthiazol-2-yl substructure (7a,b; Fig. 1.10).26 The 
resulting compounds were reported to be superior to the imidazole analogues concerning H2 
receptor selectivity, in particular vs. the H3 receptor.26 
 
N
HN
N
H
N
H
NH
S
N
N
H
N
H
NH
5d  Arpromidine
H2N
CH3
N
F
Ar
7  a, R = H, Ar = Ph
     b, R = 3,4-diCl2, Ar = 2-pyridyl
R
 
Fig. 1.10: Arpromidine and analogous N-[3-(2-amino-4-methylthiazol-2-yl)propyl]- 
guanidines (7a,b) 
 
1.2.3 Species selectivity of histamine H2 receptor agonists 
The guinea-pig right atrium was successfully used as a pharmacological in vitro model for 
the characterization of H2 receptor ligands including the antagonists developed as antiulcer 
drugs. Nevertheless, discrepancies in potencies and efficacies of H2 receptor agonists as 
well as different H2 receptor blocking activities e. g. in models of gastric acid secretion, 
were found on different tissues of various species and appeared to be dependent on the 
lipophilicity of the compounds.35,51,67,68 Previous investigations of guanidine-type agonists 
on the human H2 receptor (hH2R), using neutrophils as a model, and on the guinea pig H2 
receptor (gpH2R), using the isolated right atrium, showed that, in contrast to H2 antagonists 
and amine type H2 agonists, there were considerable differences in the potencies of 
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guanidines between both species. Specifically on the hH2R the arpromidine-type 
compounds were less potent than expected and generally only partial agonists.35,49,69 
However, interpretation of the result was difficult because human neutrophils and guinea 
pig atrium represent very different analysis systems concerning receptor expression levels 
and diffusion of the compounds.35  
 
Table 1.4. Agonist efficacies and potencies at hH2R-Gsαs, gpH2R-Gsαs fusion proteins 
and at the hH2R-A271D-Gsαs mutant expressed in Sf9 cells (results from GTPase 
assay on cell membrane preparations)63 
N
HN
N
H
N
H
A
NH
X
Y
5b-d  
hH2R-Gsαs gpH2R-Gsαs hH2R-A271D-GsαsNo.a
Efficacy pD2 Efficacy pD2 Efficacy pD2
 Aminesb       
1 histamine 1.00 5.90 1.00 5.92 1.00 6.46 
dimaprit 0.85 5.71 0.93 5.40 - - 2 
3 amthamine 0.90 6.35 1.40 6.36 - - 
 Imidazolylpropylguanidinesc       
 A X Y       
4 impromidine 0.84 6.70 1.00 7.41 0.85 7.57 
5b (CH2)3 2-pyridyl Ph 0.56 6.55 0.93 6.72 0.76 6.55 
5c (CH2)2 2-pyridyl Ph 0.86 6.38 1.02 7.14 0.95 7.10 
5d (CH2)2 2-pyridyl 4-FC6F4 0.79 6.72 1.02 7.12 0.91 7.22 
aNumbers of amine as in Fig. 1.3, numbers of imidazolylpropylguanidines as in Table 1.2, bFor 
structure of amines, see Fig. 1.3; cFor structure of imidazolylpropylguanidines see Fig. 1.6. 
 
Very recently, the groups of Seifert and Buschauer63 investigated in detail the species 
differences of H2 receptor agonists of different structural classes by using the GPCR-Gα 
fusion protein technique70,71. The coupling of hH2R and gpH2R to Gsαs could be compared 
under identical experimental conditions, so that an unequivocal dissection of the 
pharmacological difference between hH2R and gpH2R with respect to agonistic activity of 
amine and guanidine was possible. This is demonstrated by the efficacies and potencies of 
representative H2 receptor agonists of each structural class in the steady state GTPase assay 
(Table 1.4). 
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The efficacies of histamine, dimaprit and amthamine were similar at hH2R-GsαS and 
gpH2R-GsαS, whereas the guanidines were significantly less efficacious at hH2R-GsαS than 
at gpH2R-GsαS. Elongation of the alkyl chain between the guanidino group and the phenyl 
ring (5c vs. 5b) and introduction of Br or of multiple Cl atoms into the phenyl ring strongly 
decreased agonist efficacy at hH2R-GsαS but not at gpH2R-GsαS. These results indicate 
that the hH2R-GsαS and gpH2R-GsαS conformations stabilized by one of the small amines 
similarly promote GDP/GTP exchange. In contrast, the guanidines stabilize a hH2R-GsαS 
conformation considerably less efficient for GDP/GTP exchange than the corresponding 
gpH2R-GsαS conformation.63 
 
The potencies of amines differed by not more than 0.21 log units between hH2R-GsαS and 
gpH2R-GsαS (Table 1.4). All guanidines except 5b were significantly less potent at hH2R-
GsαS than at gpH2R-GsαS. The pD2 differences between hH2R-GsαS and gpH2R-GsαS are 
rather similar (ca. 0.4 – 0.8), indicating a nearly constant contribution of the guanidino-
alkylaryl moiety to the different ligand interactions with hH2R and gpH2R. Agonist potency 
was decreased by almost three-fold at gpH2R-GsαS by elongation of the alkyl chain 
between the guanidino group and the phenyl ring (5c vs. 5b), but slightly increased at 
hH2R-GsαS. Taken together, guanidines stabilize an active conformation in gpH2R not only 
more efficiently but also with higher affinity than in hH2R, and the structure-activity 
relationships for guanidines at hH2R and gpH2R are slightly different.63 
 
Considerations from a sequence alignment of hH2R and gpH2R and from gpH2R models 
suggested that an exchange of Ala271 (hH2R) against Asp271 (gpH2R) in TM7 should be 
the main difference of the agonist binding site between both receptor species. Results on a 
hH2R-A271D-GsαS fusion protein mutant (Fig. 1.11)63 confirmed this hypothesis (Table 
1.4). 
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Fig. 1.11. Schematic representation of hH2R-A271D-GsαS and chimeric H2 receptor fusion 
proteins63 
 
The pD2 values of guanidines at hH2RA271D-GsαS and gpH2R-GsαS are nearly identical. 
Thus, the Ala-271→Asp-271 mutation increased the potency of hH2R for guanidines to the 
level of gpH2R. These findings indicate that ion-dipole or H-bond interactions with Asp271 
may play a role. Such interactions cannot occur with Ala271 in hH2R, explaining why the 
guanidines exhibit substantially lower potencies at hH2R than at gpH2R. Regarding the 
properties of some specific agonists, it becomes obvious that elongation of the alkyl chain 
between the guanidino group and the phenyl ring (5c vs. 5b) decreased agonist potency at 
hH2R-A271D-GsαS by 0.55 log units (Table 1.4). This decrease in potency is similar to 
that observed at gpH2R-GsαS. 
Conversely, at hH2R-GsαS the longer alkyl chain slightly increased agonist potency. These 
data suggest that the amino acid at position 271 of H2Rs affects the size and flexibility of 
the guanidine binding pocket. With Ala271, the binding pocket is wider, more flexible and 
accommodates the longer (5b) as well as the shorter guanidine (5c). In contrast, with 
Asp271, the fit of the longer guanidine must probably be enforced by conformational strain. 
 
Among all guanidines studied, the amino acid substitution at position 271 had the greatest 
and most consistent impact on the potency of impromidine (4). With Asp271 the potencies 
(pD2 values) of impromidine (4) were consistently about 0.7 to 0.9 log units higher than 
with Ala271. For other guanidines, the impact of the amino acid substitution at position 271 
was less consistent. These data indicate that the binding of impromidine to H2Rs is 
considerably more dependent on interaction with Asp271 than the binding of other 
guanidines to H2R. 
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So, guanidines stabilize an active conformation in gpH2R more efficiently and potently than 
in hH2R. Studies on a hH2R-A271D-GsαS fusion protein mutant and also on chimeric 
hH2R/gpH2R receptors confirmed that Asp271 accounts for the high potency of the 
guanidines. However, their high efficacy observed in gpH2R was not restored by the 
mutants. The data show that hH2R and gpH2R selectively interact with a single class of 
synthetic agonists, that high agonist potency is mainly due to interaction with a single 
amino acid and agonist potency and efficacy are regulated independently of each other. The 
inverse order of potency of compounds 5c and 5b at hH2R and gpH2R, respectively, 
indicates that it is possible to develop guanidines with high, selective potency and efficacy 
at hH2R. Such compounds could be useful for the treatment of cardiac failure, acute 
myelogenous leukemia and inflammatory diseases. 
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 Chapter 2 
 
Objectives 
 
 
The strongly basic guanidino group is essential for the histamine H2 receptor (H2R) 
agonistic activity of arpromidine and analogues,1,2 but it is also responsible for very low 
oral bioavailability and the lack of penetration across the blood-brain barrier.3 Impromidine, 
arpromidine and related guanidines are nearly quantitatively protonated at physiological pH 
and are virtually inactive after oral administration. It has been shown in previous work that 
prodrugs of the arpromidines can be prepared by changing the physicochemical properties 
through introducing electron-withdrawing substituents such as an ethyl ester group at the 
guanidine.4 These compounds were inactive as H2R agonists in vitro but proved to be active 
after introduodenal application in guinea pigs. The ester group is cleaved in vivo and the 
active molecule, free guanidine, is formed by spontaneous decarboxylation of the 
intermediate guanidine-N-carboxylic acid. This approach was successful to obtain 
peripherally active H2R agonists, which may be useful, for example, for the treatment of 
congestive heart failure. However, centrally active guanidine-type histamine H2R agonists 
are not accessible in the same way. Centrally active H2R agonists could be valuable 
pharmacological tools to investigate the role of H2Rs in the brain. Such compounds are not 
available so far.  
 
The objective of this work was to design, synthesize and characterize histamine H2 receptor 
agonists, structurally related to arpromidine, but with lower basicity in order to achieve 
more favourable pharmacokinetic properties, in particular, oral bioavailability and 
penetration across the blood-brain barrier. Previous preliminary investigations from our 
group gave a first hint to a possibly successful general strategy for the structural 
modification of arpromidine-type H2R agonists: a few synthesized diphenylalkanoyl-
guanidines were found to have about the same H2R agonistic potency as the corresponding 
diphenylalkylguanidines regardless of considerably reduced pKa values of the guanidino 
group (pKa ≈ 8 compared to ≈ 13 for guanidine). Obviously, the acylguanidine may be 
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considered a bioisostere of the alkylguanidine moiety in arpromidine-like compounds. 
Based on this working hypothesis the preparation of a large series of new H2R agonists 
including the analogues of the most potent arpromidine analogues and the investigation of 
the structure activity relationships were in the focus of the present work.  
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    group
C
O
C
O
Alkyl or aryl, heteroaryl 
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N
S
NH2
Me
Synthesis of pure enantiomers
 
Fig. 2.1: General structure of potential histamine H2 receptor agonists to be synthesized 
 
• The first part of this project was to develop a general synthetic route for the synthesis of 
NG-acylated imidazolylpropylguanidines, i. e. a methylene had to be replaced with a 
carbonyl group in the connecting chain between the diaryl and guanidine group.  
• Then the substitution patterns had to be optimised according to the structure activity 
relationships gained previously from a large series of diphenylpropylguanidines, in 
particular, fluorine in p-position should be introduced because fluorinated compounds 
are known to be at least half an order of magnitude more active H2R agonists.  
• As an alternative the carbonyl group should be introduced in the imidazolylpropyl 
portion of the molecule to verify the role of the other guanidine nitrogen atoms in the 
interaction with Asp 98 in transmembrane domain 3 of the H2R protein. 
• Furthermore, one of the phenyl rings should be omitted or replaced by heterocycle, 
alkyl or cyclohexyl groups or by partial structures having functional groups capable of 
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interacting with the H2 receptor protein in the region identified as important for the 
binding of arpromidine and impromidine. 
• The 3-(imidazol-4-yl)propyl moiety of NG-acylated imidazolylpropylguanidines should 
be replaced by a 3-(2-amino-4-methylthiazol-5-yl)propyl side chain to reduce the H3 
receptor activity. 
• With respect to the development of models for the ligand receptor interactions 
enantiomerically pure agonists of defined 3D structure are valuable tools to explain the 
species dependent potency and to optimise the structure of the substances. So, the 
enantiomers of several chiral new H2R agonists should be selectively prepared or 
separated. 
• The synthesized compounds should be pharmacologically studied for histamine H2R 
agonism and selectivity for H2R versus the other histamine receptors. Moreover, the 
compounds should be investigated at H2R agonists of different species (human and 
guinea pig H2R) to study the species dependent structure-activity relationships and to 
refine the H2R model3 based on bovine rhodopsin.a  
• Moreover, selected compounds should be investigated for absorption from the 
gastrointestinal tract and for penetration into the brain.b 
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 Chapter 3 
Synthesis and Pharmacological Activity of NG-Acylated 
Imidazolylpropylguanidines 
 
 
The only thing that I know is that I don’t know anything                                      Plato 
 
 
3.1. Introduction 
 
Histamine (1) is a neurotransmitter, an autacoid and involved in numerous biological 
processes in the CNS and in peripheral tissues.1-5 The biological effects of histamine are 
mediated by four receptor subtypes, H1, H2, H3 and H4 receptors, which all belong to the G-
protein coupled receptor (GPCR) superfamily.1 The histamine H2 receptor (H2R) couples to 
the G-protein Gs to mediate adenylyl cyclase activation1 The discovery and pharmacological 
characterisation of the H2R by Black and collaborators6 in 1972, the development and clinical 
use of drugs for the treatment of gastric and duodenal ulcer have provided evidence for an 
important physiological role of histamine (1, Fig. 3.1) in the regulation of gastric acid 
secretion. Meanwhile, H2Rs were detected in numerous other peripheral tissues and cells, for 
example, in leukocytes, the heart, airways, uterus and vascular smooth muscle, and in the 
brain1,7-10 Subsequently, the H2R was cloned from several species including rat, guinea pig, 
mouse, dog and humans.11  
 
Numerous histamine H2 receptor agonists12-15 are known which may be roughly classified into 
two classes: the amine- and the guanidine-type H2R agonists corresponding to histamine-like 
(Fig. 3.1, 1-3) and impromidine-like compounds (Fig 3.1, 4 and 5). Impromidine16, the 
prototypical guanidine-type H2R agonist, is nearly 50-fold more potent than histamine on the 
isolated spontaneously beating guinea pig right atrium, a standard model for the 
pharmacological investigation of H2R ligands. By using Impromidine, Baumann and his co-
workers demonstrated that H2R stimulation may be an effective treatment for patients 
suffering from severe catecholamine-insensitive congestive heart failure.17 
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Fig. 3.1: Structure of some histamine H2 receptor agonists 
 
This proof of concept encouraged to search for new H2R agonists with better pharmacological 
profile than that of impromidine. Buschauer and his co-workers developed Arpromidine14 
(5d) and a large series of related imidazolylpropylguanidines [5e] (‘cardiohistaminergics’), as 
positive inotropic vasodialators.14,18-20 The most active analogues achieve about 400 times the 
activity of histamine on the isolated spontaneously beating guinea pig right atrium. These 
arpromidine-like H2R agonists, in particular 3,4- and 3,5 difluorinated analogues proved to be 
superior to impromidine in potency, hemodynamic profile and side effects when tested in the 
guinea pig under physiological conditions and in a pathological model of severe congestive 
heart failure20. Moreover, it has been speculated that H2 agonists might be useful as anticancer 
agents in leukemia to induce cell differentiation21 and as anti-inflammmatory drugs.22,23 
 
The arpromidines proved to be less potent or to act as partial agonists at human (hH2R) 
compared to guinea pig H2 receptors (gpH2R)24. It has been suggested from in vitro 
mutagenesis combined with molecular modelling studies that the presence of Ala-271 in the 
hH2R in place of Asp-271 in the gpH2R accounts for this species difference. The strongly 
basic guanidino group (pKa value about 13), which is supposed to interact with Asp-98 in 
transmembrane domain 3, is essential for the agonistic activity of 5 and analogues but it is 
also the main reason for very low oral bioavailability, non-H2R-mediated effects and lack of 
penetration across the blood-brain barrier. Impromidine, arpromidine and related guanidines 
are nearly quantitatively protonated at physiological pH and are virtually inactive following 
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oral administration. So our aim was to change the physciochemical properties by introducing 
electron withdrawing substituents, for instance a carbonyl group, at the guanidine group to 
increase oral bioavailability, reduce the non-H2R-mediated effects and to have better 
penetration across the blood-brain barrier.    
 
Here we report the successful synthetic route for the preparation and the pharmacology of NG-
acylated imidazolylpropylguanidines, which turned out to be a novel class of H2 receptor 
agonists.  
 
3.2. Chemistry  
 
3.2.1. Retrosynthetic analysis of NG-acylated imidazolylalkylguanidines 
 
According to the concept of retrosynthesis the target molecules (R) could be assembled as 
schematically shown in Fig. 3.2. The acyl part (RI) was thought to be attached to an iminium 
precursor (RII) to give a N-acyl iminium precursor (RIII), which could be converted to the 
target R by nucleophilic addition elimination with imidazolylalkylamine (RIV). 
 
A N
H
N
H
X Ar/AlN
HN
NH O Ar/Al
A NH2
N
HN
N
H
X Ar/Al
NH O Ar/Al
X Ar/Al
O Ar/AlNH2
NH
RI
RII
RIII
RIV
R
Fig. 3.2: Retrosynthetic analysis of NG-acylated guanidines: Approach I 
 
3.2.2. Synthesis of S-methyl thiourea  
S-Methyl thiourea (S-methyl isothiourea, 8), an iminium cation precursor was best prepared 
from thiourea and methyl iodide according to the known procedure (Scheme 3.1).25 
H2N NH2
S
H2N NH
SCH3
.HIMeI, EtOH
rt, 16 h
8  
Scheme 3.1: Synthesis of S-methyl thiourea 
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3.2.3. Synthesis of homohistamine  
Starting from the commercially available urocanic acid (9), the intermediate ester 11 can be 
obtained via esterification in absolute methanol at a constant flow of dry HCl, followed by 
hydrogenation of the double bond over Pd/C catalyst [Scheme 3.2].26 
N
N
H
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O
N
N
H
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O
N
N
H
OMe
O
N
N
H
NH2
O
N
N
H
CN N
N
H
NH2
Reagents: (i) MeOH, dry HCl, 2 h reflux; (ii) H2, Pd/C (10 %), MeOH; (iii) NH3, reflux, 70 °C; (iv) SOCl2, 
DMF, 60 °C; (v) H2, Ra-Ni, 25 bar, NH3, reflux.
(i) (ii) (iii)
(v)(iv)
.2 HCl
9 10 11 12
13 14
Scheme 3.2: Synthesis of homohistamine from urocanic acid 
The ammonolysis of the ester 11 in aqueous ammonia produced amide 12 which on treatment 
with thionyl chloride gave nitrile 13. Subsequent reduction of nitrile with hydrogen over 
Raney-Ni in liquid ammonia provided homohistamine (14).25 
 
3.2.4. Synthesis of NG-acylated imidazolylpropylguanidines via the S-methyl thiourea 
and cyanamide route  
3,3-Diphenylpropanoic acid (15) was activated with excess oxalylchloride to yield the acyl 
chloride intermediate 16. Then without purification the S-methyl thiourea 8 was added to 
obtain the acylated intermediate 17.  
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H
N
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H
N NH
N
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OPh
H
N NH
N
traces
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Reagents: (i) excess (COCl)2, rt, 2 h; (ii) 8, Et3N, DCM, 0 °C, rt, 24 h; (iii)H2N-CN, NaOH, acetone, 0°C, 4h; 
(iv) 8, KOtBu, HOtBu
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Scheme 3.3: Towards synthesis of NG-acylated imidazolylpropylguanidine 
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Unfortunately, when homohistamine (14) was treated with 17, in spite of producing the 
desired acylguanidine 18, the amide 19 was formed as major product as a result of the 
nucleophilic attack to the carbonyl instead of the isothiourea group. 
As an alternative, cyanamide was used as an iminium cation equivalent. By analogy with the 
aforementioned procedure the acid 15 was activated with excess oxyl chloride followed by 
addition of cyanamide to obtain the acyl cyanamide 20. Unfortunately, treatment with 
homohistamine (14) as in case of the acylated thiourea gave 19 as the major product and only 
traces of the desired product (18). 
 
Therefore, we changed our strategy and developed an alternative synthesis route, which was 
retrosynthetically analysed as: first introduction of guanidine group to the imidazolylalkyl 
chain then acylation at the guanidine group, then acylation of the guanidine group. 
 
A N
H
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X Ar/AlN
HN
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H
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O Ar/Al
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HN
H2N NH
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Fig. 3.3: Retrosynthetic analysis of NG-acylated guanidines: Approach II 
 
3.2.5. Protection of guanidine  
Guanidine is a strong base and only available as salt. It is generally not soluble in organic 
solvents, so it was protected with benzyl formate to yield the di-Cbz protected guanidine (22), 
which is soluble in organic solvents and can be purified either by column chromatography or 
recrystallisation (Scheme 3.4).27 This is a versatile nucleophilic guanidinylation28 reagent 
towards alcohols. Further, a triflate group was introduced to the di-Cbz protected guanidine 
22 to provide compound 23, which is an electrophilic guanidinylation reagent towards 
amines. 
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Reagents: (i) CbzCl, NaOH, DCM / H2O (4:2), 0 °C, 20 h; (ii) Tf2O, NaH, THF, -45 to 0 °C, 16 h  
Scheme 3.4: Protection of the guanidine group 
 
3.2.6. Synthesis of the imidazolylpropylguanidine building block 
Towards the synthesis of imidazolylpropyl guanidine, the intermediate imidazolylpropanol 
(25) was synthesized from urocanic acid (9) via esterification, hydrogenation of the double 
bond, trityl protection of the imidazole N-H to obtain a more lipophilic and easily separable 
intermediate, and finally reduction of the ester functionality is done by using lithium 
alanate.26 Thereafter, the protected guanidine (22) was coupled to the imidazolylpropyl chain 
of the primary alcohol 25 under Mitsunobu conditions27  with excellent yield, using triphenyl-
phosphine and DIAD. Subsequent quantitative cleavage of the Cbz groups by hydrogenolysis 
produced trityl protected imidazolylpropylguanidine (27) [Scheme 3.5]. 
N
N
H
OH
O
N
N
H
OMe
O
N
N
H
OMe
O
N
N
OMe
O
Ph3C
N
N
OH
Ph3C
N
N
N
Cbz
Ph3C
NH2
NCbz
N
N
N
H
Ph3C
NH2
NH
9 10 24
25 26 27
(i) (ii) (iii)
(v)(iv) (vi)
11
77 %
86 %
88 %
97 % 99 %
98 %
Reagents: (i) MeOH, dry HCl, 2 h reflux; (ii) H2, Pd/C (10 %), MeOH, 20 h; (iii) TrCl, MeCN, 12 h; 
(iv) LAH, THF, 2 h; (v) 22, Ph3P, DIAD, THF, overnight; (vi) H2, 5 bar, Pd/C (10 %), THF, 9 h.
 
Scheme 3.5: Synthesis of the imidazolylpropylguanidine building block 
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3.2.7. Synthesis of the imidazolylethylguanidine building block 
For the synthesis of the trityl protected imidazolylethylguanidine building block (33), we 
started from histamine (28) (Scheme 3.6).  
N
N
H
NH2 (i)
N
N
CPh3
NHCPh3 N
N
CPh3
NH2
(ii) N
N
CPh3
H
N NHCbz
NCbz
N
N
CPh3
H
N NH2
NH
(iv)
(iii)
28 29 30 32
33
62 % 68 % 92 %
96 %
Reagents: (i) TrCl, Et3N; (ii) 5 % TFA in DCM, 30 min, rt; (iii) 5 , Et3N, 3 h; (iv) H2, Pd/C (10 %), THF, overnight.
2HCl
 
Scheme 3.6: Synthesis of the imidazolylethylguanidine building block 
 
The trityl protection of both imidazole N-H and primary NH2 of the chain was carried out 
according to a known procedure29. Then the side chain amino group was detritylated at low 
concentration of TFA for a short period to give 30. The difference in acidity of imidazole N-H 
and primary NH2 made it possible to selectively deprotect the trityl group. Subsequently, the 
introduction of the guanidine group was carried out by following the Goodmann’s 
procedure27 for guanidinylation of amines, using di-Cbz- and Tf-protected guanidine (23). 
Then, the Cbz groups of 32 were quantitatively removed by hydrogenation over Pd/C catalyst 
to obtain compound 33. 
 
3.2.8. Synthesis of the arylalkylguanidine building block 
The preparation of the arylalkylguanidine building block 37 (Scheme 3.7) was performed by 
analogy with the aforementioned procedure for the synthesis of compound 32.  
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Ph
CH3
OH
O
Ph
CH3
OH Ph
CH3
Cbz
N NH2
NCbz
Ph
CH3
H
N NH2
NH
(i) (ii) (iii)
34 35 36 37
93 % 97 % 98 %
Reagents: (i) LAH, THF, 2 h; (ii) 22, Ph3P, DIAD, THF, 12 h; (iii) H2 5 bar, Pd/C (10 %), THF, 10 h.
 
Scheme 3.7: Synthesis of the arylalkylguanidine building block 
 
3.2.9. Synthesis of the alkanoic acids 
A large series of alkanoic acids were synthesized by applying standard synthetic methods as 
summarized in Scheme 3.8. The ketones 39a-d were prepared from nitriles via addition of 
lithium organyls, which were obtained from the corresponding heteroaryl bromides, followed 
by acid hydrolysis30 (Scheme 3.8). The resulting ketones 39a-d as well as the commercially 
available ketones 43a,b were treated with triethyl phosphonoacetate to give the corresponding 
3,3-disubstituted compounds 40a-d31 and 44a,b32. The hydrogenation of the alkenoates to the 
corresponding alkanoic acid ethyl esters 41a-d and 45a,b, followed by hydrolysis produced 
the 3,3-disubstituted propanoic acids 42a-d and 46a,b. 
 
1-(Pyridin-2-yl)ethanol (47a) was prepared from methyl magnesium bromide and pyridine-2-
carbaldehyde by using a known procedure.33 1-(Thiazol-2-yl)ethanol (47b) was prepared by 
Grignard reaction from 2-bromothiazole and acetaldehyde.34  
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R1 O
R2
R1
R2
OH
O
R1 X
R2
OH
O
(x)
R1X
R2
HO
O
R2
R1HO
R2
R1MsO (vi)(vii)
R2
R1
R2
R1 O
R2
R1
R2
R1 OEt
O
OEt
O
(ii) (iii) MeO2C
CO2Me
R1Br R1Br
R1O
R1HO
O
(xii)
R1 OH
R2
39a-e, 
43a-b
40a-e, 
44a-b
41a-e, 45a-b 49a,b 48a,b 47a,b
51
59a-e
53a-c 54a-c
55a-c
56a,b57a,b
58a,b
X = SCH2
52
(iv)
(v)
(ix)
(viii)
(xi) (xiii)
(xiv)
42a-e, 46a-b 50a,b
R2CN R2CHO
60a-e
(i)
 
 
 
53-55 a 4-F-C6H4 4-F-C6H4
          b Ph 4-F-C6H4
          c Ph 3,4-diF-C6H3
56-58a25 4-Cl-C6H4 4-Cl-C6H4
          b 4-Br-C6H4 4-Br-C6H4
X  
59ba 
 
Ph 
 
CH3 CH2
      b Ph H - 
      c Ph CH3 - 
60ba c-hexyl CH3 CH2
      b c-hexyl H - 
      c c-hexyl CH3 - 
61b 1-trityl-2-
imidazolyl 
H (CH2)2
 
No. R1 R2
39-42 a Ph 2-pyridyl 
          b 4-F-C6H4 2-pyridyl 
          c Ph 2-thiazolyl 
          d 3,4-diF-C6H3 2-thiazolyl 
          e 3,4-diF-C6H3 1-PhCH2-2-
imidazolyl 
43-46 a CH3 2-pyridyl 
          b CH3 2-thienyl 
47-50 a CH3 2-pyridyl 
          b CH3 2-thiazolyl 
51-52 H 5-Me-4-imida 
zolyl 
b prepared by Anja Kraus37   
Reagents: (i) n-BuLi, THF/Et2O, 0 °C, H30+; (ii) triethyl phosphonoacetate, NaH, THF, reflux; (iii) H2, Pd/C 
(10 %), MeOH, rt; (iv) LiOH, DMEG or THF/H2O, 5-12 h;(v) A: Mg, THF, rt; B: BuLi, THF, -78 °C; (vi) 
MsCl, DMAP, DCM; (vii) DMM, NaH, THF, rt, 12 h; (viii) a. NaOH, reflux; b. HCl, reflux, 12 h; (ix) 
HSCH2COOH, Na2CO3, AcOH, reflux, 24 h; (X) triethyl phosphonoacetate, KOtBu, tBuOH, reflux, 12-16 h; 
(xi) H2, Pd/C (10 %), MeOH, rt; (xi) triethyl phosphonoacetate, KOtBu, tBuOH, reflux, 12-16 h; (xii) ArX, 
AlCl3; (xiii) Rh/Al2O3, AcOH, H2 3 bar, 36-40 h. 
 
Scheme 3.8: General procedure for the synthesis of acids 
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The alcohols were then converted to the mesitylate35 48a,b, followed by nucleophilic 
displacement with dimethyl malonate36, basic hydrolysis, and decarboxylation to produce the 
corresponding 3-substituted propanoic acids 50a,b. Acid 52 was prepared according to the 
known procedure from 51. The 3,3-diarylpropanoic acids 55a-c were prepared by a very 
straightforward method via Wittig-Horner Reaction of corresponding ketones 53a-c treated 
with triethyl phosphonoacetate, followed by in situ hydrolysis31 to acids 54a-c and final 
hydrogenation over Pd/C catalyst. The acids 58a,b and 60a-e were synthesized by Carsten 
Götte25 and Anja Kraus37 respectively. 
 
3.2.10. Synthesis of the acylguanidines 
The most critical step was the coupling of the guanidine building blocks 27, 33, and 37 with 
acids. N,N’–carbonyldiimidazole (CDI), an acylation activating agent, was used for its high 
reactivity towards nucleophilic residues38,39 The activated acids were reacted with free 
guanidines which led to acyl guanidines (61-91)Tr, where Tr indicates the trityl protection. 
The deprotection of the trityl group with trifluoroacetic acid (TFA)40 yielded the acyl 
guanidines 61-91, as a TFA salt. 
CH3
R
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R2XHO
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R
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H
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R2X
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(61- 81, 83-88, 
90-91)Tr
R3 N
H
N
H
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(ii) 61- 81, 83-88, 90-91
27, 33, 37 42a-d
46a-b
52
55a-c
58a,b
60a-e
30-60% 91-96%
N
N
H
N
N
H
R3 =
             61, 63- 77, 79-89                    62                              76
Reagents: (i) CDI, THF, rt, 2-6 h, 30-60 %; (ii) 20 % TFA in DCM, rt, 6-16 h, 90-95 %.
R3 N
H
N
H
NH
X
O
82, 89
R3 N
H
N
H
NH
X
O
(82, 89)Tr
 
Scheme 3.9: General procedure for coupling of acids with guanidine building blocks 
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Table 3.1: Synthesized compounds 
No. R1 R2 X Yield 
(%)a 
Formulab HRMS: m/z  
foundf 
(calcd.) 
tr c 
(0.05%TFA:
CH3CN) 
61 5-Me-4-
imidazolyl 
H CH2S 
 
83 C14H21N7OS (3 TFA) 335.1607 
(335.1528) 
8.75 
62 Ph Ph CH2 92 C21H23N5O (2 TFA) 361.1901 
(361.1903) 
14.66 
63 Ph Ph CH2 92 C22H25N5O (2 TFA) 376.2137 
(376.2138) 
16.51  
64 Ph Ph - 92 C21H23N5O (2 TFA) 361.1903 
(361.1903) 
14.72 
65 4-F-C6H4 4-F-C6H4 CH2 85 C22H23F2N5O (2 TFA 411.1866 
(411.1871) 
19.50 
66 Ph 4-F-C6H4 CH2 91 C22H24FN5O (2 TFA) 393.1964 
(393.1965) 
18.18 
67 Ph 3,4-diF-
C6H3
CH2 91 C22H23F2N5O (2 TFA) 411.1865 
(411.1865) 
18.59 
68 d 4-Cl-C6H4 4-Cl-C6H4 CH2 88 C22H23Cl2N5O (2 
TFA) 
444.1357 
(444.1351) 
8.36 
 
69 d 4-Br-C6H4 4-Br-
C6H4
CH2 83 C22H23Br2N5O (2 
TFA) 
532.0347 
(532.0347) 
9.42 
 
70 2-pyridyl Ph CH2 85 C21H24N6O (3 TFA) 376.2002 
(376.2012) 
14.27 
71 2-pyridyl 4-F-C6H4 CH2 79 C21H23FN6O (3 TFA) 394.1917 
(394.1917) 
17.51 
72 2-thiazolyl Ph CH2 85 C19H22N6OS (2 TFA) 382.1576 
(382.1576) 
10.91 
73 2-thiazolyl 3,4-diF-
C6H3
CH2 86 C19H20F2N6OS (2 
TFA) 
418.1387 
(418.1387) 
12.62 
74 1-PhCH2-2-
imidazolyl 
3,4-diF-
C6H3
CH2 87 C26H27F2N7O (2 TFA) 491.2234 
(491.2245) 
13.78 
75 2-
imidazolyl 
3,4-diF-
C6H3
CH2 88 C19H21F2N7O (3 TFA) 402.1842 
(402.1776) 
9.12 
76 e  4-
imidazolyl 
H CH2 82 C17H23N5O (3 TFA) - - 
77 e  CH3 Ph - 83 C16H21N5O (2 TFA) 299.1745 
(299.1746) 
11.59 
78 e  CH3 Ph CH2 92 C17H23N5O (2 TFA) 313.1902 
(313.1902) 
9.54 
79 CH3 2-thienyl CH2 92 C15H21N5OS (2 TFA) 319.1469 
(319.1467) 
9.03 
80 CH3 2-pyridyl CH2 89 C16H22N6O (3 TFA) 314.1863 
(314.1855) 
9.29 
81 CH3 2-
thiazolyl 
CH2 84 C14H20N6OS (2 TFA) 321.1508 
(321.1419) 
11.95 
82 e - -  Ph 89 C14H17N5O (2 TFA) 271.1433 16.23 
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(271.1433) 
83 e  H Ph - 77 C15H19N5O (2 TFA) 285.1590 
(285.1590) 
15.10 
84 e  H Ph CH2 78 C16H21N5O (2 TFA) - 14.75 
85 H Ph (CH2)2 72 C17H23N5O (2 TFA) 313.1903 
(313.1903) 
- 
86 e  H Ph (CH2)3 74 C18H25N5O (2 TFA) - 13.98 
87 e  CH3 c-hexyl  86 C16H27N5O (2 TFA) 305.2212 
(305.2216) 
12.18 
88 e  CH3 c-hexyl CH2 91 C17H29N5O (2 TFA) 319.2372 
(319.2372) 
17.12 
89 e - -  c-hexyl 79 C14H23N5O (2 TFA) 277.1900 
(277.1900) 
13.14 
90 e  H c-hexyl  75 C15H25N5O (2 TFA) - 17.15 
91 e  H c-hexyl CH2 81 C16H27N5O (2 TFA) 305.2213 
(305.2213) 
14.60 
a  After preparative HPLC; b isolated as trifluoroacetic acid salt; c retention time in minutes; the solvent system (0.05 
% TFA / acetonitrile; gradient) is presented in experimental section and the experimental setup is in the experimental 
section; representative chromatogram in Fig. 5 , d  Ph.D. thesis of C. Götte25; e Diploma thesis of Anja Kraus; 37 f 
Techniques for HRMS is described in experimental section of respective compounds;  
 
The intermediate 64-(Tr) was isolated and recrystalized for x-ray analysis. The crystal 
structure (view A in Fig. 3.4) shows that a hydrogen bond is possible between oxygen of 
amide C=O and the hydrogen of guanidine nitrogen, which is attached to alkyl group. In view 
B the co-planar orientation of guanidine and C=O group is obvious.  
 
 A                                                                     B   
 
Fig. 3.4: Crystal structure (ORTEP diagram) of trityl protected acylguanidine 64-(Tr). 
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Fig. 3.5: Representative analytical HPLC chromatograms of 64 (Rt: 14.72 min; UV detection
.3. Pharmacological results and discussion  
H2 receptor (H2R) agonistic activitya 
 
                                                
11
.2
09
 
at 210 nm) and 72 (Rt: 11.21 min; UV detection at 254 nm). Detailed description is given in 
experimental section. 
 
 
3
The synthesized compounds were tested for histamine 
on the isolated spontaneously beating guinea pig right atrium6 (positive chronotropic 
response). Most of the acylguanidines were also investigated for H1 antagonism on the 
isolated guinea pig ileum and on U-373 MG human cells. The results are summarized in 
Table 3.2. Moreover, the agonistic activity was studied in the GTPase assay using guinea pig 
and human H2R expressing Sf9 insect cellsb (see Table 3.3). Acylguanidines 73 and 78 were 
investigated in mice for absorption after peroral administration and for penetration into the 
brain.41 Additionally, selected compounds were studied for histamine H3 receptor antagonism 
on the isolated electrically stimulated guinea pig ileum (results reported in Chapter 4) and 
for activity on histamine H4 receptors using H4R expressing Sf9 cells (GTPase assay). In the 
latter experiments highly potent H4R agonists were identified (R. Seifert, personal 
communcation), however, data was not included in this thesis, as these studies are subject of 
an ongoing project.  
 
a Co-operation with Prof. Dr. S. Elz, Dept. Pharm./Medicinal Chemistry I, University of Regensburg 
b Co-operation with Prof. Dr. R. Seifert, Dept. Pharmacology & Toxicology, University of Regensburg 
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Table 3.2: Histamine H2 receptor agonism on guinea pig right atrium, H1 receptor 
 Histamine H2 receptor agonism Histamine H1 receptor antagonism 
antagonism on isolated guinea pig ileum and U-373 MG human cells (Ca2+-assay) 
 
 isolated guinea pig right atrium g lls uinea pig ileum U-373 MG ce
(Ca2+-assay) 
No. pEC50a ± SEMj rel. pot.b Emax ( %)c Nd PA2a,c± SEM 
[or ]e
Nd 0
 pD’2a,c ± SEM
IC5  [µM]i
1, HIS 6.00 ± 0.10 100 100 ± 2 >50    
4 7.70 ± 0.10 5000 100 4 5.47 ± 0.01 - - 
5d 8.01 ± 0.10 10200 100 5 7.65 ± 0.01 7 - 
61 7.38 ± 0.09 2370 101 ± 2 56 4 5.37 ± 0.05 12 
62 6.06 ± 017 114 64 ± 3 3 5.01 ± 0.10 
[4.55 ± 0.06] 
11 
16 
57 
63 7.22 ± 0.09 1650 85 ± 3 5 
[5.00 ± 0.09] 
- 5.93 ± 0.05 10 
18 
64 5.85 ± 0.18 70 69 ± 5 3 26 - - 
65 6.37 ± 0.07 234 76 ± 2 4 [5.76 ± 0.15] 4 9 
66 6.93 ± 0.09 857 95 ± 3 4 [5.19 ± 0.03] 4  
67 6.95 ± 0.05 887 81 ± 3 4 [5.87 ± 0.14] 4 8 
68 6.51 ± 0.10 320 60 ± x 3 -  - 
69 6.11 ± 0.10 130 60 ± x 3 -  - 
70 7.16 ± 0.03 1455 97 ± 1 4 4.95 ± 0.04 10 32 
71 7.34 ± 0.12 2170 100 ± 1 3 5.43 ± 0.03 12 34 
72 7.29 ± 0.03 1950 100 ± 1 3 5.33 ± 0.05 18 45 
73 7.17 ± 0.06 1480 90 ± 4 3 5.33 ± 0.07 16 30 
74 6.26 ± 0.08 186 54 ± 5 3 -  19 
75 6.88 ± 0.16 764 100 ± 4 3 -  41 
76 5.10 ± 0.19 K - 7 ± 1l  3 - - - 
77 5.06 ± 0.20 12 <5.0 58.1 88 ± 5 3 2 
78 7.45 ± 0.07 2710 6.31 ± 0.06 99 ± 2 4 2 19.5 
79 7.29 ± 0.10 1950 99 ± 2 3 -  14 
80 7.29 ± 0.06 1940 98 ± 2 3 -  49 
81 7.28 ± 0.11 1920 91 ± 2 4 -  73 
82 5.53 ± 0.12 34 89 ± 4 3 <5.0 2 104 
83 6.35 ± 0.01 222 97 ± 2 3 5.98 ± 0.02 2 18.7 
84 6.40 ± 0.10 253 97 ± 5 3 5.42 ± 0.14 5 60.8 
85 6.88 ± 0.10 759 94 ± 2 4 5.50 ± 0.20 2 46.9 
86 5.96 ± 0.03 92 86 ± 5 4 6.02 ± 0.03 4 - 
87 6.49 ± 0.11 311 86 ± 3 3 5.39 ± 0.01 4 57.7 
88 6.81 ± 0.07 641 101 ± 3 3 5.43 ± 0.09 5 0.95 
89 6.93 ± 0.07 851 102 ± 1 3 5.03 ± 0.07 2 39.2 
90 6.62 ± 0.10 417 95 ± 1 3 5.36 ± 0.07 4 28.2 
91 6.84 ± 0.11 687 98 ± 3 3 4.97 ± 0.26 2 10.2 
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a E ion s see a ix; b Pot ive to mine cacy, al resp %), 
re  the max  h e indu e reference comp e; d Num er of experi s; e 
Most of the synthesized acylguanidines (61-91, Table 3.2) proved to be full or nearly full 
istamine H2R agonism on the isolated guinea pig right atrium:  
or a methylene group is 
xplanat
lative to
 of abbreviation
imal increase in
ppend
eart rat
ency relat
ced by th
 hista  = 100 %, c effi
ound histamin
maxim
b
onse ( 
ment
pD’  values given in brackets for compounds producing a significant, concentration-dependent reduction of histamine’s 
maximal response; 
2
f non-surmountable; g competitive/surmountable ; h competitive/non-surmountable;  i IC  values for 
the inhibition of the histamine (30 µM) induced increase in intracellular calcium; mean of at least 3 independent 
experiments; SEM < 10 %; 
50
j pEC  was calculated from the mean shift ΔpEC  of the agonist curve relative to the 
histamine reference curve by the equation: pEC  = 6.00 + ΔpEC . The SEM given for pEC  is the SEM calculated for 
ΔpEC ; 
50 50
50 50 50
50
K Antagonist (pA ); 2 l Emax at 100 µM; E  of histamine in the presence of 100 μM 76 was 45 ± 5%. 
 
max
histamine H2R agonists on the spontaneously beating guinea pig right atrium, supporting the 
working hypothesis that the strongly basic guanidine group may be replaced by a 
considerably less basic acylguanidine without loss of H2R agonistic activity. In contrast, on 
the guinea pig ileum as well as on human U373 cells all tested compounds proved to be 
devoid of histamine H1 receptor agonistic activity. In both test systems weak H1R antagonism 
was found, for instance, on the guinea pig ileum the compounds were by 1 - 2.5 orders of 
magnitude less active than arpromidine.  
 
 
H
The suitability of a carbonyl group as a bioisosteric substitute f
strongly depending on the substitution pattern of the H2R agonist molecule, i.e. the 
substituents R1, R2 and the chain length, as shown in Fig. 3.6 for a selection of pairs of 
compounds. As arpromidine and related phenyl(heteroaryl)alkyl-substituted imidazolyl-
propylguanidines are the most potent H2R agonists known so far, we expected highest activity 
to reside in the corresponding acylated analogues, too. “Oxo-arpromidine” (71) was found to 
be about 5 times less potent than arpromidine or half as potent as impromidine, respectively. 
This tendency to lower pEC50 values compared to the alkylguanidines was confirmed by 
investigation of related compounds such as 70, 72, 73 and 75 and was most obvious for 
compounds having a mono- or two-fold fluorinated phenyl ring such as 71, 73 and the 
fluorinated diphenylpropanoylguanidines 65-67. Taking into consideration that improved 
pharmacokinetic properties of the aforementioned substances can compensate for that, in 
principle, a moderate decrease in potency can be accepted. However, a decrease in activity is 
not inevitable: the compounds 63, 68, and in particular the 3-(hetero)arylbutanoyl-substituted 
guanidines 78-81 were found to be as potent as the corresponding 3-
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(hetero)arylbutylguanidines, i. e., when one of the aryl group is replaced with a methyl group, 
the potencies become similar comparing the alkyl and the acylguanidine series. As in the 
arpromidine series a three-membered carbon chain between guanidine and aromatic ring is 
optimum. Among these H2R agonists 78 is about 28 times, and the thienyl, pyridyl and 
thiazolyl analogues (79-81) are about 20 times more potent than histamine on the isolated 
guinea pig right atrium. The corresponding cyclohexyl analogue 88 is only 6 times more 
potent than the reference compound. Interestingly, substance 61, the oxo-derivative of 
impromidine, was about half as potent as the parent compound. This result further supports 
the idea that the acylguanidines and the alkylguanidines bind to the H2R in a similar way. It is 
conceivable that the acylated guanidine forms a charge-assisted hydrogen bond with Asp98 in 
transmembrane domain 3 of the H2R.    
pEC50
5,0 5,5 6,0 6,5 7,0 7,5 8,0
5,0 5,5 6,0 6,5 7,0 7,5 8,0
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Fig 3.6: H2R agonistic potency of alkyl (X = CH2) and acyl guanidines (X = CO) on the
isolated spontaneously beating guinea pig right atrium (pEC50 values).  
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A concentration-response curve is exemplarily shown for histamine and compound 78 in Fig. 
3.7. The curve shows that the compound 78 is 28 times more potent than the reference 
compound, histamine. The positive chronotropic response to compound 78 is inhibited by the 
H2R cimetidine resulting in a rightward shift of the concentration-response curve (see Fig. 
3.7). The pA2 determined for cimetidine (6.31) versus 78 as the agonist is not significantly 
different from the values obtained versus other agonists like histamine, impromidine or 
arpromidine. As 78 is a potent chiral H2R agonist the compound was one of the 
acylguanidines selected for the synthesis of the enantiomers (see Chapter 5). 
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Fig 3.7: Concentration-response curves of histamine and compound 78 on the guinea pig 
right atrium.  
pecies selectivity - agonism on guinea pig and human H2R-Gsα fusion proteins  
 model for 
 
 
 
S
The isolated guinea pig right atrium was successfully used as a predictive standard
the pharmacological characterisation of H2R antagonists developed as antiulcer agents. 
Recently, a discrepancy between activity on guinea pig and human H2R was demonstrated for 
arpromidine and related H2R agonists, whereas the differences between agonistic potencies of 
small amine-like agonists at both species was negligible. Moreover, a binding mode for 
arpromidine-like H2R agonists was suggested on the basis of site-directed mutagenesis and 
molecular modelling. In order to study the species selectivity and to investigate the structure-
activity relationships in comparison to the arpromidines, the synthesized compounds were 
also tested for potency and efficacy on hH2R-Gsαs and gpH2R-Gsαs fusion proteins expressed 
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Table 3.3: Activity on the human and guinea pig receptor (GTPase assay* on human and 
 
gpH2R-GsαS
in Sf9 cells (investigations on cell membrane preparations according to the procedure 
reported by Kelley et al.24). The results are summarized in Table 3.3. Moreover, graphical 
presentations of efficacies and potencies at H2R of both species, concentration-response 
curves of a number of acylguanidines as well as radioligand displacement curves for selected 
compounds are shown in Figures 3.8 and 3.9.  
guinea pig H2R-Gsα fusion proteins)  
  hH2R-GsαS
No Efficacy EC50, nM pEC50 Rel. 
Pot. 
Efficacy EC50, nM pEC50 Rel. 
Pot. 
EC50 hH2R-GsαS
SEC50 gpH2R-Gsα
HISa 1,00 1260 ± 250 5.90 100 1,00 1200 ± 240 5.92 100 1.05 
4 0.84 ± 0.04 200 ± 20 6.70 1.00 ± 0.12 40 ± 10 7.41 a 641 3060 5.00 
5da 0.7 7 1.0 4 9 ± 0.0 0.19 ± 0.04 6.72 659 2 ± 0.0 70 ± 10 7.15 1600 2.71 
61 0.79 ± 0.04 267 ± 38 6.57 480 0.93 ± 0.01 60 ± 1 7.22 2000 4.44 
62 0.17 ± 0.01 186 ± 9 6.73 680 0.54 ± 0.02 175 ± 27 6.76 700 1.06 
63 0.69 ± 0.09 78 ± 42 7.11 1600 0.93 ± 0.32 6 ± 1 8.22 19000 12.1 
64 0.08 ± 0.04 - - 740 0.60 ± 0.11 400 ± 86 6.40 300 0.42 
65 0.61 ± 0.02 48 ± 16 7.32 2600 0.81 ± 0.13 2  5 ± 17 7.60 4800 1.88 
66 0.67 ± 0.07 113 34 6.  ± 95 1100 1.00 ± 0.11 20 ± 15 7.70 5900 5.56 
67 0.72 ± 0.09 61 ± 15 7.22 2100 1.02 ± 0.11 7 ± 1 8.15 16000 8.23 
70 0.86 ± 0.01 547 ± 33 6.26 230 1.03 ± 0.07 60 ± 14 7.22 2000 9.17 
71 0.73 ± 0.03 415 ± 90 6.38 320 0.93 ± 0.04 45 ± 4 7.35 2700 9.21 
72 0.93 ± 0.08 550 ± 80 6.26 260 1.08 ± 0.27 20 ± 10 7.70 6000 23.1 
73 0.76 ± 0.01 298 ± 4 6.53 420 1.01 ± 0.09 75 ± 5 7.12 1600 3.96 
74 0.38 ± 0.01 782 ± 52 6.11 160 0.28 ± 0.01 359 ± 38 6.44 340 2.18 
75 0.88 ± 0.10 654 ± 92 6.18 200 0.90 ± 0.01 2  61 ± 10 6.58 460 2.51 
77 0.81 ± 0.03 75 ± 26 7.12 1680 0.89 ± 0.03 29 ± 7 7.54 3680 2.59 
78 0.87 ± 0.01 67 ± 2 7.17 1880 1.03 ± 0.06 12 ± 1 7.92 1  0300 5.58 
79 0.97 ± 0.01 109 ± 31 6.96 1156 1.05 ± 0.13 21 ± 19 7.67 5714 4.97 
80 1.11 ± 0.06 5  1  20 ± 140 6.28 246 1.22 ± 0.08 30 ± 11 6.89 923 3.75 
81 0.92 ± 0.01 188 ± 99 6.72 670 0.94 ± 0.04 33 ± 3 7.48 3636 5.43 
82 0.50 ± 0.01 1390 ± 37 5.86 91 0.84 ± 0.06 636 ± 99 6.20 158 2.18 
83 0.76 ± 0.01 147 ± 8 6.83 857 0.90 ± 0.01 76 ± 13 7.12 1420 1.93 
84 0.84 ± 0.03 100 ± 16 7.00 1  260 1.05 ± 0.11 23 ± 1 7.64 5480 4.35 
85 0.61 ± 0.01 67 ± 9 7.17 1880 0.84 ± 0.01 21 ± 2 7.68 4800 3.19 
86 0.60 ± 0.01 72 ± 23 7.14 1750 0.80 ± 0.06 56 ± 5 7.25 1710 1.29 
87 0.74 ± 0.06 99 ± 8 7.00 1270 0.90 ± 0.08 37 ± 8 7.43 2920 2.68 
88 0.87 ± 0.05 23 ± 3 7.64 5480 1.11 ± 0.16 9 ± 1 8.04 14800 2.56 
89 0.76 ± 0.05 38 ± 4 7.42 3320 0.99 ± 0.08 21 ± 1 7.68 5660 1.81 
90 0.87 ± 0.04 62 ± 6 7.21 2030 1.01 ± 0.13 23 ± 1 7.64 5270 2.70 
91 0.76 ± 0.04 46 ± 2 7.34 2740 1.02 ± 0.11 22 ± 1 7.66 5560 2.09 
a Data fro
* nc acie nds 2R
m ref.24 
Pote ies and effic s of liga at hH -Gs S and gpH2R-Gs S w rmin the se ass TP 
ermined as described in literature. Reaction mixtures contained membranes of Sf9 cells expressing 
ere dete ed in  GTPa ay. G
hydrolysis was det
fusion proteins and agonists at concentrations from 1 nM to 1 mM as appropriate to generate saturated concentra-
tion/response curves. Curves were analyzed by nonlinear regression. Typical basal GTPase activities ranged between 
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~1 and 2 pmol/mg/min, and typical GTPase activities stimulated by HIS (100 µM) ranged between ~4 and 
8 pmol/mg/min. To calculate agonist efficacies, the maximum stimulatory effect of HIS was set at 1.00, and the stim-
ulatory effects of other agonists were referred to this value. Data shown are the means ± SD of four to six experiments 
performed in duplicate. The relative potency (Rel. Pot.) of HIS was set at 100, and the potencies of other agonists 
were referred to this value to facilitate comparison of agonist potencies. Efficacies and potencies, respectively, of 
ligands at hH2R-Gs S were compared with the corresponding parameters at gpH2R-Gs S using the t test. 
 
Efficacy at hH2R and gpH2R. Similar to the results published for arpromidine-like guanidines 
otency at hH2R and gpH2R. Generally, acylguanidines are more potent at gpH2R-GsαS than 
 
 
the efficacies at the human H2R-Gsαs were significantly lower than at guinea pig H2R-Gsαs 
(Fig. 3.8). As demonstrated by Kelley et al.24 the efficacy of agonists strongly depends on the 
presence of Tyr or Cys in position 17 of the guinea pig and the human H2R, respectively. The 
difference is more pronounced for the diaryl (e. g., 63-73) and the cyclohexyl analogues (87-
91) and smaller for the monoaryl analogues, especially the methyl branched compounds (77-
81). Compounds 62 and 64, the shorter homologues of compound 63 with either an 
imidazolylethylguanidine or a diphenylacetyl moiety, have lower efficacies than 63 and very 
low intrinsic acitivity at the hH2R. As the number of halogen substituents in the ring increases 
the difference in efficacy increases (63, 65-67, 70 vs 71, 72 vs 73). In case of benzyl 
protected imidazole analogue 74, the efficacy is much lower in comparison to its deprotected 
75, which has the same efficacy at both hH2R and gpH2R.  
 
P
at hH2R-GsαS. This result is in accordance with the structure-activity relationship of 
arpromidine, impromidine and related imidazolylpropylguanidine-type H2R agonists (Kelley 
et al.24), suggesting a similar binding mode of the affinity-conferring group regardless of the 
presence of a CH2 or a CO group adjacent to the guanidine nitrogen. The differences are 
depending on the substitution pattern (e.g., diaryl, aryl/heteroaryl, mono(hetero)aryl, or 
cyclohexyl series; see Fig. 3.8, diagram taken from data in Table 3.3). For instance, the 
species selectivities of “oxo-arpromidine” (71), diarylalkanoylguanidines (63-67) and “oxo-
impromidine” (61) are comparable with those of the corresponding alkylguanidines. 
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Fig. 3.8: Efficacies of acylguanidine-type agonists at gpH2R-GsαS and hH2R-GsαS    
 
As in the diarylalkylguanidine series of compounds, incorporation of a shorter connecting 
chain results in a decrease in H2R agonistic activity (62 vs. 63) and the difference in potency 
at gpH2R-GsαS and hH2R-GsαS becomes negligible (62). Similarly, in the aryl(heteroaryl)-
alkanoylguanidine series (70-75), the agonistic potency was much higher at gpH2R-GsαS than 
at hH2R-GsαS. Surprisingly, the most interesting result was found in methyl branched 
monoaryl, heteroaryl and cyclohexyl analogues (77-81, 87, 88). These compounds have 
nearly the same potency as the diaryl analogues but the difference in activity at guinea pig 
and human H2R is considerably lower. This result indicates that methyl branched aryl and 
cyclohexyl analogues stabilize an active hH2R-GsαS conformation considerably more efficient 
for GDP/GTP exchange than the diaryl or aryl-heteroaryl analogues. 
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Fig 3.9: Potencies (pEC50 values) of acylguanidine-type agonists at gpH2R-GsαS and hH2R-
GsαS  
 
Due to the completely different experimental setup the absolute values for agonistic potencies 
on the isolated guinea pig atrium (positive chronotropic response) and the gpH2R-GsαS fusion 
proteins (GTPase assay) are not identical, but the results are essentially comparable. 
Neveretheless, there are some quantitative differences. On the atrial gpH2R the 3-
phenylbutanoyl-substituted imidazolylpropylguanidin 78 was most active (28 times as potent 
as histamine), but at the gpH2R-GsαS the diphenyl analogue 63 was superior to 78 (190 versus 
103 times the potency of histamine). Unexpectedly, at hH2R-GsαS compound 88, the 
cyclohexyl analogue of 78, was found to be most active (54 times the potency of histamine). 
In Fig. 3.10  several concentration response curves of acyl guanidines at gpH2R-GsαS [a), and 
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c)] and hH2R-GsαS [b) and d)] are shown. The maximum response is always higher for 
gpH2R-GsαS than hH2R-GsαS.  
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Fig. 3.10: Concentration response curves of acylguanidine-type agonists at gpH2R-GsαS and 
hH2R-GsαS (GTPase assay). 
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Histamine H2R binding. Selected compounds were investigated for H2R binding on gpH2R-
GsαS and hH2R-GsαS in competition assays using the H2R antagonist [3H]tiotidine as the 
radioligand. As an example the displacement curves for compound 71 are shown in Fig. 3.11. 
The Ki values at both human and guinea pig H2R are in the same range as the potencies found 
in the GTPase assay.   
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Fig. 3.11. Displacement of the radioligand [3H]tiotidine (10 nM) from gpH2R-GsαS and hH2R-
GsαS (cell membrane preparations from H2R-GsαS expressing Sf9 cells) in absence and 
presence of GTPγS (10 µM). The experiments were performed according to the procedure 
described.24  
 
 
The pKa value of acylguanidinium cations is by 4-5 orders of magnitude lower than that of 
guanidinium ions (guanidinium: pKa ≈ 12.5; acetylguanidinium: pKa = 7.642). On one hand, 
the acylguanidines are still sufficiently basic to form a cation which is supposed to interact 
with Asp98 in transmembrane domain 3 of the H2R by analogy with the binding mode 
suggested for arpromidine-like agonists. On the other hand, the reduced basicity of 
acylguanidines results in absorption from the gastrointestinal tract and penetration across the 
blood brain barrier, as a considerable portion of the substance remains uncharged under 
physiological conditions. This has been exemplarily proven for compounds 73 and 78 in 
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mice.41 Both compounds were detected in plasma after peroral administration and in the brain 
after intraperitoneal administration.  
 
3.4. Conclusion 
Starting from a working hypothesis based on structure-activity relationship of arpromidine-
like H2R agonists structurally related compounds with reduced basicity were prepared in 
order to obtain agonists with improved pharmacokinetic profile. we were successful to 
establish a complete route for the synthesis of NG-acylated imidazolylpropylguanidines. The 
synthesized compounds were pharmacologically tested on isolated guinea pig tissues (ileum: 
H1R, right atrium: H2R) as well as on cells and membrane preparations of guinea pig and 
human histamine H1, H2, or H4 receptor expressing cells. The basicity of the acylguanidines is 
by 4-5 orders of magnitude lower than that of the corresponding guanidines. However, 
alkanoylguanidines and alkylguanidines appear to be bioisosteres, and it may be speculated 
that the acylguanidines are capable of interacting with Asp98 in transmembrane domain 3 of 
the H2R by a charge-assisted hydrogen bond. Compounds having a carbonyl instead of a 
methylene group adjacent to the guanidine are about equipotent as, for instance, demonstrated 
for the diphenylpropyl versus the diphenylpropanoyl and for impromidine versus the oxo-
substituted analogue. However, a considerable decrease in activity was found when the 
methylene group in arpromidine was converted to a carbonyl group. Surprisingly, compounds 
77-86, which have only one phenyl ring are equally or even more potent than the diaryl 
analogues, whereas in the arpromidine series of histamine H2R agonists highest potency 
resides in the 3-phenyl-3-hetarylpropyl-substituted imidazolylpropylguanidines. This may be 
interpreted as a first hint to different modes of interaction of the affinity-conferring moiety 
with the receptor protein. On the isolated guinea pig right atrium the most active H2R agonist, 
the 3-phenylbutanoyl substituted guanidine 78, was about 30 times more potent than the 
natural ligand. In terms of agonistic potency on the guinea pig atrium the new compounds are 
inferior to the arpromidines. However, the acylated imidazolylpropylguanidines are superior 
with respect to pharmakokinetic properties.  A very important finding is that the compounds 
are capable of penetrating through the blood-brain barrier (tested by HPLC-MS analysis after 
administration to mice). Centrally active H2R agonists will be useful pharmacological tools to 
study the role of histamine H2 receptors in the brain.  
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Meanwhile, imidazolylpropylguanidines and corresponding acylated analogues were found to 
be useful building blocks beyond the preparation of H2R agonists, for instance, the synthesis 
of ligands preferentially binding to other histamine receptor subtypes, like neuropeptide Y 
Y143 or Y4 receptors 44. Thus, there is increasing evidence that in terms of medicinal 
chemistry the imidazolylpropylguanidine moiety and the acylated analogues may be 
considered as “privileged structures”. An extremely promising perspective results from very 
recent studies: surprisingly, some of the acylguanidines proved to be rather potent as either 
agonists or inverse agonists at the recently discovered H4R (R. Seifert, personal communi-
cation; data not shown). The elaboration of the structure-activity relationships based on these 
results and the design of H4R selective ligands will be a subject of a new project.  
 
 
 
3.5. Experimental section 
 
3.5.1. Chemistry 
General procedures 
Where indicated, reactions were carried out under a dry, oxygen-free atmosphere of N2 using 
Schlenk-technique or under argon atmosphere. Commercially available reagents were used as 
received. DMF, CH3CN and CH2Cl2 were distilled over P4O10 and stored under N2 over 
molecular sieves 3Å. EtOH and MeOH were dried over Mg and stored under N2. THF, 1,4-
dioxane and Et2O were dried with Na/benzophenone and stored over Na wire under N2. 
EtOAc, petroleum ether (60/40), CHCl3, CH2Cl2, MeOH and hexane for chromatographic 
separations were distilled before use. For column chromatography silica gel Geduran 60 
(Merck, 0.063-0.200 mm) was used. TLC-analysis was done on silica gel 60 F254 (Merck) 
coated on aluminium sheets. NMR-spectra were recorded on Bruker Avance 300 (1H: 300 
MHz, 13C: 75.5 MHz) and Bruker Avance 600 (1H: 600 MHz; 13C: 150.29 MHz) with TMS 
as internal standard. IR spectroscopy was done on a Mattson Genesis Series FT-IR (sample 
preparation as indicated). X-ray analysis was performed by the Crystallography Laboratory 
(University of Regensburg, M. Zabel, S. Stempfhuber). Elemental analysis (Heraeus 
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Elementar Vario EL III) and mass spectrometry (Finnigan ThermoQuest TSQ 7000) were 
done by the Central Analytical Laboratory (Universität Regensburg).  
The following chromatographic methods were used to assess compound purity: 
Preparative chromatography: The pump model was Knauer K-1800 and column was 
Eurosphere-100 (250 x 32 mm) which was attached to a Knauer-Detector K-2000 UV-
detector. UV detection was done at 254 nm. Temperature was 25°C, Flow rate was 40 
mL/min. The mobile phase was 0.1% TFA in Millipore water and MeOH. Injection volume 
was 500 µL. 
Analytical chromatography (referred to Table 1): The pump was P4000 (Thermo 
Separation Products) and the columns were: Column A: Nucleodur 100-5 C18 (250 * 4.0, 5 
µ), Column B: Luna C18 (150 x 4.6, 3µ), which was attached to AS3000 (Thermo Separation 
Products) Autosampler, UV-VIS Detektor Spectra Focus detector, SN4000 Controller 
(Thermo Separation Products). The temperature was 30 °C; UV detection was set to 254 and 
210 nm. Injection volume was 50 µL of ≈150 µM solution. The mobile phase was 0.05% 
TFA in Millipore water and CH3CN. 
 
(E)-Methyl 3-(1H-imidazol-4-yl)propenoate [10]26 
Urocanic acid (10 g, 72.4 mmol) was added to refluxing absolute methanol (100 mL) and dry 
HCl gas was bubbled through the mixture, according to the literature procedure. After 
refluxing for 2 h, the solvent was removed, and the solid residue was recrystallized to obtain 
the ester as hydrochloride (13.2 g). 
 
Yield 97 %; colorless crystalline solid; C7H8N2O2⋅HCl (188.6); mp 230-231 °C; IR (neat): 
3080, 2992, 2716, 2612, 1691, 1583, 1444, 1285, 1234, 1053, 981, 861, 832 cm-1;  1H-NMR 
(DMSO-d6), δ (ppm): 9.06 (s, 1H, Im-2-H), 7.90 (s, 1H, Im-5-H), 7.60 (d, 1H, J =16.3 Hz, 
Im-4-CHCH), 6.63 (d, 1H, J = 16.3 Hz, Im-4-CHCH), 3.78 (s, 3H, OCH3); 13C-NMR 
(DMSO-d6),  δ (ppm): 165.8 (quart, CO), 136.2 (+, Im-C-2), 129.3 (+, CH=CHCO), 128.4 
(quart, Im-C-4), 121.6 (+, CH=CHCO), 120.0 (+, Im-C-5), 51.7 (+, CH3); EI-MS, m/z (rel. 
intensity, %): 152 (M+·, 50), 120 ([M-OMe]+, 100).  
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Methyl 3-(1H-imidazol-4-yl)propanoate [11]26 
To a solution of 10 (9.88 g, 52.4 mmol) in 100 mL of MeOH in a beaker (250 mL) was added 
slowly 1.0 g of Pd/C (10 %) at room temperature and placed in a hydrogenation chamber at 5 
bar H2 pressure for 20 h. After completion of reaction (monitored by TLC; CHCl3 : MeOH, 
90 : 10 under NH3 atmosphere) the mixture was filtered through a celite pad, which was 
rinsed with MeOH, and the solution was concentrated in vacuo to get a solid (9.9 g). 
 
Yield 99 %; colorless crystalline solid; C7H10N2O2⋅HCl (190.6); mp 107-109 °C; IR (neat): 
3128, 3082, 2996, 2736, 2610, 1722, 1619, 1436, 1262, 1244, 1160, 1027, 1002, 837 cm-1;  
1H-NMR (DMSO-d6), δ (ppm): 14.7 (br s, 1H, Im-NH), 9.03 (s, 1H, Im-2-H), 7.43 (s, 1H, 
Im-5-H), 3.60 (s, 3H, OCH3), 2.99 (t, 2H, J = 7.1 Hz, Im-4-CH2CH2), 2.77 (t, 2H, J = 7.1 Hz, 
Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 171.9 (quart, CO), 133.1 (+, Im-C-2), 131.9 
(quart, Im-C-4), 115.5 (+, Im-C-5), 51.4 (+, OCH3), 31.8 (+, CH2CH2CO), 19.4 (+, 
CH2CH2CO);  EI-MS, m/z (rel. intensity, %): 154 (M+·, 35), 122 ([M-OMe]+, 20), 94 ([M-
CO2Me]+, 100). 
 
N1,N2-Bis(benzyloxycarbonyl)guanidine [22]27 
CH2Cl2 (80 mL) was added to a solution of guanidine hydrochloride (5, 3.82 g, 40 mmol) and 
sodium hydroxide (8.0 g, 0.20 mol) in H2O (40 mL), and the resulting mixture was cooled to 
0 °C. Benzyloxycarbonyl chloride (17.1 mL, 120 mmol) was added dropwise with vigorous 
stirring over a period of 45 min. After the addition was complete, stirring was continued for 
20 h at 0 °C. The mixture was diluted with CH2Cl2 (100 mL), the layers were separated, and 
the aqueous layer was extracted with CH2Cl2 (100 mL). The extracts were combined, washed 
with water, and dried with magnesium sulfate. After filtration and removal of the solvent 
under reduced pressure, the crude product was recrystallized from methanol. Compound 22 
(9.85 g) was obtained as colorless crystals.  
Yield 65  %; C17H17N3O4 (327.3); mp 145-146 °C; IR (neat) 3397, 3228, 2359, 1732, 1652, 
1618, 1542, 1440, 1382, 1275, 1209, 949, 750 cm-1;  1H-NMR (CDCl3), δ (ppm): 10.87 (br s, 
1H, NH); 8.68 (br s, 2H, NH), 7.41-7.27 (m, 10H, Ph-H), 5.11 (s, 4H, OCH2Ph); 13C-NMR 
(CDCl3), δ (ppm): 159.0 (quart, CO), 135.6 (quart, Ph-C-1), 128.5, 128.3, 128.0 (+, Ph-C), 
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67.4 (+, OCH2Ph);  MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), m/z: 328 ([M + H]+), 349 
([M + Na]+). 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-trifluoromethanesulfonylguanidine [23]27  
Sodium hydride (400 mg, 60 % dispersion in oil) was added to a solution of N1,N2-
bis(benzyloxycarbonyl)guanidine (22) (1.65 g, 5.0 mmol) in anhydrous chlorobenzene (50 
mL) at 0 °C under an argon atmosphere. After being stirred for 1 h at 0 °C, the mixture was 
cooled to -45 °C. Triflic anhydride (0.84 mL, 5.0 mmol) was added, and the mixture was 
allowed to warm to room temperature and stir overnight. The solvent was removed under 
reduced pressure, and the residue was dissolved in a mixture of ethyl acetate (100 mL) and 
2M sodium bisulfate (25 mL). The phases were separated, the organic layer was washed with 
H2O, brine and dried over magnesium sulfate. After filtration and removal of the solvent 
under reduced pressure, the crude product was purified by flash column chromatography on 
silica gel (eluent, CH2Cl2/ethyl ether, 95 : 5). Compound 23 (1.58 g, 75  %) was obtained as a 
solid.  
 
Yield: 75  %; C18H16F3N3O6S (459.4); mp 74-75 °C; 1H-NMR (CDCl3), δ (ppm): 10.29 (br, 
2H, NH), 7.37 (s, 10H, Ar-H), 5.24 (s, 2H, Ph-CH2O); 13C-NMR (CDCl3), δ (ppm): 150.9 
(quart, CO), 150.1 (quart, C=NH), 133.6 (quart, Ph-C-1), 129.3, 128.9,128.8 (+, Ph-C), 119.2 
(quart, q, J = 319.9 Hz, CF3), 69.8 (-, OCH2Ph); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc), m/z: 957 ([2M + K]+), 491 ([2M + Na]+), 936 ([2M + NH4]+), 477 ([M + NH4]+), 
460 ([M + H]+). 
 
Methyl 3-(1-trityl-1H-imidazol-4-yl)propanoate [24]26 
To a solution of methyl 3-(1H-imidazol-4-yl)propanoate hydrochloride 11 (9.5 g, 50 mmol) 
in 100 mL of acetonitrile and triethylamine (19.6 mL, 0.14 mol) was added dropwise a 
solution of triphenylmethyl chloride (15.5 g, 55 mmol) in acetonitrile under external cooling 
with ice. The mixture was allowed to warm up at ambient temperature and was stirred for 12 
h. The solvent was evaporated under reduced pressure, and the solid residue was suspended in 
300 mL of water. After stirring for 1 h, the slightly yellow solid was isolated and crystallized 
from dry ethanol (16.1 g).  
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Yield 77 %; colorless crystalline solid; C26H24N2O2 (396.5); mp 131-132 °C;  IR (neat): 3004, 
2359, 1732, 1490, 1444, 1278, 1219, 1121, 748, 701 cm-1; 1H-NMR (DMSO-d6), δ (ppm): 
7.32-7.12 (m, 16H, H of CPh3 & Im-2-H), 6.56 (s, 1H, Im-5-H), 3.61 (s, 3H, OCH3), 2.87 (t, 
2H, J = 7.5 Hz, Im-4-CH2CH2), 2.66 (t, 2H, J = 7.5 Hz, Im-4-CH2CH2); EI-MS, m/z (rel. 
intensity, %): 396 (M +·, 10), 243 ([Ph3C] +, 100). 
 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol [25]26 
To a suspension of LiAlH4 (1.9 g, 50 mmol) in 75 mL of freshly distilled THF and 25 mL of 
dry Et2O was added 24 (10.0 g, 25 mmol) in portions under cooling with ice. The reaction 
mixture was refluxed for 2 h. The excess LiAlH4 was decomposed by dropwise addition of a 
0.1 N NaOH solution. The solution was extracted with CH2Cl2, and the solvent was removed 
in vacuo. The product (7.9 g) was crystallized from Et2O. 
Yield 86  %; colorless crystalline solid; C25H24N2O (368.5); mp 138 °C; IR (neat): 3255, 
2362, 1487, 1443, 1131, 1081, 1069, 995, 748, 700 cm-1;  1H-NMR (CDCl3), δ (ppm): 7.34-
7.10 (m, 16H, Im-2-H and Ph-H), 6.55 (s, 1H, Im-5-H), 3.71 (t, J = 6.0 Hz, 2H, CH2O), 2.67 
(t, J = 7.0 Hz, 2H, Im-4-CH2), 1.85 (m, 2H, CH2CH2O); 13C-NMR (CDCl3), δ (ppm): 142.2 
(quart, Ph-C-1), 140.6 (quart, Im-C-4), 137.9 (+, Im-C-2), 129.7, 129.4, 128.1, 127.8 (+, Ph-
CH), 118.0 (+, Im-C-5), 75.4 (quart, Ph3C), 62.5 (-, CH2OH), 31.9 (-, Im-4-CH2), 25.6 (-, Im-
4-CH2CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), m/z: 369 ([M + H]+, 60), 242 
([Ph3C]+, 100); Anal. (C25H24N2O) C, H, N. 
 
N1,N2-Bis(benzyloxycarbonyl)-N1-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine [26]27 
A solution of the alcohol 25 (1.0 mmol), di-Cbz protected guanidine 22 (3.0 mmol), and PPh3 
(1.25 mmol) in anhydrous THF (20 mL) was cooled to -5 °C under argon atmosphere. DIAD 
(1.2 mmol) was added dropwise at a rate such that the reaction mixture was completely 
colorless before addition of the next drop. After the addition was complete, the reaction 
mixture was heated at reflux for 15-18 h. The solution was then cooled to room temperature, 
and the precipitate of excess 22 that formed was collected by filtration and washed with a 
mixture of THF/hexanes 1 : 1. The filtrate was concentrated in vacuo, and the product was 
isolated by flash column chromatography on silica gel. 
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Yield: 88  %; colorless crystalline solid; C42H39N5O4 (677.8); mp 94-96  °C; IR (neat): 3375, 
2360, 2341, 1715, 1602, 1510, 1446, 1373, 1253, 1217, 1110, 1086, 1000, 749, 700 cm-1; 1H-
NMR (CDCl3), δ (ppm): 7.20-7.48 (m, 11H, Im-2-H & Cbz-Ph), 7.03-7.14 (m, 15H, CH of 
CPh3), 6.57 (s, 1H, Im-5-H), 5.19 (s, 2H, CH2Ph), 5.06 (s, 2H, CH2Ph), 4.02 (t, 2H, J = 7.3 
Hz, Im-CH2CH2CH2), 2.59 (t, 2H, J =7.7 Hz, Im-CH2CH2CH2), 2.04 (s, 2H, NH2), 1.95 (m, 
2H, Im-CH2CH2CH2); 13C-NMR (CDCl3), δ (ppm): 163.9 (quart, CO), 160.7 (quart, CO), 
156.0 (quart, C=N), 142.3 (quart, Ph-C-1), 140.3 (quart, Im-C-4), 137.9 (quart, Ph-C-1), 
137.0 (+, Im-C-2), 134.8 (quart, Ph-C-1), 129.7, 128.7, 128.6, 128.3, 127.8, 127.7, 126.9 (+, 
Ph-CH), 118.0 (+, Im-C-5), 75.4 (quart, Ph3C), 68.8, 66.9 (-, OCH2Ph), 44.5 (-, CH2NH), 
28.1 (-, Im-4-CH2), 25.5 (-, Im-4-CH2CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), 
m/z: 678 ([M + H]+, 100); Anal. (C42H39N5O4) C, H, N. 
 
N-[3-(1-Trityl-1H-imidazol-4-yl)propyl]guanidine [27]  
To a solution of 26 (6.59 g, 9.7 mmol) in 150 mL THF: MeOH (1:1) was added 1.2 g of Pd/C 
(10 %) and then the mixture was stirred under H2 (5 bar) overnight. The mixture was filtered 
through a small pad of celite, washed with MeOH, and the solvent was removed to obtain a 
foam-like solid (3.9 g). 
 
Yield: 98  %; colorless amorphous solid; C26H27N5 (409.5); mp 140-143  °C; IR (neat): 2934, 
1635, 1444, 1296, 1234, 1130, 824, 747, 699, 658, cm-1; 1H-NMR (CDCl3 + CD3OD), δ 
(ppm): 7.67 (s, 1H, Im-2-H), 7.37-7.30 (m, 10H, Ph-H), 7.16-7.06 (m, 5H, Ph-H), 6.56 (s, 
1H, Im-5-H), 3.36 (t, J = 6.8 Hz, 2H, CH2NH), 2.57 (m, 2H, Im-CH2), 1.87 (m, 2H, 
ImCH2CH2); 13C-NMR (CDCl3 + CD3OD), δ (ppm): 161.7 (quart, NH=CNH), 142.2 (quart. 
Ph-C), 140.2 (quart, Im-C-4), 137.9 (+, Im-C-2), 135.0 (+, Ph-C), 129.7 (+, Ph-C), 128.1, 
128.0 (+, Ph-C), 118.3 (+, Im-C-5), 75.2 (quart, Ph3C), 39.9 (-, CH2NH), 29.0 (-, Im-4-
CH2CH2), 27.5 (-, Im-4-CH2CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), m/z: 410 
([M + H]+). 
 
N-Trityl-2-(1-trityl-1H-imidazol-4-yl)ethanamine [29]29 
To a soluton of histamine dihydrochloride (3.7 g, 20 mmol) and Et3N (8.1 g, 80 mmol) in 50 
mL CHCl3 was added dropwise a solution of trityl chloride (14.1 g, 50 mmol) in 50 mL 
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CHCl3 under external cooling with ice. The mixture was allowed to warm up at ambient 
temperature and stirred for 20 h. The solvent was evaporated under reduced pressure, and the 
solid residue was suspended in 100 mL of water. After stirring for 1 h, the product was 
extracted with CHCl3 (2 x 100 mL), dried over anhydrous sodium sulphate and evaporated to 
give crystalline solid (7.4 g).  
 
Yield: 62  %; colorless crystalline solid; C43H37N3 (595.8); mp 202-203 °C; IR (neat): 1489, 
1445, 1238, 1161, 1127, 1083, 1029, 129 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.42-7.30 (m, 
7H, Ph-H & Im-2-H), 7.31-7.08 (m, 24H, Ph-H), 6.50 (s, 1H, Im-5-H), 2.73 (t, J = 6.2 Hz, 
2H, Im-CH2), 2.40 (t, J = 6.3 Hz, 2H, CH2NH2); 13C-NMR (CDCl3), δ (ppm): 146.2 (quart, 
Ph-C-1), 142.4 (quart, Ph-C-1), 139.9 (quart, Im-C-4), 138.2 (+, Im-C-2), 129.6, 128.6, 128.1, 
127.9, 127.6, 126.3 (+, Ph-C), 118.4 (+, Im-C-5), 75.0 (quart, Ph3C), 70.7 (quart, Ph3C), 42.7 
(-, CH2NH2), 29.3 (-,  Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), m/z: 596 
([M + H]+). 
 
2-(1-Trityl-1H-imidazol-4-yl)ethanamine [30]29  
To a solution of 29 (10 g, 0.017 mol) in 47.5 mL CH2Cl2 at 0 °C, 2.5 mL of TFA was added 
drop by drop. After stirring for 10 min at the same temperature, the mixture was allowed to 
come to rt and was stirred for additional 45 min. After removing the solvent, the residue was 
neutralised with saturated sodium bicarbonate solution and then extracted with CHCl3 (4 x 50 
mL), washed with, water, brine and dried over anhydrous sodium sulfate. After removing the 
solvent, the residue was chromatographed with CHCl3/MeOH/TEA (94 : 5 : 1) on silica to 
obtain a hygroscopic solid (C24H23N3).  
Yield: 68  %; yellowish sticky oil; C24H23N3 (353.5); mp 126-128 °C; IR (neat) 1681, 1491, 
1444, 1199, 1128, 1036, 829 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.40 (s, 1H, Im-2-CH), 7.35-
7.28 (m, 9H, Ph-H), 7.18-7.10 (m, 6H, Ph-H), 6.60 (s, 1H, Im-5-CH), 2.97 (t, J = 6.7 Hz, 2H, 
CH2NH2), 2.70 (t, J = 6.7 Hz, 2H, Im-4-CH2), 1.78 (s br., 2H, CH2NH2); 13C-NMR (CDCl3), 
δ (ppm): 142.5 (quart, Ph-C-1), 139.4 (quart, Im-C-4), 138.6 (+, Im-C-2), 129.7 (+, Ph-CH), 
128.0 (+, Ph-CH), 118.6 (+, Im-C-5), 75 (quart, CPh3), 41.8 (-, CH2NH2), 32.3 (-, Im-4-CH2); 
MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), m/z: 354 ([M + H]+), 243 ([Ph3C]+). 
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N1,N2-Bis(benzyloxycarbonyl)-N1-[2-(1-trityl-1H-imidazol-4-yl)ethyl]guanidine [32]27  
The amine 30 (0.35 g, 1.0 mmol) was added to a solution of 23 (0.41 g, 0.9 mmol) and 
triethylamine (0.1 g, 1.0 mmol) in CH2Cl2 (5 mL, filtered over neutral alumina), and the 
mixture was allowed to stir at room temperature until 23 was consumed (3 h) as evidenced by 
TLC. After the reaction was complete, the mixture was diluted with CH2Cl2 (6 mL) and 
washed with 2M sodium bisulfate, saturated sodium bicarbonate, and brine. The organic 
extract was then dried over sodium sulfate and filtered, and the solvent was removed under 
reduced pressure. The crude product was further purified by flash column chromatography 
with CH2Cl2 to afford material suitable for NMR. 
 Yield: 92 %; colorless crystalline solid; C41H37N5O4 (663.8); mp 98 °C; IR (neat): 1729, 
1637, 1569, 1444, 1380, 1320, 1261, 1203, 1132, 1055, 804 cm-1; 1H-NMR (CDCl3), δ 
(ppm): 11.70 (s, 1H, NH), 8.64 (t, J = 5.4 Hz, 1H, NH), 7.43 (s, 1H, Im-2-H), 7.27-7.40 (m, 
19H, Ar-H), 7.10-7.16 (m, 6H, Ar-H), 6.64 (s, 1H, Im-5-H), 5.15 (s, 2H, PhCH2O), 5.10 (s, 
2H, PhCH2O), 3.74 (dd, J1 =  6.3 Hz, J2 = 12.0 Hz, 2H, CH2NH), 2.81 (t, J = 6.4 Hz, Im-4-
CH2); 13C-NMR (CDCl3), δ (ppm): 163.7 (quart, CO), 155.9 (quart, CO), 153.5 (quart, 
C=NH), 142.3 (quart, Ph-C-1), 138.7 (+, Im-C-2), 137.8 (quart, Im-C-4), 136.8 (quart, 
benzyl-C), 134.7 (quart, benzyl-C), 129.8, 128.7, 128.4, 128.1, 128.0, 127.9 (+, Ph-C), 118.8 
(+, Im-C-5), 75.38 (quart, Ph3C), 67.9 (-, PhCH2O), 67.1 (-, PhCH2O), 40.6 (-,CH2NH), 27.6 
(-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), m/z: 664 ([M + H]+), 242 
([Ph3C]+). 
 
[2-(1-Trityl-1H-imidazol-4-yl)ethyl]guanidine [33] 
To a solution of 32 (3.3 g, 5.0 mmol) in 15 mL THF/MeOH (1 : 1) was added 0.5 g of Pd/C 
(10 %) and then the mixture was stirred under H2 (5 bar) overnight. The mixture was filtered 
through celite bed, washed with MeOH, removed solvent to obtain a hygroscopic semisolid. 
 
Yield 96 %, hygroscopic semisolid; C25H15N5 (395.5); IR (neat): 3140, 1646, 1492, 1444, 
1156, 1131, 1085, 1034, 1001, 831 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.51 (s, 1H, NH), 7.56 
(s, 1H, Im-2-H), 7.43-7.01 (m, 15H, Ph-H), 6.86 (s, 1H, Im-5-H), 3.43 (t, J =  7.1 Hz, 2H, 
CH2NH), 3.31 (m, 1H, NH), 2.80 (t, J = 7.1 Hz, Im-4-CH2); 13C-NMR (CDCl3), δ (ppm): 
158.5 (quart, C=NH), 143.3 (quart, Ph-C-1), 139.5 (+, Im-C-2), 137.7 (quart, Im-C-4), 131.0, 
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130.0, 129.1 (+, Ph-C), 121.0 (+, Im-C-5), 77.2 (quart, Ph3C), 42.1 (-, NHCH2), 28.3 (-, Im-4-
CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc), m/z: 791 ([2M + H]+), 396 ([M + H]+), 
242 ([Ph3C]+). 
 
General procedure for synthesis of the ketones 39a-d 
A 250 mL three-necked flask fitted with a magnetic pallet was connected to a sidearm 
dumper that contained of the pertinent benzonitrile (ArCN) (23 mmol), to a pressure 
equalizing addition funnel, and to the Schlenk line by a vacuum adapter. The apparatus was 
purged with N2 for 30 min, and then 23 mmol of the appropriate heteroarylbromide (ArBr) 
and 100 mL of Et2O were added sequentially by syringe to the flask via the addition funnel. 
Then, 14 mL of 1.6 M solution (23 mmol) of nBuLi in hexanes and 20 mL of Et2O were 
transferred to the addition funnel. The flask was cooled to -78 °C, and the nBuLi solution was 
added dropwise to the ethereal ArBr solution. After complete addition, the resulting red 
solution of 2-lithioaryl was stirred for 20 min, and then ArCN was added in several portions 
over 5 min. The reaction mixture was stirred at -78 °C for 1 h, the cold bath was removed, 
and the mixture was allowed to warm to room temperature with stirring over the course of 4 
h. The resulting red-violet slurry was poured into 100 mL of cold (0 °C) 3 M HCl. After the 
mixture had been stirred for 20 min, the organic and aqueous fractions were separated, 3 M 
NaOH was added to the aqueous fraction until the mixture was slightly basic to litmus, and 
the aqueous fraction was extracted with CH2Cl2 (3 X 100 mL) portions of. The combined 
organic fractions were dried over MgSO4 and filtered, and solvent was removed by rotary 
evaporation to leave dark orange oil. The residue was purified by flash column 
chromatography. 
 
Phenyl(pyridin-2-yl)methanone [39a]30  
Synthesized from 2-bromopyridine and benzonitrile. Yield: 77 %; colorless crystalline solid; 
C12H9NO (183.2); mp 42 °C; IR (neat): 1990, 1665, 1579, 1448, 1303, 1281, 1245, 940, 746, 
697, 651 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.73 (m, 1H, Pyr-6-H), 8.05 (m, 3H, Pyr-H & Ph-
H), 7.90 (m, 1H, Pyr-H), 7.59 (m, 1H, Pyr-H), 7.48 (m, 3H, Ph-H); 13C-NMR (CDCl3), δ 
(ppm): 193.9 (quart, CO), 155.0 (quart, Pyr-C-2), 148.6 (+, Pyr-C-6), 137.1 (+, Pyr-C-4), 
136.2 (quart, Ph-C-1), 132.9 (+), 130.9 (+), 128.2 (+, Ph-C), 126.2 (+, Pyr-C-3), 124.6 (+, 
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Pyr-C-5); EI-MS, m/z (rel. intensity, %): 183 (M+·, 63), 182 (73), 156 (12), 155 (86), 154 
(29), 105 ([M – Pyr]+, 100), 78 ([Pyr]+, 18), 77 ([Ph]+, 84), 51 (29); Anal. (C12H9NO) C, H, 
N. 
 
4-Fluorophenyl(pyridin-2-yl)methanone [39b]  
Synthesized from 2-bromopyridine and 4-fluorobenzonitrile. Yield 69 %; colorless crystalline 
solid; C12H8FNO (201.2); mp 68-69 °C; IR (neat): 1651, 1595, 1581, 1567, 1504, 1433, 1411, 
1310, 1288, 1241, 1218, 1153, 1015, 993, 934, 857, 741 cm-1; 1H-NMR (CDCl3), δ (ppm): 
8.73 (m, 1H, Pyr-6-H), 8.21-8.11 (m, 2H, Ar-H), 8.06 (m, 1H, Pyr-H), 7.93 (m, 1H, Pyr-H), 
7.50 (ddd, 1H, J1 = 1.4 Hz, J2 = 4.7 Hz, J3 = 7.7 Hz,  Pyr-H), 7.22-7.12 (m, 2H, Ar-H);  13C-
NMR (CDCl3), δ (ppm): 191.8 (quart, CO), 165.7 (quart, d, J = 255.1 Hz, Ar-CF), 154.6 
(quart, Pyr-C-2), 148.2 (+, Pyr-C-6), 137.4 (+, Pyr-C-4), 133.8 (+, d, J = 9.9 Hz, 2 Ar-C-2,6), 
132.4 (quart, d, J = 3.0 Hz, Ar-C-1), 126.4 (+, Pyr-C-3), 124.7 (+, Py-C-5), 115.4, (+, d, J = 
21.9 Hz, Ar-C); EI-MS, m/z (rel. intensity, %): 201 (M+·, 40), 173 ([M – CO]+, 79), 123 ([M – 
Pyr]+, 100), 95 ([M - Pyr-CO]+, 63), 75 (14), 51 (8); Anal. (C12H8FNO) C, H, N. 
 
 
Phenyl(thiazol-2-yl)methanone [39c]  
Synthesized from 2-bromothiazole and benzonitrile. Yield 86 %; colorless crystalline solid; 
C10H7NOS (189.2); mp 35-37 °C; IR (neat): 3120, 1642, 1596, 1385, 1297, 1121, 761, 612 
cm-1; 1H-NMR (CDCl3), δ (ppm): 8.50-8.45 (m, 2H, Ph-H), 8.10 (d, J = 3.0 Hz, 1H, Thiaz-4-
H), 7.72 (d, J = 3.0 Hz, 1H, Thiaz-5-H), 7.68-7.6 (m, 1H, Ph-H), 7.57-7.49 (m, 2H, Ph-H); 
13C-NMR (CDCl3), δ (ppm): 181.2 (quart, CO), 154.5 (quart, Thiaz-C-2), 145.2 (+, Thiaz-C-
4), 132.3 (quart, Ph-C-1), 131.5 (+) 128.5 (+), 126.7 (+), 125.7 (+, Ph-C), 126.5 (+, Thia-C-
5); EI-MS, m/z (rel. intensity, %): 189 (M+·, 41), 161 ([M – CO]+, 54), 105 ([M – Thiaz]+, 
100), 77 ([M – Thiaz-CO]+, 77), 58 (16), 51 (27); Anal. (C10H7NOS) C, H, N. 
 
3,4-Difluorophenyl(thiazol-2-yl)methanone [39d]  
Synthesized from 2-bromothiazole and 3,4-difluorobenzonitrile. Yield 87 %; colorless 
crystalline solid; C10H5F2NOS (225.2); mp 59-60 °C; IR (neat): 3134, 3077, 1650, 1600, 
1431, 1386, 1290, 1081, 911, 760, 602 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.09 (d, J = 3.0 Hz, 
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1H, Thiaz-4-H), 7.75 (d, J = 3.0 Hz, 1H, Thiaz-5-H), 7.30 (m, 3H, Ar-H), 13C-NMR (CDCl3), 
δ (ppm): 181.0 (quart, CO), 156.3 (quart, Thiaz-C-2), 152.4 (quart, dd, J1 = 12.0 Hz, J2 = 
46.2 Hz, C-F), 149.1 (quart, dd, J1 = 12.0 Hz, J2 = 46.2 Hz, C-F), 144.2 (+, Thiaz-C-4), 135.5 
(quart, Ar-C-1), 124.4 (+, Ar-C-6), 122.4 (+, Thiaz-C-5), 117.5 (+, d,  J = 17.0 Hz, Ar-C-5), 
117.1 (+, d,  J = 17.0 Hz, Ar-C-2); EI-MS, m/z (rel. intensity, %): 225 (M+·, 44), 197 ([M – 
CO]+, 40), 141 ([M – Thiaz]+, 100), 113 ([M – Thiaz-CO]+, 59), 58 (15); Anal. 
(C10H5F2NOS) C, H, N. 
 
General procedure for the synthesis of the ethyl propenoates 40a-d, 44a,b 
To a stirred suspension of sodium hydride (0.74 g, 18.5 mmol as 60 % dispersion in oil) in 20 
mL of dry THF, triethyl phosphonoacetate (3.95 g, 17.4 mmol) under nitrogen atmosphere 
was added at a rate such that the reaction temperature was maintained at 30-35 °C. The 
mixture was stirred at room temperature for 1h and the solution of the pertinent ketone (18 
mmol) in 40 mL of THF was added dropwise over 30 min. The mixture was refluxed for 16-
24 h and poured into ice water, extracted with diethyl ether, washed with water, dried and 
concentrated to give a mixture of E and Z isomeric ethyl esters, as an oil. The residue was 
separated by flash column chromatography. 
 
Ethyl 3-phenyl-3-pyridin-2-ylpropenoate [40a] 
Synthesized from phenyl(pyridin-2-yl)methanone (39a). yield 72 %; colorless oil; C16H15NO2 
(252.3); IR (neat) 2985, 1716, 1622, 1585, 1468, 1446, 1429, 1367, 1269, 1158, 1030, 994, 
876 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.68 (m, 1H, Pyr-6-H), 7.72 (m, 1H, Pyr-4-H), 7.35-
7.25 (m, 7H, 2 Pyr-H and 5 Ph-H), 6.48 (s, 1H, CHCOOEt), 4.05 (q, J = 7.2 Hz, 2H, 
COOCH2CH3), 1.11 (t, J = 7.2 Hz, 3H, COOCH2CH3); 13C-NMR (CDCl3), δ (ppm): 165.8 
(quart, CO), 157.7 (quart, Pyr-C-2), 154.6 (quart, Ar2C=CH), 149.3 (+, Pyr-C-6), 138.9 
(quart, Ph-C-1), 135.8 (+, Pyr-C-4), 129.5 (+, Ph-C), 128.5 (+, Ph-C), 127.9 (+, Ph-C), 124.2 
(+, Pyr-C-5), 122.6 (+, Pyr-C-3), 118.9 (+, Ar2C=CH), 60.2 (-, OCH2CH3), 14.0 (+, 
OCH2CH3); EI-MS, m/z (rel. intensity, %): 254 (10), 253 (65), 252 (M+·, 96), 224 ([M – Et]+, 
90), 208 ([M – OEt]+, 35), 206 (19), 180 ([M – CO2Et]+, 100), 167 ([M – CHCOOEt]+, 9).  
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Ethyl 3-(4-fluorophenyl)-3-pyridin-2-ylpropenoate [40b] 
Synthesized from 4-fluorophenyl(pyridin-2-yl)methanone (39b). yield 75 %; colorless oil; 
C16H14FNO2 (241.3); IR (neat): 2983, 1716, 1600, 1564, 1506, 1469, 1431, 1411, 1367, 1270, 
1227, 1158, 1095, 1033, 994, 836, 813 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.75 (m, 1H, Pyr-6-
H), 7.74 (m, 1H, Pyr-4-H), 7.30 (m, 4H, 2 Pyr-H and 2 Ph-H), 7.01 (m, 2H, 2 Ph-o-H), 6.42 
(s, 1H, CHCOOEt), 4.04 (q, J = 7.2 Hz, 2H, COOCH2CH3), 1.11 (t, J = 7.2 Hz, 3H, 
COOCH2CH3); 13C-NMR (CDCl3), δ (ppm): 165.6 (quart, CO), 165.0 (quart, d, J = 250.6 Hz, 
CF), 157.5 (quart, Pyr-C-2), 153.5 (quart, Ar2C=CH), 149.4 (+, Pyr-C-6), 136.0 (+, Pyr-C-4), 
135.0 (quart, d, J = 3.1 Hz, Ar-C-1), 129.9 (+, d, J = 10.1 Hz, 2C, Ar-C-2,6), 124.2 (+, Pyr-C-
3), 122.7 (+, Pyr-C-5), 118.8 (+, CHCOOEt), 115.6 (+, d, J = 21.0 Hz, 2C, Ar-C-3,5), 60.2 (-, 
COCH2CH3), 14.0 (+, COCH2CH3); EI-MS, m/z (rel. intensity, %): 271 ((M+·, 78), 242 ([M – 
Et]+, 68), 226 ([M – OEt]+, 47), 198 ([M – CO2Et]+, 100), 170 (10), 120 (6), 78 (14), 51 (3). 
 
Ethyl 3-phenyl-3-thiazol-2-ylpropenoate [40c]  
Synthesized from phenyl(thiazol-2-yl)methanone (39c). 12 h refluxed; yield  79 %; colorless 
oil; C14H13NO2S (259.3); IR (neat): 2981, 1716, 1618, 1489, 1446, 1365, 1334, 1264, 1172, 
1096, 1026, 977, 877, 771 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.91 (d, J = 3.0 Hz, 1H, Thiaz-
4-H), 7.47-7.38 (m, 4H, Ph-H), 7.37-7.30 (m, 2H, Ph-H and Thiaz-5-H), 7.10 (s, 1H, 
CH=CO), 4.04 (q, J = 7.1 Hz, 2H, COOCH2), 1.09 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C-NMR 
(CDCl3), δ (ppm): 168.9 (quart, CO), 165.3 (quart, Thiaz-C-2), 146.7 (quart, C=CHCOOEt), 
144.3 (+, Thiaz-C-4), 137.0 (quart, Ph-C-1), 128.9, 128.6, 128.3, 128.1 (+, Ph-C), 122.5 (+, 
C=CHCO), 119.1 (+, Thiaz-C-5), 60.3 (-, OCH2), 13.9 (+, OCH2CH3); EI-MS, m/z (rel. 
intensity, %): 259 (M+·, 45), 230 ([M – Et]+, 70), 214 ([M – OEt]+, 40), 186 ([M – CO2Et]+, 
100), 173 ([M – CHCO2Et]+, 3), 128 (11), 102 (6), 77 (4), 58 (6). 
 
Ethyl 3-(3,4-difluorophenyl)-3-thiazol-2-ylpropenoate [40d]  
Synthesized from 3,4-difluorophenyl(thiazol-2-yl)methanone (39d). 12 h refluxed; yield 68 
%; colorless oil; C14H11F2NO2S (295.3); IR (neat): 2979, 1716, 1601, 1516, 1268, 1230, 
1200, 1163, 1121, 1090, 1029, 871, 819, 776, 729 cm-1;  1H-NMR (CDCl3), δ (ppm): 7.96 (d, 
J = 3.0 Hz, 1H, Thiaz-4-H), 7.56 (d, J = 3.0 Hz, 1H, Thiaz-5-H), 7.26-7.14 (m, 3H, Ar-H), 
6.56 (s, 1H, CH=CO), 4.03 (q, J = 7.2 Hz, 2H, COOCH2), 1.10 (t, J = 7.2 Hz, 3H, 
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OCH2CH3); 13C-NMR (CDCl3), δ (ppm): 164.9 (quart, CO), 163.3 (quart, Thiaz-C-2), 152.4 
(quart, dd, J1 = 12.0 Hz, J2 = 46.2 Hz, C-F), 149.4 (quart, dd, J1 = 12.0 Hz, J2 = 46.2 Hz, C-
F),  144.5 (quart, C=CHCOOEt), 143.2 (+, Thiaz-C-4), 135.5 (quart, Ar-C-1), 124.4 (+, Ar-
C-6), 122.6 (+, C=CHCO), 121.4 (+, Thiaz-C-5), 117.5 (+, d,  J = 17.0 Hz, Ar-C-5), 117.2 (+, 
d,  J = 17.0 Hz, Ar-C-2), 60.8 (-, OCH2), 13.9 (+, OCH2CH3); EI-MS, m/z (rel. intensity, %): 
295 (M+·, 27), 266 ([M – Et]+, 26), 250 ([M – OEt]+, 49), 222 ([M – CO2Et]+, 100), 164 (19), 
151 (12), 138 (20), 111 (8), 87 (8), 73 (13), 58 (37), 43 (16), 28 (47). 
 
(E)-Ethyl 3-pyridin-2-ylbut-2-enoate [44a]  
Synthesized from 1-pyridin-2-ylethanone. Yield 89 %; colorless oil; C11H13NO2 (191.2); IR 
(neat): 2930, 1709, 1633, 1581, 1432, 1341, 1277, 1172, 1093, 1039, 878 cm-1; 1H-NMR 
(CDCl3), δ (ppm): 8.60 (m, 1H, Pyr-6-H), 7.67 (m, 1H, Pyr-4-H), 7.53 (m, 1H, Pyr-3-H), 
7.23 (m, 1H, Pyr-5-H), 6.67 (q, J = 1.3 Hz, CHCO), 4.19 (q, J = 7.1 Hz, OCH2), 2.59 (d, J = 
1.3 Hz, CH3C=CH), 1.28 (t, J = 7.1 Hz, OCH2CH3); 13C-NMR (CDCl3), δ (ppm): 166.9 
(quart, CO), 157.9 (quart, Pyr-C-2), 152.8 (quart, C=CHCO), 149.1 (+, Pyr-C-6), 136.8 (+, 
Pyr-C-4), 123.6 (+, Pyr-C-3), 120.9 (+, CHCO), 119.4 (+, Pyr-C-5), 60.0 (-, OCH2), 16.0 (+, 
CH3C=CH), 14.3 (+, OCH2CH3); EI-MS, m/z (rel. intensity, %): 191 (M+·, 26), 162 ([M - 
Et]+, 18), 146 ([M – OEt]+, 43), 117 (([M – CO2Et]+, 100), 90 (13), 78 (15), 51 (15). 
 
(E)-Ethyl 3-thiophen-2-ylbut-2-enoate [44b] 
Synthesized from 1-thiophenyl-2-ylethanone; yield 83 %; colorless oil; C10H12O2S (196.3); 
IR (neat): 3020, 1703, 1613, 1425, 1366, 1258, 1220, 1154, 1037, 853 cm-1; 1H-NMR 
(CDCl3), δ (ppm): 7.30 (m, 2H, Thio-3-H and -5-H), 7.03 (m, 1H, Thio-4-H), 6.25 (d, J = 1.4 
Hz, CHCOO), 4.19 (q, J = 7.1 Hz, OCH2CH3), 2.60 (d, J = 1.4 Hz, 2H, CH3C=CH), 1.30 (t, J 
= 7.1 Hz, 3H, OCH2CH3); 13C-NMR (CDCl3), δ (ppm): 166.7 (quart, CO), 147.7 (quart, 
C=CH), 145.5 (quart, Thio-C-2), 127.9, 127.1, 126.7 (+, Thio-C-3,4,5), 114.2 (+, CHCOO), 
59.8 (-, OCH2), 17.2 (+, CH3C=CH), 14.3 (+, OCH2CH3); EI-MS, m/z (rel. intensity, %): 196 
(M+·, 53), 151 ([M – OEt]+, 100), 124 ([M – CO2Et]+, 57), 111 ([M – CHCO2Et]+, 15), 97 
(18), 79 (25), 71 (26), 57 (52). 
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General procedure for the synthesis of the ethyl propanoates 41a-d, 45a,b 
The ethyl acrylates were dissolved in THF (100 mL) and 10 % Pd/C (1.00 g) was added, and 
the mixture was stirred at room temperature for 12 h under a hydrogen atmosphere. The 
catalyst was filtered off through Celite pad and the filtrate was concentrated to obtain 
colorless oil. 
 
Ethyl 3-phenyl-3-pyridin-2-ylpropanoate [41a]  
Synthesized from ethyl 3-phenyl-3-pyridin-2-ylpropenoate (40a); yield 96 %; colorless oil; 
C16H17NO2 (255.3); IR (neat): 2981, 1729, 1589, 1568, 1494, 1472, 1432, 1371, 1311, 1246, 
1156,1096, 1021, 996, 962, 847, 805 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.54 (m, 1H, Pyr-6-
H), 7.52 (m, 1H, Pyr-4-H), 7.35- 7.00 (m, 7H, Pyr-3-H, Pyr-5-H and 5 Ph-H), 6.64 (dd, J1 = 
8.8 Hz, J2 = 6.8 Hz, 1H, CHCH2COOEt), 4.03 (ddq, J = 8.7 and 6.8 Hz, 2H, COOCH2CH3), 
3.44 (dd, J1 = 8.7 Hz, J2 = 16.0 Hz, 1H, CH2COOEt ), 2.98 (dd, J1 = 6.8 Hz, J2 = 16.0 Hz, 
1H, CH2COOEt), 1.12 (t, J = 7.1 Hz, 3H, COOCH2CH3); 13C-NMR, (CDCl3), δ (ppm): 172.2 
(quart, CO), 162.0 (quart, Pyr-C-2), 148.9 (+, Pyr-C-6), 142.7 (quart, Ph-C-1), 136.3 (+, Pyr-
C-4), 128.6, 128.4, 127.9, 126.7 (+, Ph-C), 123.3 (+, Pyr-C-5), 121.4 (+, Pyr-C-5), 60.2 (-, 
OCH2CH3), 49.0 (+, Ar2CHCH2), 39.6 (-, CH2CO), 14.0 (+, OCH2CH3); EI-MS, m/z (rel. 
intensity, %): 255 (M+·, 19), 254 (17), 210 ([M – OEt]+, 20), 182 ([M – CO2Et]+, 100), 167 
([M – CH2CO2Et]+, 60).   
 
Ethyl 3-(4-fluorophenyl)-3-pyridin-2-ylpropanoate [41b]  
Synthesized from ethyl 3-(4-fluorophenyl)-3-pyridin-2-ylpropenoate (40b): yield 93 %; 
colorless oil; C16H16FNO2 (273.3); IR (neat): 2938, 1730, 1686, 1590, 1508, 1472, 1433, 
1372, 1307, 1221, 1158, 1098, 1017, 963, 838 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.53 (m, 1H, 
Pyr-6-H), 7.54 (m, 1H, Pyr-4-H), 7.33-7.25 (m, 2H, 2 Ph-o-H), 7.16-7.05 (m, 2H, Pyr-H), 
7.03-6.89 (m, 2H, 2 Ph-m-H), 4.62 (ddq, J = 8.2 and 7.1 Hz, 1H, CHCH2COOEt), 4.02 (q, J 
= 7.1 Hz, 2H, COOCH2CH3), 3.40 (dd, J1 = 8.2 Hz, J2 = 15.9 Hz, 1H, CH2COOEt), 2.96 (dd, 
J1 = 7.1 Hz, J2 = 15.9 Hz, 1H, CH2COOEt), 1.11 (t, J = 7.1 Hz, 3H, COOCH2CH3); 13C-
NMR (CDCl3), δ (ppm): 172.0 (quart, CO), 161.6 (quart, d, J = 245.1 Hz, CF), 161.7 (quart, 
Pyr-C-2), 148.9 (+, Py-C-6), 138.4 (quart, Ar-C-1), 136.6 (+, Pyr-C-4), 129.4 (+, d, J = 9.9 
Hz, 2C, Ar-C-2,6), 123.2 (+, Pyr-C-5(3)), 121.6 (+, Pyr-C-3(5)), 115.3 (+, d, J = 21.1 Hz, 2C, 
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Ar-C-3,5), 60.3 (-, OCH2), 48.1 (+, CHCH2CO), 39.8 (-, CHCH2CO), 14.0 (+, OCH2CH3); 
EI-MS, m/z (rel. intensity, %): 273 (M+·, 19), 228 ([M – OEt]+, 18), 200 ([M – CO2Et]+, 100), 
185 ([M – CH2CO2Et]+, 55), 122 (24), 84 (15), 55 (4). 
 
Ethyl 3-phenyl-3-thiazol-2-ylpropanoate [41c]  
Synthesized from ethyl 3-phenyl-3-thiazol-2-ylpropenoate (40c): Yield 91 %; colorless oil; 
C14H15NO2S (261.1); IR (neat): 1730, 1496, 1454, 1373, 1252, 1186, 1031, 963, 722, 699 cm-
1; 1H-NMR (CDCl3), δ (ppm): 7.71 (d, J = 3.3 Hz, 1H, Thiaz-4-H), 7.50-7.20 (m, 5H, Ph-H), 
7.18 (d, J = 3.3 Hz, 1H, Thiaz-5-H), 4.90 (ddq, J = 7.9 and 7.1 Hz, 1H, CHCH2COOEt), 4.06 
(q, J = 7.1 Hz, 2H, COOCH2CH3), 3.45 (dd, J1 = 7.9 Hz, J2 = 16.1 Hz, 1H, CH2COOEt ), 
2.96 (dd, J1 = 7.5 Hz, J2 = 16.1 Hz, 1H, CH2COOEt), 1.14 (t, J = 7.1 Hz, 3H, COOCH2CH3); 
13C-NMR (CDCl3), δ (ppm): 172.8 (quart, CO), 171.2 (quart, Thiaz-C-2), 142.1 (+, Thiaz-C-
4), 141.2 (quart, Ph-C-1), 128.8, 128.6, 127.9, 127.5 (+, Ph-CH), 119.1 (+, Thiaz-C-5), 60.6 
(-, OCH2), 45.4 (+, CHCH2COOEt), 40.5 (-, CH2COOEt), 14.0 (+, OCH2CH3); EI-MS, m/z 
(rel. intensity, %): 261 (M+·, 45), 216 ([M – OEt]+, 18), 188 ([M – CO2Et]+, 100), 173 ([M – 
CH2CO2Et]+, 28), 130 (2), 103 (7), 77 (6), 58 (6). 
 
Ethyl 3-(3,4-difluorophenyl)-3-thiazol-2-ylpropanoate [41d]  
Synthesized from ethyl 3-(3,4-difluorophenyl)-3-thiazol-2-ylpropenoate (40d), 16 h refluxed; 
yield 88 %; colorless oil; C14H13F2NO2S (297.3); IR (neat): 1730, 1609, 1517, 1434, 1373, 
1278, 1174, 1117, 1016, 818, 777, 725 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.72 (d, J = 3.3 Hz, 
1H, Thiaz-4-H), 7.23 (d, J = 3.3 Hz, 1H, Thiaz-5-H), 7.22-7.04 (m, 3H, Ar-H), 4.85 (ddq, J = 
7.5 and 7.8 Hz, 1H, CHCH2CO), 4.08 (q, J = 7.1 Hz, 2H, COOCH2), 3.41 (dd, J1 = 7.5 Hz, J2 
= 16.3 Hz, 1H, CH2COOEt ), 3.01 (dd, J1 = 7.8 Hz, J2 = 16.3 Hz, 1H, CH2COOEt), 1.17 (t, J 
= 7.1 Hz, 3H, OCH2CH3); 13C-NMR (CDCl3), δ (ppm): 171.3 (quart, CO), 170.8 (quart, 
Thiaz-C-2), 151.6 (quart, dd, J1 = 12.6 Hz, J2 = 249.0 Hz, C-F), 148.3 (quart, dd, J1 = 12.6 
Hz, J2 = 249.0 Hz, C-F), 142.4 (+, Thiaz-C-4), 138.2 (quart, Ar-C-1), 124.0 (+, Ar-C-6), 
119.3 (+, Thiaz-C-5), 117.5 (+, d,  J = 17.0 Hz, Ar-C-5), 117.0 (+, d,  J = 17.0 Hz, Ar-C-2), 
60.8 (-, OCH2), 44.5 (+, CHCH2CO), 40.5 (-,CHCH2CO), 14.0 (+, OCH2CH3); EI-MS, m/z 
(rel. intensity, %): 297 (M+·, 34), 252 ([M – OEt]+, 17), 224 ([M – CO2Et]+, 100), 209 ([M – 
CH2CO2Et]+, 33), 166 (3), 139 (7), 119 (6), 86 (2), 57 (13), 28 (12). 
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Ethyl 3-pyridin-2-ylbutanoate [45a]  
Yield 92 %; colorless oil; C11H15NO2 (193.2);  IR (neat): 2974, 1729, 1592, 1434, 1371, 
1166, 1032 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.58 (m, 1H, Pyr-6-H), 7.67 (m, 1H, Pyr-4-H), 
7.25 (m, 1H, Pyr-3-H), 7.17 (m, 1H, Pyr-5-H), 4.07 (q, J = 7.1 Hz, OCH2), 3.45 (m, 1H, 
CHCH2CO), 2.90 (dd, J1 = 7.9 Hz, J2 = 15.6 Hz, 1H, CH2CO), 2.63 (dd, J1 = 7.1 Hz, J2 = 
15.6 Hz, 1H, CH2CO), 1.36 (d, J = 6.9 Hz, 3H, CH3CHCH2CO), 1.18 (t, J = 7.1 Hz, 3H, 
OCH2CH3); 13C-NMR (CDCl3), δ (ppm): 173.4 (quart, CO), 164.0 (quart, Pyr-C-2), 148.5 (+, 
Pyr-C-6), 137.3 (+, Pyr-C-4), 122.3 (+, Pyr-C-3), 121.7 (+, Pyr-C-5), 64.2 (-, OCH2), 40.8 (-, 
CH2CO), 37.1 (+, CHCH2CO), 20.6 (+, CH3CHCH2), 14.1 (+, OCH2CH3); EI-MS, m/z (rel. 
intensity, %): 193 (M+·, 3), 148 ([M – OEt]+, 25), 120 ([M – CO2Et]+, 100), 106 ([M – 
CH2CO2Et]+, 36), 84 (7), 78 (12), 55 (4), 51 (7). 
 
Ethyl 3-thiophen-2-ylbutanoate [45b] 
Yield 96 %; colorless oil; C10H14O2S (198.3); IR (neat): 2926, 1732, 1616, 1457, 1369, 1345, 
1281, 1159, 1030, 849, 825 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.12 (m, 1H, Thio-5-H), 6.90 
(m, 1H, Thio-3-H), 6.83 (m, 1H, Thio-4-H), 4.11 (ddq, J = 7.1 Hz, OCH2), 3.59 (m, 1H, 
CHCH2CO), 2.68 (dd, J1 = 6.9 Hz, J2 = 15.4 Hz, 1H, CH2CO), 2.54 (dd, J1 = 7.9 Hz, J2 = 
15.4 Hz, 1H, CH2CO), 1.38 (d, J = 6.9 Hz, 3H, CH3CHCH2CO), 1.22 (t, J = 7.1 Hz, 3H, 
COOCH2CH3); 13C-NMR (CDCl3), δ (ppm): 171.9 (quart, CO), 147.8 (quart, Thio-C-2), 
126.5, 122.9, 122.8 (+, Thio-C-3,4,5), 59.8 (-, OCH2), 43.9 (-, CH2CO), 22.6 (-, CH3CHCH2), 
14.1 (+, OCH2CH3); EI-MS, m/z (rel. intensity, %): 198 (M+·, 17), 169 ([M – Et]+, 5), 151 
([M – OEt]+, 23), 124 ([M – CO2Et]+, 56), 111 ([M – CH2CO2Et]+, 100), 97 (15), 84 (16), 71 
(10), 57 (14). 
 
General procedure for the synthesis of the propanoic acids 42a-d, 46a,b 
To a solution of 5.0 mmol of the pertinent ethyl ester in 20 mL of dimethoxyethane, was 
added a solution of 7.5 mmol of LiOH in 5 mL of water, and the mixture was stirred at room 
temperature for 3 h. The pH of the reaction mixture was adjusted with aqueous 1 N HCl to 
6.5, and the solution was extracted twice with 300 mL portions of ethyl acetate. The 
combined extracts were dried with anhydrous MgSO4 and concentrated in vacuo to give the 
desired product as a crystalline solid. 
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3-Phenyl-3-pyridin-2-ylpropanoic acid [42a]  
Synthesized from ethyl 3-phenyl-3-pyridin-2-ylpropanoate (41a): yield 96 %; colorless 
crystalline solid; C14H13NO2 (227.3); mp 105 °C; IR (neat): 2362, 1703, 1593, 1453, 1416, 
1369, 1307, 1264, 1209, 1102, 801, 755 cm-1; 1H-NMR (CDCl3), δ (ppm): 12.98 (br, 1H, 
COOH), 8.53 (m, 1H, Pyr-6-H), 7.61 (m, 1H, Pyr-4-H), 7.35-7.10 (m, 7H, 2 Pyr-H and 5 Ph-
H), 4.64 (ddq, J1 = 5.2 Hz, J2 = 8.2 Hz, 1H, CHCH2COOH), 3.37 (dd, J1 = 8.2 Hz, J2 = 15.9 
Hz, 1H, CH2COOH), 3.06 (dd, J1 = 5.2 Hz, J2 = 15.9 Hz, 1H, CH2COOH); 13C-NMR 
(CDCl3), δ (ppm): 174.9 (quart, CO), 161.8 (quart, Pyr-C-2), 147.7 (+, Pyr-C-6), 141.7 
(quart, Ph-C-1), 137.7 (+, Pyr-C-4), 128.8, 128.4 (+, 2 Ph-C), 128.0, 127.9 (+, 2 Ph-C), 127.0 
(+, Ph-C), 123.8 (+, Pyr-C-5), 122.1 (+, Pyr-C-3), 48.1 (-, CHCH2CO), 40.5 (+, CH2CO); EI-
MS, m/z (rel. intensity, %): 227 (M+·, 27), 226 (28), 182 ([M – CO2H]+, 100), 167 ([M – 
CH2CO2H]+, 62). 
 
3-(4-Fluorophenyl)-3-pyridin-2-ylpropanoic acid [42b]  
Synthesized from ethyl 3-(4-fluorophenyl)-3-pyridin-2-ylpropanoate (41b). yield 97 %; 
colorless crystalline solid; C14H12FNO2 (245.2); mp 127 °C; IR (neat): 2500 (br.), 1702, 1599, 
1508, 1418, 1370, 1265, 1216, 1159, 1104, 1012, 867, 833, 789, 751 cm-1; 1H-NMR (CDCl3), 
δ (ppm): 11.85 (br. 1H, COOH), 8.56 (m, 1H, Pyr-6-H), 7.66 (m, 1H, Pyr-4-H), 7.20 (m, 4H, 
2 Pyr-H and 2 Ph-H), 6.96 (m, 2H, 2 Ph-H), 4.63 (ddq, J1 = 5.5 Hz, J2 = 8.2 Hz, 1H, 
CHCH2COOH), 3.34 (dd, J1 = 8.2 Hz, J2 = 15.9 Hz, 1H, CH2COOH), 3.07 (dd, J1 = 5.5 15.9 
Hz, J2 = 15.9 Hz, 1H, CH2COOH); 13C-NMR (CDCl3), δ (ppm): 174.7 (quart, CO), 162.4 
(quart, d, J = 145.9 Hz, CF), 160.1 (quart, Pyr-C-2), 147.9 (+, Pyr-C-6), 137.9 (+, Pyr-C-4), 
137.4 (quart, Ar-C-1), 129.4 (+, d, J = 8.2.1 Hz, 2C, Ar-o-C), 123.7 (+, Pyr-C-3), 122.3 (+, 
Pyr-C-5), 115.6 (+, d, J = 21.4 Hz, 2C, Ar-m-CH), 47.3 (+, CHCH2CO), 40.5 (+, CH2CO); 
EI-MS, m/z (rel. intensity, %): 245 (M+·, 32), 227 ([M – OH]+, 5), 200 ([M – CO2H]+, 100), 
185 ([M – CH2CO2H]+, 51), 170 (2), 157 (2), 92 (3), 78 (6), 51 (4), 28 (3). 
3-Phenyl-3-thiazol-2-ylpropanoic acid [42c]  
Synthesized from ethyl 3-phenyl-3-thiazol-2-ylpropanoate (41c): Yield: 82 %; colorless 
crystalline solid; C12H11NO2S (233.3); mp 208 °C ; IR (in CH2Cl2) 2963, 1771, 1496, 1261, 
1119 cm-1; 1H-NMR (CDCl3 + CD3OD), δ (ppm): 7.70 (d, J = 3.4 Hz, 1H, Thiaz-4-H), 7.21-
7.43 (m, 6H, Ph-H and Thiaz-5-H), 4.89 (ddq, J = 7.1 and 8.0 Hz, CHCH2CO), 3.45 (dd, J1 = 
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8.0 Hz, J2 = 16.5 Hz, 1H, CH2CO), 3.07 (dd, J1 = 7.1 Hz, J2 = 16.5 Hz, 1H, CH2CO); 13C-
NMR (CDCl3), δ (ppm): 177.7 (quart, CO), 177.4 (quart, Thiaz-C-2), 145.3 (+, Thiaz-C-4), 
144.8 (quart, Ph-C-1), 132.8, 131.7, 131.6 (+, Ph-C), 123.4 (+, Thiaz-C-5), 49.0 (+, 
CHCH2CO), 44.0 (-, CH2CO); EI-MS, m/z (rel. intensity, %): 233 (M+·, 51), 215 ([M – OH]+, 
7), 188 ([M – CO2H]+, 100), 173 ([M – CH2CO2H]+, 40), 147 (2), 130 (4), 115 (3), 103 (12), 
77 (15), 58 (13). 
 
3-(3,4-Difluorophenyl)-3-thiazol-2-ylpropanoic acid [42d]  
Synthesized from ethyl 3-(3,4-difluorophenyl)-3-thiazol-2-ylpropanoate (41d). Yield: 92 %; 
colorless crystalline solid; C12H9F2NO2S (269.3); mp 90 °C; IR (neat) 2471, 1709, 1610, 
1518, 1436, 1361, 1282, 1222, 1119, 917, 730 cm-1;  1H-NMR (CDCl3), δ (ppm): 10.70 (s br, 
1H, COOH), 7.72 (d, J = 3.3 Hz, 1H, Thiaz-4-H), 7.25 (d, J = 3.3 Hz, 1H, Thiaz-5-H), 7.20-
7.02 (m, 3H, Ar-H), 4.84 (t, J = 7.4 Hz, CHCH2CO), 3.44 (dd, J1 = 7.4 Hz, J2 = 16.7 Hz, 1H, 
CH2CO), 3.05 (dd, J1 = 7.4 Hz, J2 = 16.7 Hz, 1H, CH2CO); 13C-NMR (CDCl3), δ (ppm): 
175.3 (quart, CO), 171.8 (quart, Thiaz-C-2), 250.3 (quart, dd, J1 = 12.7 Hz, J2 = 249.5 Hz, C-
F), 249.8 (quart, dd, J1 = 12.7 Hz, J = 255.1 Hz, C-F), 142.1 (+, Thiaz-C-4), 137.7 (quart, Ph-
C-1), 123.9 (+, Ar-C), 119.5 (+, Thiaz-C-5), 117.7 (+, d, J = 17.3 Hz, Ar-C), 117.0 (+, d, J = 
17.8 Hz, Ar-C), 44.1 (-, CH2CO), 40.1 (+, CHCH2CO); EI-MS, m/z (rel. intensity, %): 269 
(M+·, 30), 251 ([M – OH]+, 6), 224 ([M – CO2H]+, 100), 210 ([M – CH2CO2H]+, 24), 191 (3), 
166 (4), 143 (3), 139 (7), 119 (7), 111 (10), 86 (3), 58 (16). 
 
3-Pyridin-2-ylbutanoic acid [46a]  
Yield 91 %; colorless crystalline solid; C9H11NO2 (165.2); IR (neat) 2935, 1721, 1662, 1434, 
1272, 1174, 1007, 943, 834 cm-1; 1H-NMR (CD3OD), δ (ppm): 8.45 (m, 1H, Pyr-6-H), 7.77 
(m, 1H, Pyr-4-H), 7.36 (m, 1H, Pyr-3-H), 7.25 (m, 1H, Pyr-5-H), 3.40 (m, 1H, CH3CHCH2), 
2.80 (dd, J1 = 7.4 Hz, J2 = 15.6 Hz, 1H, CH2CO), 2.63 (dd, J1 = 7.1 Hz, J2 = 15.6 Hz, 1H, 
CH2CO), 1.32 (d, J = 6.9 Hz, 3H, CH3CHCH2CO); 13C-NMR (CDCl3), δ (ppm): 174.1 
(quart, CO), 163.1 (quart, Pyr-C-2), 146.5 (+, Pyr-C-6), 137.2 (+, Pyr-C-4), 121.5 (+, Pyr-C-
3), 121.2 (+, Pyr-C-5), 40.1 (+, CHCH2CO), 36.1 (+, CHCH2CO), 19.4 (+, CHCH3); EI-MS, 
m/z (rel. intensity, %): 165 (M+·, 4), 150 ([M – OH]+, 6), 132 ([M – O2H]+, 12), 120 ([M – 
CO2H]+, 100), 106 ([M – CH2CO2H]+, 62), 93 (9), 78 (21), 65 (3), 51 (13). 
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3-Thiophen-2-ylbutanoic acid [46b] 
Yield 95 %; colorless crystalline solid; C8H10O2S (170.2); IR (neat): 1704, 1533, 1378, 1290, 
1225, 1193, 1164, 849, 825, 692 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.13 (m, 1H, Thio-5-H), 
6.94-6.89 (m, 1H, Thio-4-H), 6.86-6.83 (m, 1H, Thio-3-H), 3.61 (m, 1H, CHCH2CO), 2.76 
(dd, J1 = 6.6 Hz, J2 = 15.7 Hz, 1H, CH2CO), 2.62 (dd, J1 = 8.0 Hz, J2 = 15.7 Hz, 1H, 
CH2CO), 1.43 (d, J = 6.9 Hz, 3H, CH3CHCH2CO), 13C-NMR (CDCl3), δ (ppm): 178.6 
(quart, CO), 149.3 (quart, Thio-C-2), 126.5, 122.9, 122.8 (+, Thio-C-3,4,5), 43.5 (-, CH2CO), 
31.4 (+, CHCH2CO), 22.6 (-, CH3CHCH2); EI-MS, m/z (rel. intensity, %): 170 (M+·, 44), 154 
([M – OH]+, 6), 125 ([M – CO2H]+, 8), 111 ([M – CH2CO2H]+, 100), 84 (6), 77 (9), 66 (7), 45 
(11).  
 
1-Pyridin-2-ylethanol [47a]33 
To an ethereal solution (186 mL) of pyridine-2-carboxaldehyde (2 g, 18.7 mmol) was added 
methylmagnesium bromide in ether (24.27 mmol) at 0 °C. The mixture was stirred for 2 h, 
quenched with ice-water (5 mL), and extracted with EtOAc. The organic phase was washed 
with water, brine and dried over MgSO4. The solvent was removed, and the residue was 
purified by column chromatography on silica gel eluted with EtOAc to obtain a liquid. 
 
Yield 87 %; colorless oil; C7H9NO (123.2), IR (neat) 1594, 1571, 1474, 1435, 1118, 1081, 
1015, 999, 903, 785, 749 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.50 (m, 1H, Pyr-6-H), 7.69 (m, 
1H, Pyr-4-H), 7.33 (m, 1H, Pyr-3-H), 7.18 (m, 1H, Pyr-5-H), 4.90 (quart, J = 6.5 Hz, 1H, 
PyrCH(OH)), 1.50 (d, J = 6.5 Hz, CHCH3); 13C-NMR (CDCl3), δ (ppm): 163.4 (quart, Pyr-C-
2), 148.0 (+, Pyr-C-6), 136.9 (+, Pyr-C-4), 122.2 (+, Pyr-C-3), 119.8 (+, Pyr-C-5), 69.1 (+, 
CHOH), 24.2 (+, CH(CH3)OH); EI-MS, m/z (rel. intensity, %): 123 (M+·, 4), 122 (11), 108 
([M – OH]+, 100), 78 ([Pyr]+, 33), 52 (18), 32 (16). 
 
1-Thiazol-2-ylethanol [47b]34  
A solution of i-PrMgBr (36 mmol) in THF (0.8 M, 18 mL) was added dropwise over 15 min 
to a stirred solution of 2-bromothiazole (4.9 g, 30 mmol) in THF (150 mL) at -40 °C under 
argon. The resulting solution was then stirred for 30 min, and acetaldehyde (3.4 mL, 60 
mmol) was added. The reaction mixture was allowed to warm to rt, brine (20 mL) was added, 
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and the reaction was worked up as usual. The crude residue was purified by column 
chromatography on silica to give the alcohol 47b (3.8 g, 98 %). 
 
Yield: 98 %; colorless oil; C5H7NOS (129.2); IR (neat): 1721, 1504, 1370, 1246, 1193, 1144, 
1106, 1053, 1006, 726 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.58 (d, J = 3.3 Hz, 1H, Thiaz-4-H), 
7.19 (d, , J = 3.3 Hz, 1H, Thiaz-5-H), 5.07 (q, J = 6.5 Hz, 1H, CHOH), 1.53 (d, , J = 6.5 Hz, 
3H, CHCH3); 13C-NMR (CDCl3), δ (ppm): 177.4 (quart, Thiaz-C-2), 141.8 (+, Thiaz-C-4), 
118.8 (+, Thiaz-C-5), 67.6 (+, CHOH), 23.4 (+, CHCH3); EI-MS, m/z (rel. intensity, %): 129 
(M+·, 18), 113 ([M – OH]+, 37), 85 ([Thiaz]+, 100), 58 (35), 43 (50). 
 
General procedure for preparation of the tosylates 48a,b 
To a stirred solution of alcohol 47a or 47b (29 mmol) and DMAP (7.1 g, 58 mmol) in CH2Cl2 
(100 mL) was added MsCl (5.6 mL, 72.5 mmol) at 0 °C. The mixture was stirred for 10 min 
at the same temperature and for an additional time (see below) at rt. An ice water was added 
to the reaction mixture and the mixture was extracted with CH2Cl2. The organic layer was 
washed with water, brine and dried over anhydrous sodium sulfate. After removal of the 
solvent, the residual oil was purified by column chromatography on flash silica gel (elution 
with a mixture of EtOAc and hexane). 
 
1-Pyridin-2-ylethyl methanesulfonate [48a]35 
Stirred for 1 h; Yield: 96 %; colorless oil; C8H11NO3S (201.2); IR (neat): 1624, 1463, 1208, 
1155, 1035, 769 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.52 (m, 1H, Pyr-6-H), 7.69 (m, 1H, Pyr-
4-H), 7.40 (m, 1H, Pyr-3-H), 7.25 (m, 1H, Pyr-5-H), 5.71 (quart, J = 6.6 Hz, 1H, 
PyrCH(OTs)), 2.86 (s, 3H, SO2CH3), 1.68 (d, J = 6.6 Hz, CHCH3); 13C-NMR (CDCl3), δ 
(ppm): 158.1 (quart, Pyr-C-2), 149.4 (+, Pyr-C-6), 137.3 (+, Pyr-C-4), 123.6 (+, Pyr-C-3), 
120.9 (+, Pyr-C-5), 80.6 (+, CHOTs), 38.7 (+, SO2CH3), 21.7 (+, CH(CH3)OTs); CI-MS 
(NH3), m/z (rel. intensity, %): 202 ([M + H]+). 
 
1-Thiazol-2-ylethyl methanesulfonate [48b]  
Stirred for 16 h; Yield: 96 %;  colorless oil; C6H9NO3S2 (207.3); IR (neat): 1498, 1443, 1375, 
1230, 1142, 1042, 955 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.72 (d, J = 3.3 Hz, 1H, Thiaz-4-H), 
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7.34 (d, J = 3.3 Hz, 1H, Thiaz-5-H), 5.36 (q, , J = 6.8 Hz, 1H, CHOTs), 3.66 (s, 3H, 
SO2CH3), 1.96 (d, , J = 6.8 Hz, 3H, CHCH3); 13C-NMR (CDCl3), δ (ppm): 171.7 (quart, 
Thiaz-C-2), 142.4 (+, Thiaz-C-4), 120.3 (+, Thiaz-C-5), 54.0 (+, CHOTs), 52.5 (+, SO2CH3), 
25.5 (+, CHCH3); CI-MS (NH3), m/z (rel. intensity, %): 208 ([M + H]+). 
 
General procedure for preparation of the 2-substituted dimethyl malonates 49a,b  
To a suspension of sodium hydride (72 mg, 3.0 mmol) in THF (6.0 ml) was added the 
dimethyl malonate (3.22 mmol) at 0 °C. After the hydrogen was ceased at room temperature, 
the mixture was added to a solution of 1-pyridin-2ylethyl methanesulfonate (48a) or 1-
thiazol-2ylethyl methanesulfonate (48b) (1.0 mmol) in DMSO (4.0 ml). The reaction mixture 
was warmed to 60 °C and stirred until the reaction was completed (2h). After cooling, EtOAc 
and water were added. The organic phase was separated and the aqueous layer was extracted 
with EtOAc. The combined organic extracts were washed with water, brine and dried over 
MgSO4. After the solvent was removed, the residue was purified by flash column 
chromatography on silica gel (eluent: mixture of EtOAc and hexane) to give the products. 
 
Dimethyl 2-(1-pyridin-2-ylethyl)malonate [49a]36  
Yield 82 %; colorless oil; C12H15NO4 (237.3); IR (neat): 2954, 1736, 1593, 1570, 1435 cm-1; 
1H-NMR (CDCl3), δ (ppm): 8.49 (m, 1H, Pyr-6-H), 7.61 (m, 1H, Pyr-4-H), 7.23 (m, 1H, Pyr-
3-H), 7.11 (m, 1H, Pyr-5-H), 4.17 (d, J = 10.4 Hz, CH(CO2Me)2), 3.77 (s, 3H, COOCH3), 
3.70 (dq, J1 = 7.0 Hz, J2 = 10.4 Hz, 1H, CHCH3), 3.54 (s, 3H, COOCH3), 1.23 (d, J = 7.0 Hz, 
3H, CHCH3); 13C-NMR (CDCl3), δ (ppm): 169.4, 168.9 (quart, CO), 162.6 (quart, Pyr-C-2), 
149.0 (+, Pyr-C-6), 136.5 (+, Pyr-C-4), 122.9 (+, Pyr-C-3), 121.7 (+, Pyr-C-5), 56.6 (+, 
CH(CO2Me)2), 52.5, 52.2 (+, COOCH3), 41.2 (+, CHCH3), 19.2 (+, CH(CH3)); CI-MS 
(NH3), m/z (rel. intensity, %): 238.0 ([M + H]+, 100).  
 
Dimethyl 2-(1-thiazol-2-ylethyl)malonate [49b] 
Yield 87 %; colorless oil; C10H13NO4S (243.3); IR (neat) 1732, 1500, 1434, 1275, 1198, 
1147, 1006 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.59 (d, J = 3.3 Hz, 1H, Thiaz-4-H), 7.16 (d, , J 
= 3.3 Hz, 1H, Thiaz-5-H), 3.98 (d, J = 10.3 Hz, CH(CO2Me)2), 3.93 (dq, J1 = 6.7 Hz, J2 = 
10.3 Hz, 1H, CHCH3), 3.68 (s, 3H, COOCH3), 3.56 (s, 3H, COOCH3), 1.38 (d, J = 6.7 Hz, 
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3H, CHCH3); 13C-NMR (CDCl3), δ (ppm): 172.3 (quart, Thiaz-C-2), 169.0 (quart, 2 CO), 
142.0 (+, Thiaz-C-4), 118.6 (+, Thiaz-C-5), 56.9 (+, CH(CO2Me)2), 52.6, 52.5 (+, COOCH3), 
37.5 (+, CHCH3), 19.3 (+, CH(CH3)); EI-MS, m/z (rel. intensity, %): 243 (M+·, 9), 212 ([M – 
2 x Me]+, 17), 184 ([M – CO2Me]+, 100), 180 ([M – 2 x OMe]+, 21), 152 ([C7H7NOS]+, 97), 
124 ([M – 2 x CO2Me]+, 29), 112 ([M – CH(CO2Me)2]+, 38). 
 
General procedure for preparation of the 3-heteroarylbutanoic acids 50a,b  
A solution of diester 49a or 49b (1 mmol) in MeOH (3 mL) was treated with NaOH (2.2 N, 
1.8 mL) in water, the resulting mixture was heated to reflux, and the reaction was monitored 
by TLC. When no starting material remained (12-18 h), the reaction mixture was allowed to 
come to room temperature. Volatiles were removed in vacuo and the crude dicarboxylic acid 
was taken up in AcOH (6 mL) and heated to reflux. The reaction was monitored by TLC, and 
when no starting material remained (12-18 h), the solution was concentrated in vacuo. The 
resultant crude acid was dissolved in water (5 mL), extracted with EtOAc (3 x 3 mL), and the 
combined extract was dried over MgSO4 and concentrated to give product.  
 
3-Pyridin-2-ylbutanoic acid [50a]  
Refluxed for 15 h each time; yield 87 %; colorless crystalline solid; C9H11NO2 (165.2); IR 
(neat) 2935, 1721, 1662, 1434, 1272, 1174, 1007, 943, 834 cm-1; 1H-NMR (CD3OD), δ 
(ppm): 8.45 (m, 1H, Pyr-6-H), 7.77 (m, 1H, Pyr-4-H), 7.36 (m, 1H, Pyr-3-H), 7.25 (m, 1H, 
Pyr-5-H), 3.40 (m, 1H, CH3CHCH2), 2.80 (dd, J1 = 7.4 Hz, J2 = 15.6 Hz, 1H, CH2CO), 2.63 
(dd, J1 = 7.1 Hz, J2 = 15.6 Hz, 1H, CH2CO), 1.32 (d, J = 6.9 Hz, 3H, CH3CHCH2CO); 13C-
NMR (CDCl3), δ (ppm): 174.1 (quart, CO), 163.1 (quart, Pyr-C-2), 146.5 (+, Pyr-C-6), 137.2 
(+, Pyr-C-4), 121.5 (+, Pyr-C-3), 121.2 (+, Pyr-C-5), 40.1 (+, CHCH2CO), 36.1 (+, 
CHCH2CO), 19.4 (+, CHCH3); EI-MS, m/z (rel. intensity, %): 165 (M+·, 4), 150 ([M – OH]+, 
6), 132 ([M – O2H]+, 12), 120 ([M – CO2H]+, 100), 106 ([M – CH2CO2H]+, 62), 93 (9), 78 
(21), 65 (3), 51 (13). 
 
3-Thiazol-2-ylbutanoic acid [50b]  
Refluxed for 15 h each time; yield 91 %; colorless oil; C7H9NO2S (171.2); IR (neat): 2969, 
1707, 1503, 1366, 1276, 1051, 875 cm-1; 1H-NMR (CDCl3), δ (ppm): 12.42 (s, COOH), 7.71 
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(d, J = 3.3 Hz, 1H, Thiaz-4-H), 7.22 (d, , J = 3.3 Hz, 1H, Thiaz-5-H), 3.75 (m, 1H, 
CHCH2CO2H), 2.90 (dd, J1 = 6.9 Hz, J2 = 16.0 Hz, 1H, CHCH2CO2H), 2.65 (dd, J1 = 7.3 Hz, 
J2 = 16.0 Hz, 1H, CHCH2CO2H), 1.45 (d, J = 7.0 Hz, 3H, CH3CH); 13C-NMR (CDCl3), δ 
(ppm): 176.9 (quart, CO), 176.7 (quart, Thiaz-C-2), 141.7 (+, Thiaz-C-4), 118.2 (+, Thiaz-C-
5), 42.0 (+, CH2COOH), 34.4 (+, CHCH3), 21.1 (+, CHCH3); EI-MS, m/z (rel. intensity, %): 
171 (M+·, 21), 156 ([M – Me]+, 7), 126 ([M – CO2H]+, 100), 112 ([M – CH2CO2H]+, 23), 99 
(2), 86 (4), 58 (15). 
 
(5-Methyl-1H-imidazol-4-ylmethylsulfanyl)acetic acid [52]  
A soluton of (5-methyl-1H-imidazol-4-yl)methanol (4 g, 21.7 mmol) and sulfanylacetic acid 
(1.51 mL, 21.7 mmol) in 50 ml acetic acid was refluxed for 24 h. After removing the solvent 
in vacuo, the residue was neutralised by sodium carbonate. The precipitate was filtered off 
and washed with water, dried and recrystallized.  
Yield: 82 %; colorless crystalline solid; C7H10N2O2S (186.2); mp 170 °C; IR (neat) 1640, 
1543, 1414, 1370, 1253, 1193, 1146, 868, 824 cm-1; 1H-NMR (DMSO-d6), δ (ppm): 14.49 (br 
s, 1H, COOH), 8.93 (s, 1H, Im-2-H), 3.89 (s, 2H, Im-4-CH2S), 3.24 (s, 2H, CH2COOH), 
2.25 (s, 3H, CH3); 13C-NMR (DMSO-d6), δ (ppm): 170.9 (quart, CO), 132.9 (+, Im-C-2 ), 
126.3 (quart, Im-C-4), 124.9 (quart, Im-C-5), 32.7 (-, SCH2COOH), 23.5 (-, Im-4-CH2S), 8.3 
(-, CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 187 ([M + H]+). 
 
General procedure for the synthesis of the propenoic acids 54a-c 
The ketones 53a, 53b or 53c (8.7 mmol) and potassium tert-butoxide (2.25 g, 20 mmol) were 
taken in a 250 mL flask with tert-butanol (100 mL) and triethyl phosphonacetate (1.95 g, 8.7 
mmol) was added. The mixture was refluxed for overnight. After cooling, the solvent was 
removed on a rotatory evaporator. After addition of 100 mL 1N NaOH and 75 mL MeOH the 
mixture was refluxed for 24 h, concentrated in vacuo to remove MeOH, diluted with water 
(300 mL) and extracted with CHCl3 (3 x 75 mL). The aqueous layer was acidified by 
concentrated hydrochloric acid, extracted again with CHCl3, washed with brine and water, 
and dried over anhydrous sodium sulfate. The solvent was removed in vacuo and the 
remaining solid was recrystallized from EtOAc/n-hexane. 
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3,3-Bis(4-fluorophenyl)propenoic acid [54a]  
Synthesized from bis(4-fluorophenyl)methanone (53a); yield 91 %; colorless crystalline 
solid; C15H10F2O2 (260.2); mp 97-98 °C;  IR (neat): 2959, 1688, 1598, 1504, 1418, 1287, 
1208, 1156, 900, 837, 804 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.3-7.15 (m, 4H, Ph-H), 7.1- 
6.99 (m, 4H, Ph-H), 6.52 (s,1H, Ar2CCH); 13C-NMR (CDCl3), δ (ppm): 170.3 (quart, CO), 
163.7 (quart, d, J = 251.2 Hz, C-F), 162.9 (quart, d, J = 248.5 Hz, C-F), 157.0 (quart, 
C=CHCO), 136.8 (quart, d, J = 3.4 Hz, Ar-C-1), 134.0 (quart, d, J = 3.4 Hz, Ar-C-1), 131.1 
(+, d, J = 8.3 Hz, 2C, Ar-C-2,6), 130.4 (+, d, J = 8.3 Hz, 2C, Ar-C-2,6), 116.2 (+, CHCO), 
115.5 (+, d, J = 21.8 Hz, 2C, Ar-C-3,5), 115.1 (+, d, J = 21.8 Hz, 2C, Ar-C-3,5); EI-MS, m/z 
(rel. intensity,  %): 260 (M+·, 100), 259 (43), 243 ([M – OH]+, 20), 214 ([M – CO2H]+, 61), 
201 ([M – CHCO2H]+, 30), 194 (18),165 (11), 123 (18), 107 (18), 28 (54); Anal. 
(C15H10F2O2) C, H, N. 
  
3-(4-Fluorophenyl)-3-phenylpropenoic acid [54b]  
Synthesized from (4-fluorophenyl)phenylmethanone, a mixture of E and Z (53b); yield 85 %; 
colorless crystalline solid; C15H11FO2 (242.2); mp 97-98 °C; IR (neat): 2947, 1689, 1598, 
1505, 1415, 1353, 1269, 1210, 1156, 924, 879, 837, 744 cm-1; 1H-NMR (CDCl3), δ (ppm): 
11.00 (s br, 0.8H, COOH), 7.45-6.95 (m, 9H, Ph-H), 6.28 (s, 1H, CHCOOH); 13C-NMR 
(CDCl3), δ (ppm): 171.1 (quart, CO), 163.6 (quart, d, J = 250.6 Hz, CF), 162.8 (quart, d, J = 
248.2 Hz, CF), 158.2, 157.0 (quart, for 2 CH=CHCOOH), 140.7, 138.2 (quart, 2 Ph-C-1), 
136.9, 134.2 (quart, d each, J = 3.4 Hz, Ar-C-1), 131.2 (+, d, J = 8.3 Hz, Ar-C-2,6)  130.4 (+, 
d, J = 8.3 Hz, Ar-C-2,6), 129.9, 128.6 (+, Ph-C-4), 129.2, 128.5, 128.4, 128.0 (+, Ph-C-
2,6,3,5), 116.6, 116.1 (+, CH=CHCOOH), 115.5 (+, d, J = 21.6 Hz, Ar-C-3,5), 115.1 (+, d, J 
= 8.3 Hz, Ar-C-3,5); EI-MS, m/z (rel. intensity, %): 242 (M+·, 100), 225 ([M – OH]+, 16), 196 
([M – CO2H]+, 53), 183 ([M – CHCO2H]+, 16), 170 (7), 165 (5), 147 (2), 120 (5), 98 (8), 51 
(5), 28 (4); Anal. (C15H11FO2) C, H, N. 
 
3-(3,4-Difluorophenyl)-3-phenylpropenoic acid [54c]  
Synthesized from (3,4-difluorophenyl)phenylmethanone (53c); yield 89 %; colorless 
crystalline solid; C15H10F2O2 (260.2); mp 134-136 °C; IR (neat): 2943, 1692, 1583, 1504, 
1484, 1439, 1277, 1225, 1201, 1157, 1124, 886, 837, 805, 784, 729, 691 cm-1; 1H-NMR ( 
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CDCl3), δ (ppm): 7.40-7.15 (m, 3H, Ph-H), 7.14-6.80 (m, 5H, Ph-H), 6.30 (s, 1H, 
CHCOOH); 13C-NMR (CDCl3), δ (ppm): 170.2 (quart, CO), 163.7 (quart, d, J = 251.4 Hz, 
CF), 162.0 (quart, d, J = 246.5 Hz, CF), 157.4 (quart, C=CH), 140.7 (quart, Ph-C-1), 136.1, 
(quart, d, J = 3.2 Hz, Ar-C-1),  130.3 (+, Ph -C-2,6), 129.7 (+, d, J =- 8.1 Hz, Ar-C-6), 124.9 
(+, Ph-C-4), 116.6 (+, CHCO), 116.1 (+, d, J = 22.3 Hz, Ar-C-5), 115.5 (+, d, J = 21.0 Hz, 
Ar-C-2), 115.8, 115.5 (+, Ph-C-3,5); EI-MS, m/z (rel. intensity, %): 260 (M+·, 100), 243 ([M – 
OH]+, 21), 214 ([M – CO2H]+, 70), 194 (20), 183 (13), 165 (13), 120 (17), 107 (22), 94 (15), 
75 (14), 28 (12); Anal. (C15H10F2O2) C, H, N. 
 
General procedure for the synthesis of the propanoic acids 55a-c 
0.05 g of Pd/C (10 %) was added to solution of the pertinent acrylic acid (54a-c, 8 mmol) in 
methanol (100 mL). The mixture was hydrogenated with constant stirring at 5 bar H2 pressure 
overnight, filtered through celite pad, washed with methanol, and the solvent was removed in 
vacuo. The remaining crude solid was recrystallized from chloroform/n-hexane. 
 
3,3-Bis(4-fluorophenyl)propanoic acid [55a]  
Synthesized from 3,3-bis(4-fluorophenyl)propenoic acid (54a), yield 94 %; colorless 
crystalline solid; C15H12F2O2 (262.3); mp 97-98 °C; IR (neat): 3083, 1698, 1602, 1509, 1410, 
1303, 1265, 1229, 1212, 1159, 1104, 865, 829 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.2-7.1 (m, 
4H, Ph-H), 7.05-6.80 (m, 4H, Ph-H), 4.48 (t, J = 7.9 Hz, 1H, Ar2CH), 3.02 (d, J = 7.9 Hz, 
2H, CH2COOH); 13C-NMR (CDCl3), δ (ppm): 177.4 (quart, CO), 161.5 (quart, d, J = 245.4 
Hz, CF), 138.7 (quart, d, J = 3.2 Hz, Ar-C-1), 129.0 (+, d, J = 8.3 Hz, Ar-C-2,6), 115.5 (+, d, 
J = 8.3 Hz, Ar-C-3,5), 45.1 (+, CHCH2CO), 40.6 (-, CH2CO); EI-MS, m/z (rel. intensity, %): 
262 (M+·, 22), 203 ([M – CH2CO2H]+, 100), 183 (([M – FCH2CO2H]+, 11), 121 (3), 101 (4); 
Anal. (C15H10F2O2) C, H, N. 
 
3-(4-Fluorophenyl)-3-phenylpropanoic acid [55b]  
Synthesized from (4-fluorophenyl)phenylpropenoic acid (54b); yield 96 %; colorless 
crystalline solid; C15H13FO2 (244.3); mp 108-110 °C; IR (neat) 2909, 1701, 1602, 1507, 1411, 
1308, 1266, 1209, 1161, 1102, 1014, 918, 836, 799, 716 cm-1; 1H-NMR (CDCl3), δ (ppm): 
7.3-7.1 (m, 7H, Ph-H), 6.9-7.0 (m, 2H, Ph-H), 4.5 (t, J = 8.0 Hz, 1H, Ar2CH), 3.0 (d, J = 8.0 
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Hz, 2H, CH2COOH );  13C-NMR (CDCl3), δ (ppm): 178.0 (quart, CO), 161.5 (quart, d, J = 
245.0, Hz, CF), 142.9 (quart, Ph-C-1), 138.9 (quart, d, J = 3.0 Hz, Ar-C-1), 129.0 (+, d, J = 
8.0 Hz, 2C, Ar-C-2,6), 128.7 (+, 2C, Ph-C-2,6), 127.5 (+, 2C, Ph-C-2,6), 126.8 (+, Ph-C-4), 
115.3 (+, d, J = 21.3 Hz, 2C, Ar-C-3,5), 45.8 (+, CHCH2CO), 40.5 (-, CH2CO); EI-MS, m/z 
(rel. intensity, %): 244 (M+·, 19), 185 ([M – CH2CO2H]+, 100), 165 ([M – FCH2CO2H]+, 25), 
28 (5);  Anal. (C15H10F2O2) C, H, N. 
 
3-(3,4-Difluorophenyl)-3-phenylpropanoic acid [55c]   
Synthesized from (3,4-difluorophenyl)phenylpropenoic acid (54c); yield 92 %; colorless 
crystalline solid; C15H12F2O2 (262.3); mp 105-106 °C;  IR (neat): 2981, 1697, 1588, 1508, 
1487, 1445, 1408, 1310, 1226, 1209, 837, 790, 715 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.1-7.3 
(m, 3H, Ph-H), 7.0-6.8 (m, 5H, Ph-H), 4.48 (t, J = 7.9 Hz, 1H, Ar2CH), 3.02 (d, J = 7.9 Hz, 
2H, CH2COOH); 13C-NMR (CDCl3), δ (ppm): 177.7 (quart, CO), 162.9 (quart, d,  J = 246.5 
Hz, m-CF), 161.6 (quart, d, J = 245.5 Hz,  p-CF), 145.5 (quart, Ph-C-1), 138.1 (quart, d, J = 
3.3 Hz, Ar-C-1), 130.2, 130.1 (+, Ph-C), 129.1, 129.0 (+, Ph-C-3,5), 123.1 (+, d, J = 3.0 Hz, 
Ar-C-6), 115.7, 115.4 (+, Ph-C-2,6), 114.5 (+, d, J = 21.7 Hz, Ar-C-5), 113.7 (+, d, J = 21.7 
Hz, Ar-C-2), 45.5 (+, CHCH2CO ), 40.3 (-, CH2CO); EI-MS, m/z (rel. intensity, %): 262 (M+·, 
20), 216 (([M – CO2H]+, 11), 203 (([M – CH2CO2H]+, 100), 183 (([M – FCH2CO2H]+, 34), 
101 (12), 75 (5), 28 (81); Anal. (C15H10F2O2) C, H, N. 
 
N1-[-2-(5-Methyl-1H-imidazol-4-ylmethylsulfanyl)acetyl]-N2-[3-(1-trityl-1H-imidazol-4-
yl)propyl]guanidine [61-Tr] 
(1H-Imidazol-4-ylmethylsulfanyl)acetic acid (0.372 g, 2 mmol) and 1,1’-carbonyldiimidazol 
(0.356 g, 2.2 mmol) in 2 mL of DMF were stirred for 4 h at 30 °C. On the other hand, 27 
(0.818 g, 2 mmol) and sodium hydride (160 mg, 60 % dispersion in oil) in 2 ml of DMF were 
stirred for 45 min at 50 °C. After cooling the two solutions were mixed together at rt and 
stirred for 18 h. The DMF was removed under reduced pressure and after addition of water 
(10 mL) the mixture was extracted with CHCl3, washed with saturated sodium bicarbonate, 
and brine. After removing the solvent, residue was purified by a Chromatotron™ using 
CHCl3/MeOH/TEA (90: 8 : 2). Yield 65 % 
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Yield 65 %; colorless foam; C33H35N7OS (577.7); IR (neat): 1660, 1430, 1179, 1124, 831 cm-
1; 1H-NMR (CDCl3), δ (ppm): 7.41 (s, 1H, Im-2-H), 7.33 (m, 10H, Ph-H and Im-2-H), 7.16-
7.05 (m, 6H, Ph-H), 6.57 (s, 1H, Im-5-H), 3.73 (s, 2H, Im-4-CH2S), 3.41 (m, 2H, CH2NH), 
3.12 (s, 2H, CH2CO), 2.58 (m, 2H, Im-4-CH2), 2.17 (s, 3H, CH3), 1.89 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CDCl3), δ (ppm): 181.7 (quart, CO), 162.6 (quart, C=NH), 142.2 
(quart, Ph-C-1), 140.1 (quart, Im-C-4), 138.0 (+, Im-C-2), 133.1 (+, Im-C-2), 129.7 (+, Ph-C), 
127.3 (quart, Im-C-4), 128.0 (quart, Im-C-5), 128.1 (+, Ph-C), 118.3 (+, Im-C-5), 75.3 (quart, 
Ph3C), 40.3 (-, NHCH2), 38.6 (-, SCH2CO), 32.5 (-, Im-4-CH2S), 29.1 (-, Im-4-CH2CH2), 
23.1 (-, Im-4-CH2CH2), 11.8 (-, CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 578 ([M 
+ H]+). 
 
General procedure for the preparation of the N1-acyl-N2-[ω-(1-trityl-1H-imidazol-4-yl)-
alkyl]guanidines [(62 – 81)-Tr]  
Under argon atmosphere, the pertinent carboxyclic acid (1.0 mmol) was added to a solution 
of CDI (0.162 g, 1.0 mmol) in DMF or THF (3 mL), and the mixture was stirred at rt for 1 h. 
At the same time, under argon atmosphere and stirring, sodium hydride (2 mmol, 80 mg of a 
60 % dispersion in oil) was added to a solution of an imidazolylalkylguanidine (1 mmol) in 
DMF or THF (5 mL), and the mixture was heated at 50 °C for 20 min and then allowed to 
cool to rt. The two mixtures were combined and stirred at rt for 2-16 h, then the solution was 
poured on water (10 mL) and extracted with EtOAc. The organic phase was washed with a 
saturated sodium bicarbonate and brine, dried over anhydrous Na2SO4, and evaporated in 
vacuo. The residue was purified by a Chromatotron™ under NH3 atmosphere with 
CHCl3/MeOH as solvent. 
 
N1-(3,3-Diphenylpropanoyl)-N2-[2-(1-trityl-1H-imidazol-4-yl)ethyl]guanidine [62-Tr] 
Usual procedure for coupling, mixture stirred overnight. Purification by Chromatotron™: 
eluent MeOH/CHCl3, 3 : 97, under NH3 atmosphere); yield 62 %; colorless foam; C40H37N5O 
(603.8); IR (neat): 1592, 1492, 1445, 1370, 1129, 1033 cm-1; 1H-NMR (CDCl3), δ (ppm): 
7.36-7.05 (m, 26H, Ph-H and Im-2-H), 6.59 (s, 1H, Im-5-H), 4.65 (t, J = 7.8 Hz, 1H, Ph2CH), 
3.84 (t, J = 6.1 Hz, 2H, CH2NH), 3.05 (d, J = 7.7 Hz, 2H, CH2CO), 2.71 (t, J = 6.0 Hz, 2H, 
Im-4-CH2); 13C-NMR (CDCl3), δ (ppm): 182.8 (quart, CO), 160.8 (quart, C=NH), 144.8, 
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142.1 (quart, Ph-C-1), 138.8 (+, Im-C-2), 137.5 (quart, Im-C-4), 129.6, 129.4, 128.5, 128.3, 
128.1, 127.8, 127.6, 126.2, 125.9 (+, Ph-C), 119.5 (+, Im-C-5), 75.3 (quart, Ph3C), 47.1 (+, 
CHCH2CO), 46.1 (-, COCH2), 40.5 (-, CH2NH2), 28.5 (-, Im-4-CH2); MS (ESI, 
CH2Cl2/MeOH + 10 mM NH4OAc): 604 ([M + H]+), 1207 ([2M + H]+). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine [63-Tr]  
Yield: 55 %; colorless foam-like solid; C41H39N5O (617.8); IR (neat): 3029, 1588, 1492, 
1445, 1375, 1275, 1130, 748 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.45-7.05 (m, 26 H, Ph-H and 
Im-2-H), 6.54 (s, 1H, Im-5-H), 4.65 (t, J = 7.8 Hz, 1H, Ph2CH), 3.30 (t, J = 6.7 Hz, 2H, 
CH2NH), 3.06 (d, J = 7.7 Hz, 2H, COCH2), 2.53 (m, 2H, Im-4-CH2), 1.82 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CDCl3), δ (ppm): 178.0 (quart, CO), 145.1, 142.3 (quart, Ph-C-1), 
140.3 (quart, Im-C-4), 138.0 (+, Im-C-2), 129.7, 128.3, 128.1, 128.0, 125.9 (+, Ph-C), 118.3 
(+, Im-C-5), 75.3 (quart, Ph3C), 47.3 (+, Ph2CH), 46.3 (-, CH2CO), 40.1 (-, CH2NH), 29.1 (-, 
Im-4-CH2CH2), 23.5 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 618 ([M + 
H]+), 1235 ([2M + H]+). 
 
N1-(2,2-Diphenylacetyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine [64-Tr]  
Yield 55 %; colorless foam-like solid; C40H37N5O (603.8); IR (neat): 3055, 1736, 1690, 1590, 
1492, 1442, 1370, 1127, 832, 759, 746, 728 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.39-7.01 (m, 
26H, Ph-H and Im-2-H), 6.54 (s, 1H, Im-5-H), 4.98 (s, 1H, Ph2CH), 3.24 (t, J = 6.7 Hz, 2H, 
CH2NH), 2.54 (t, J = 6.0 Hz, 2H, Im-4-CH2), 1.81 (m, 2H, Im-4-CH2CH2); 13C-NMR 
(CDCl3), δ (ppm): 184.3 (quart, CO), 162.8 (quart, C=NH), 142.3, 141.6 (quart, Ph-C), 140.4 
(quart, Im-C-4), 138.0 (+, Im-C-2), 129.7, 129.0, 128.1, 126.2 (+, Ph-C), 118.2 (+, Im-C-5), 
75.2 (quart, Ph3C), 62.34 (+, Ph2CH), 40.2 (-, CH2NH), 29.1 (-, Im-4-CH2CH2), 23.5 (-, Im-4-
CH2);; MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 604 ([M + H]+), 1207 ([2M + H]+). 
 
N1-[3,3-Bis(4-fluorophenyl)propanoyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine [65-Tr]  
Yield 61 %; colorless foam-like solid; C41H37F2N5O (653.8);  IR (neat): 1690, 1601, 1505, 
1444, 1221, 1157, 1130, 826, 747, 700 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.40-6.80 (m, 24H, 
Ar-H and Im-2-H), 6.58 (s, 1H, Im-5-H), 4.68 (t, J = 8.0 Hz, 1H, Ar2CH), 3.50 (m, 2H, 
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CH2NH), 3.22 (d, J = 8.0 Hz, 2H, COCH2), 2.50 (m, 2H, Im-4-CH2), 1.85 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CDCl3), δ (ppm): 172.9 (quart, CO), 161.6 (quart, d, J = 245.2 Hz, CF), 
155.7 (quart, C=NH), 142.1 (quart, Ph-C-1), 140.2 (quart, Im-C-4), 138.3 (quart, d, J = 3.0 
Hz, Ar-C-1),  137.6 (+, Im-C-2), 129.7 (+, Ph-C), 129.2 (+, d, J = 8.0 Hz, Ar-C-2,6) 128.3, 
128.2, 128.0 (+, Ph-C), 118.6 (+, Im-C-5), 115.6 (+, d, J = 21.3 Hz, Ar-C-3,5), 75.6 (quart, 
Ph3C), 45.0 (+, Ar2CH), 43.3 (-, COCH2), 40.1 (-, NHCH2), 28.4 (-, Im-4-CH2CH2), 22.1 (-, 
Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 654 ([M + H]+). 
 
N1-[3-(4-Fluorophenyl)-3-phenylpropanoyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine [66-Tr] 
Yield 53 %; colorless foam like solid; C41H38FN5O (635.8); IR (neat) 3061, 1589, 1488, 
1442, 1400, 1365, 1230, 1134, 977, 952, 834, 803, 745  cm-1; 1H-NMR (CDCl3), δ (ppm): 
7.42-6.73 (m, 25H, Ar-H and Im-2-H), 6.54 (s, 1H, Im-5-H), 4.62 (t, J = 7.8 Hz, 1H, Ar2CH), 
3.33 (t, J = 6.7 Hz, 2H, CH2NH), 3.00 (d, J = 7.8 Hz, 2H, CH2CO), 2.53 (m, 2H, Im-4-CH2), 
1.82 (m, 2H, Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 178.0 (quart, CO), 161.7 (quart, 
C=NH), 161.1 (quart, d, J = 245.2 Hz, CF), 142.3, 140.2 (quart, 2C, Ph-C-1), 138.5 (quart, d, 
J = 3.3, Ar-C-1), 138.3 (quart, Im-C-4), 137.9 (+, Im-C-2), 129.7 (+, Ph-C), 129.2 (+, d, J = 
8.0 Hz, 2C, Ar-C-2,6), 128.1 (+, Ph-C), 128.0 (+, Ar-C), 126.0, 123.4 (+, Ph-C), 118.2 (+, 
Im-C-5), 115.2 (+, d, J = 21.0 Hz, 2C, Ar-C-3,5), 75.4 (quart, Ph3C), 46.3 (+, Ph2CH), 46.3 (-
, COCH2), 40.0 (-, NHCH2), 28.1 (-, Im-4-CH2CH2), 23.5 (-, Im-4-CH2); MS (ESI, 
CH2Cl2/MeOH + 10 mM NH4OAc): 636 ([M + H]+), 1273 ([2M + H]+). 
 
N1-[3-(3,4-Difluorophenyl)-3-phenylpropanoyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)-
propyl]guanidine [67-Tr] 
Yield 55 %; colorless foam-like solid; C41H37F2N5O (653.8); IR (neat) 3060, 1586, 1490, 
1444, 1401, 1360, 1310, 1230, 1134, 1011, 977, 952, 905, 834, 803, 745  cm-1; 1H-NMR 
(CDCl3), δ (ppm): 7.40-6.76 (m, 24H, Ar-H and Im-2-H), 6.55 (s, 1H, Im-5-H), 4.63 (t, J = 
7.7 Hz, 1H, Ar2CH), 3.34 (t, J = 6.7 Hz, 2H, CH2NH), 3.01 (d, J = 7.9 Hz, 2H, COCH2), 2.54 
(m, 2H, Im-CH2), 1.84 (m, 2H, Im-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 178.0 (quart, CO), 
162.9 (quart, d, J = 246.6 Hz, 3-CF), 161.6 (quart, d, J = 245.8 Hz, 4-CF), 161.7 (quart, 
C=NH), 142.3 (quart, Ph-C-1), 140.2 (quart, Ph-C-1), 140.1 (quart, d, J = 3.3 Hz, Ar-C-1), 
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138.9 (quart, Im-C-4), 137.9 (+, Im-C-2), 129.8, 129.7 (+, 2C, Ph-C), 129.3, 129.2 (+, 2C, 
Ph-C-3,5), 123.4 (+, d, J = 3.3 Hz, Ar-C-6), 118.3 (+, Im-C-5), 115.3, 115.0 (+, 2C, Ph-C-
2,6), 114.8 (+, d, J = 21.3 Hz, Ar-C-5), 113.0 (+, d, J = 21.1 Hz, Ar-C-2), 75.3 (quart, Ph3C), 
46.3 (+, Ar2CHCO), 45.9 (-, COCH2), 40.1 (-, NHCH2), 29.2 (-,  Im-4-CH2CH2), 22.7 (-, Im-
4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 654 ([M + H]+). 
 
N1-(3-Phenyl-3-pyridin-2-ylpropanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine [70-Tr] 
Yield 50 %; colorless foam-like solid; C40H38N6O (618.8); IR (neat) 1732, 1651, 1568, 1492, 
1472, 1186, 1156, 1035, 870 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.52 (m, 1H, Pyr-6-H ), 7.56-
7.49 (m, 1H, Pyr-4-H), 7.40-7.00 (m, 23H, Pyr-3-H, -5-H, Im-2-H and 20 Ph-H), 6.56 (s, 1H, 
Im-5-H), 4.80 (ddq, J = 8.5 and 6.7 Hz, 1H, Ar2CH), 3.60 (dd, J1 = 8.5 Hz, J2 = 15.7 Hz, 1H, 
CH2CO), 3.45 (t, J = 6.8 Hz, 2H, NHCH2), 3.16 (dd, J1 = 6.7 Hz, J2 = 15.7 Hz, 1H, CH2CO), 
2.53 (m, 2H, Im-4-CH2), 1.86 (m, 2H, Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 175.1 
(quart, CO), 163.6 (quart, Py-C-2), 155.1 (quart, C=NH), 149.0 (+, Pyr-C-6), 143.8, 142.3 
(quart, Ph-C-1), 140.3 (quart, Im-C-4), 138.0 (+, Im-C-2), 136.3 (+, Pyr-C-4), 129.7, 128.4, 
128.1, 128.0, 126.2 (+, Ph-C), 122.9 (+, Pyr-C-3), 121.0 (+, Pyr-C-5), 118.3 (+, Im-C-5), 75.2 
(quart, Ph3C), 49.6 (+, COCH2CH), 45.3 (-, COCH2CH), 40.0 (-, NHCH2), 28.9 (-, Im-4-
CH2CH2), 23.1 (-, Im-4-CH2CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 619 ([M + 
H]+), 1237 ([2M - H]+). 
 
N1-[3-(4-Fluorophenyl)-3-pyridin-2-ylpropanoyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)-
propyl]guanidine [71-Tr] 
Yield 49 %; C40H37FN6O (636.8); IR (in CH2Cl2) 2993, 1590, 1507, 1445, 1376, 1269, 1157, 
1131, 701 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.50 (dm, 1H, Pyr-6-H ), 7.56 (dt, J1 = 1.8 Hz, J2 
= 7.7 Hz,1H, Pyr-4-H), 7.41-6.85 (m, 22H, Pyr-3-, -5-H, Im-2-H and 19 Ph-H), 6.54 (s, 1H, 
Im-5-H), 4.73 (dd, J = 7.2 and 7.8 Hz, 1H, Ar2CH), 3.30 (m, 3H, one H of CH2CO and 
CH2NH2), 2.97 (dd, J1 = 7.2 Hz, J2 = 15.6 Hz, 1H, one H of CH2CO), 2.54 (m, 2H, Im-4-
CH2), 1.84 (m, 2H, Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 182.9 (quart, CO), 163.5 
(quart, Py-C-2), 161.3 (quart, d, J = 143.9 Hz,   CF), 161.4 (quart, C=NH), 149.2 (+, Pyr-C-
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6), 142.3 (quart, Ph-C-1), 140.2 (quart, Ph-C-1), 139.5 (quart, Im-C-4), 138.0 (+, Im-C-2), 
136.3 (+, Pyr-C-4), 131.1  (+, d, J = 8.2 Hz, 2C, Ar-C-2/-6), 129.7, 129.6, 129.5, 128.1 (+, 
Ph-C),  122.9 (+, Pyr-C-3), 121.0 (+, Pyr-C-5), 118.3 (+, Im-C-5), 115.2 (+, d, J = 21.1 Hz, 
2C, Ar-C-3/-C-5), 75.2 (quart, Ph3C), 48.9 (+, COCH2CH), 45.5 (-, COCH2CH), 40.1 (-, 
NHCH2), 29.1 (-, Im-4-CH2CH2), 23.3 (-, Im-4-CH2CH2); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc): 637 ([M + H]+). 
 
N1-(3-Phenyl-3-thiazol-2-ylpropanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine [72-Tr] 
 
Yield 46 %; colorless foam-like solid; C38H36N6OS (624.8); IR (in CH2Cl2): 1597, 1493, 
1445, 1392, 1265, 1235, 1130, 1036, 732, 698 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.67 (d, J = 
3.4 Hz, 1H, Thiaz-4-H), 7.40-6.98 (m, 22H, Ph-H, Thia-5-H, Im-2-H), 6.55 (s, 1H, Im-5-H), 
4.99 (ddq, J = 7.7 Hz, 1H, CHCH2CO), 3.51 (dd, J1 = 7.7 Hz, J2 = 15.9 Hz, 1H, one H of 
CH2CO), 3.40 (t, 2H, NHCH2), 2.98 (dd, J1 = 7.7 Hz, J2 = 15.9 Hz, 1H, one H of CH2CO), 
2.54 (m, 2H, Im-4-CH2), 1.84 (m, 2H, Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 180.2 
(quart, CO), 173.9 (quart, Thiaz-C-2), 160.3 (quart, C=NH), 142.2 (+, Thia-C-4), 142.1 
(quart, Ph-C-1), 140.0 (quart, Im-C-4), 138.0 (+, Im-C-2), 129.7, 128.6, 128.0 (+, Ph-C), 
118.5 (+, Thia-C-5), 118.3 (+, Im-C-5), 75.3 (quart, Ph3C), 45.7 (+, Ar2CH), 45.5 (-, 
CH2CO), 40.1 (-, CH2NH), 28.9 (-, Im-4-CH2CH2), 23.1 (-, Im-4-CH2); MS (ESI, 
CH2Cl2/MeOH + 10 mM NH4OAc): 625 ([M + H]+). 
 
N1-[3-(3,4-Difluorophenyl)-3-thiazol-2-ylpropanoyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)-
propyl]guanidine [73-Tr]   
 
Yield 52 %; colorless foam-like solid;  C38H34F2N6OS (660.8); IR (neat) 1592, 1515, 1493, 
1443, 1378, 1130, 700 659 cm-1;  1H-NMR (CDCl3), δ (ppm): 7.95 (s br, H, NH), 7.64 (d, J = 
3.3 Hz, 1H, Thiaz-4-H), 7.40-6.98 (m, 20H, Ph-H, Thiaz-5-H, Im-2-H), 6.55 (s, 1H, Im-5-
H), 4.96 (m, 1H, CHCH2CO), 3.32 (m, 3H, CH2NH and one H of COCH2), 2.98 (dd, J1 = 7.7 
Hz, J2 = 15.9 Hz, 1H, one H of CH2CO), 2.54 (m, 2H, Im-4-CH2), 1.84 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CDCl3), δ (ppm): 181.7 (quart, CO), 173.2 (quart, Thiaz-C-2), 162.1 
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(quart, C=NH), 150.0 (quart, dd, J1 = 12.4 Hz, J2 = 247.6 Hz, CF), 149.2 (quart, dd, J1 = 12.0 
Hz, J2 = 247.6 Hz, CF), 142.4 (+, Thiaz-C-4), 142.3 (quart, Ph-C-1), 140.2 (quart, Im-C-4), 
139.4 (quart, Ar-C-1), 138.0 (+, Im-C-2), 129.7, 128.0 (+, Ph-C), 124.0 (+, Ar-C-6), 118.7 (+, 
Thia-C-5), 118.6 (+, Im-C-5), 118.4 (+, d, J = 17.0 Hz, Ar-C-5), 117.1 (+, dd, J1 = 3.4 Hz, J2 
= 17.0 Hz, Ar-C-2), 75.2 (quart, Ph3C), 46.3 (-, CH2CO), 45.2 (+, Ar2CH), 40.1 (-, CH2NH), 
29.1 (-, Im-4-CH2CH2), 23.3 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 
242 ([M-CPh3]+), 661 ([M + H]+), 1321 ([2M + H]+), 1343 ([2M + Na]+). 
 
N1-[3-(1-Benzyl-1H-imidazol-2-yl)-3-(3,4-difluorophenyl)propanoyl]-N2-[3-(1-trityl-1H-
imidazol-4-yl)propyl]guanidine [74-Tr]  
Yield 55 %; colorless foam-like solid; C45H41F2N7O (733.9); IR (in CH2Cl2): 1667, 1519, 
1496, 1444, 1266, 1182, 1128, 700, 665 cm-1; 1H-NMR (CD3OD), δ (ppm): 10.53 (s, 1H), 
9.03 (s, 1H), 8.08 (s, 1H), 7.51-6.96 (m, 24H, Im-H, Ph-H), 5.30 (m, 2H, PhCH2), 4.80 (m, 
1H, CHCH2CO), 3.78 (dd, J1 = 10.6 Hz, J2 = 16.8 Hz, 1H, one H of COCH2), 3.36 (m, 2H, 
CH2NH), 3.23 (dd, J1 = 5.2 Hz, J2 = 16.8 Hz, 1H, one H of COCH2), 2.83 (t, J = 7.3 Hz, 2H, 
Im-4-CH2), 2.00 (m, 2H, Im-4-CH2CH2); 13C-NMR (CD3OD), δ (ppm): 173.0 (quart, CO), 
154.1 (quart, C=NH), 150.3 (quart, dd, J1 = 12.3 Hz, J2 = 247.6 Hz, CF), 150.0 (quart, dd, J1 
= 12.1 Hz, J2 = 247.6 Hz, CF) 146.6 (quart, Benzyl-Im-C-2), 139.7 (quart, Ph-C-1), 135.0 (+, 
Im-C-2), 134.5 (quart, Im-C-4), 133.1 (quart, Ph-C-1), 132.9 (quart, Ar-C-1), 129.4, 129.3, 
129.0, 128.9, 127.3, 127.2 (+, Ph-C), 124.1 (+, Ar-C-6), 121.8 (+, Benzyl-Im-C-4), 120.3 (+, 
Benzyl-Im-C-5), 118.5 (+, Im-C-5) ), 118.2 (+, d, J = 17.6 Hz, Ar-C-5), 117.1 (+, d, J = 17.9 
Hz, Ar-C-2), 78.6 (quart, Ph3C), 51.2 (-, PhCH2), 40.4 (-, COCH2), 41.0 (-, NHCH2), 37.3 (+, 
COCH2CH), 28.0 (-, Im-4-CH2CH2), 21.9 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc): 734 ([M + H]+). 
 
N1-(3-Thiophen-2-ylbutanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine [79-Tr]  
Yield 47 %; colorless foam-like solid; C34H35N5OS (561.7); IR (neat): 1652, 1490, 1442, 
1325, 1233, 1178, 1131, 1033, 994, 840 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.41-7.29 (m, 
10H, Ph-H), 7.52-7.05 (m, 7H, Ph-H, Im-2-H and Thio-5-H), 6.91-6.83 (m, 2H, Thio-H) 
6.57 (s, 1H, Im-5-H), 3.67 (m, 1H, COCH2CH), 3.58 (m, 2H, NHCH2), 2.79 (dd, J1 = 6.6 Hz, 
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J2 = 15.1 Hz, 1H, one H of CH2CO ), 2.61 (dd, J1 = 8.1 Hz, J2 = 15.1 Hz, 1H, one H of 
CH2CO), 2.58 (m, 2H, Im-4-CH2), 2.00 (m, 2H, Im-4-CH2CH2), 1.36 (d, J = 7.0 Hz, 3H, 
CH3); 13C-NMR (CD3OD), δ (ppm): 180.3 (quart, CO), 159.6 (quart, C=NH), 150.6 (quart, 
Thio-C-2), 142.5 (quart, Ph-C-1), 139.9 (quart, Im-C-4), 137.9 (+, Im-C-2), 129.7, 129.4, 
128.2, 128.0, 127.9 (+, Ph-C), 127.5 (+, Thio-C-5), 122.7, 122.6 (+, Thio-C-3,4), 118.4 (+, 
Im-C-5), 69.9 (quart, Ph3C), 48.6 (-, CHCH2CO), 40.1 (-, CH2NH), 32.0 (+, CHCH2CO), 
28.9 (-, Im-4-CH2CH2), 22.8 (+, CH3), 22.0 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 
mM NH4OAc): 562 ([M + H]+). 
 
N1-(3-Pyridin-2-ylbutanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine [80-Tr] 
Yield 52 %; colorless foam-like solid; C35H36N6O (556.7); IR (neat): 1655, 1445, 1287, 1236, 
1155, 1131, 1063, 700 cm-1; 1H-NMR (CDCl3), δ (ppm): 8.57 (m, 1H, Pyr-6-H), 7.52 (m, 1H, 
Pyr-4-H), 7.63-7.00 (m, 18H, Pyr-3-H, -5-H, Im-2-H and Ph-H), 6.55 (s, 1H, Im-H-5), 3.62 
(m, 1H, CHCH2CO), 3.45 (m, 2H, CH2NH), 3.00 (dd, J1 = 8.3 Hz, J2 = 16.6 Hz, 1H, one H of 
CH2CO), 2.90 (dd, J1 = 6.2 Hz, J2 = 16.6 Hz, 1H, one H of CH2CO), 2.83 (t, J = 7.6 Hz, 2H, 
Im-4-CH2), 2.01  (m, 2H, Im-4-CH2CH2), 1.41 (d, J = 7.0 Hz, 3H, CH3CH); 13C-NMR 
(CDCl3), δ (ppm): 175.4 (quart, CO), 163.3 (quart, Py-C-2), 155.2 (quart, C=NH), 149.7 (+, 
Pyr-C-6), 142.1 (quart, Ph-C-1), 134.5 (+, Im-2-CH), 138.3 (quart, Im-C-4), 129.8, 129.7, 
128.2, 128.0 (+, Ph-C), 125.4 (+, Pyr-C-3), 124.8 (+, Pyr-C-5), 117.3 (+, Im-C-5), 75.4 
(quart, Ph3C), 43.3 (-, COCH2CH), 41.1 (-, CH2NH), 37.5 (+, COCH2CH), 27.6 (-, Im-4-
CH2CH2), 22.6 (-, Im-4-CH2), 20.9 (+, CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 
m/z  557 ([M + H]+). 
 
N1-(3-Thiazol-2-ylbutanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine [81-Tr] 
Yield 55 %; colorless foam-like solid;  C33H34N6OS (562.7); IR (in CH2Cl2): 1692, 1493, 
1445, 1265, 1130, 731, 699 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.65 (d, J = 3.3 Hz, 1H, Thiaz-
4-H), 7.41-7.05 (m, 17H, Ph-H, Thiaz-5-H and Im-2-H), 6.58 (s, 1H, Im-5-H), 3.85 (m, 1H, 
CHCH2CO), 3.51 (t, J = 6.5 Hz, 2H, NHCH2), 3.11 (dd, J1 = 7.3 Hz, J2 = 16.0 Hz, 1H, one H 
of COCH2), 2.81 (dd, J1 = 6.9 Hz, J2 = 16.0 Hz, 1H, one H of COCH2), 2.57 (m, 2H, Im-4-
CH2), 1.89 (m, 2H, Im-4-CH2CH2), 1.46 (d, J = 7.0 Hz, 3H, CH3); 13C-NMR (CDCl3), δ 
(ppm): 175.1 (quart, Thiaz-C-2), 174.6 (quart, CO), 155.2 (quart, C=NH), 142.2 (+, Thiaz-C-
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4), 142.1 (quart, Ph-C-1), 139.5 (quart, Im-C-4), 137.8 (+, Im-C-2), 129.8, 129.7, 128.2, 
128.0 (+, Ph-C), 118.5 (+, Thiaz-C-5), 118.0 (+, Im-C-5), 75.5 (quart, Ph3C), 45.0 (-, 
CHCH2CO), 40.3 (-, CH2NH), 34.4 (+, CHCH2CO), 28.7 (-, Im-4-CH2CH2), 22.4 (-, Im-4-
CH2), 21.1 (+, CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 563 ([M + H]+). 
 
General procedure for deprotection of trityl group 
The trityl protected acylguanidines (1 mmol) were dissolved in dry CH2Cl2 (8 mL), added 2 
mL of TFA drop by drop with constant stirring for 15 min at rt, and continued to stirred till 
the starting material was completely disappeared. After removing the solvent in vacuo, the 
residue was purified by preparative HPLC, using mobile phase 0.1 % TFA in water and 
MeOH (experimental setup is given at General conditions). And the compound purity was 
checked by analytical HPLC (experimental setup is given at General conditions). 
 
N1-[-2-(1H-Imidazol-4-ylmethylsulfanyl)acetyl]-N2-[3-(1H-imidazol-4-yl)propyl]-
guanidine [61]  
Stirred for 10 h; yield 83 %; sticky oil; C14H21N7OS · 3 TFA (678.0); IR (neat) 2863, 1660, 
1430, 1179, 1124, 831 cm-1; 1H-NMR (CD3OD), δ (ppm): 8.81 (s, 1H, Im-2-H), 8.75 (s, 1H, 
Im-H-2), 7.37 (s, 1H, Im-H-5), 3.95 (s, 2H, SCH2CO), 3.41-3.33 (m, 2H, NHCH2), 3.31 (s, 
2H, Im-4-CH2S), 2.90-2.80 (m, 2H, Im-4-CH2), 2.36 (s, 3H, CH3), 2.04 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CD3OD), δ (ppm): 173.4 (quart, CO), 155.4 (quart, C=NH), 134.9 (+, 
Im-C-2), 134.3 (quart, Im-C-4), 134.2 (+, Im-C-2), 128.8 (quart, Im-C-4), 126.5 (quart, Im-C-
5), 117.1 (+, Im-C-5), 41.6 (-, CH2NH), 35.7 (-, SCH2CO), 27.9 (-, Im-4-CH2CH2), 25.0 (-, 
Im-4-CH2S), 22.5 (-, Im-4-CH2), 8.9 (+, CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 
336 ([M + H]+); HRMS [FAB(glycerin)]: m/z, calculated for [C14H21N7OS + H]+ 336.1601, 
found: 336.1607;  
Analytical HPLC: Rt 8.75 min (Column A; 0 min: 0.05% TFA/CH3CN 97/3, 20 min: 85/15); 
purity: 93 %. 
 
N1-(3,3-Diphenylpropanoyl)-N2-[2-(1H-imidazol-4-yl)ethyl]guanidine [62]  
Stirred for 10 h; yield  92 %; sticky colorless oil; C21H23N5O ·2 TFA (589.8); IR (neat) 3026, 
1662, 1494, 1433, 1183, 1128, 832 cm-1; 1H-NMR (CD3OD), δ (ppm): 8.81 (s, 1H, Im-2-H), 
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7.35 (s, 1H, Im-H-5), 7.32-7.12 (m, 10H, Ph-H), 4.57 (t, J = 8.0 Hz, 1H, CHCH2CO), 3.58 (t, 
J = 6.7 Hz, 2H, CH2NH), 3.31 (m, 1H, NH), 3.25 (d, J = 8.0 Hz, 2H, COCH2), 3.03 (t, J = 
6.7 Hz, 2H, Im-4-CH2); 13C-NMR (CD3OD), δ (ppm): 175.5 (quart, CO), 162.6 (quart, 
C=NH), 144.4 (quart, Ph-C-1), 135.2 (+, Im-C-2), 131.4 (quart, Im-C-4), 129.6, 128.8, 127.8 
(+, Ph-C), 118.1 (+, Im-C-5), 48.0 (+, CHCH2CO), 43.7 (-, COCH2), 41.0 (-, CH2NH2), 28.3 
(-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 361 ([M + H]+); HRMS [EI-
MS]: m/z, calculated for (C21H23N5O) 361.1903, found: 361.1901;  
Analytical HPLC: Rt 14.66 min (Column A; 0 min: 0.05% TFA/CH3CN 95/5, 20 min: 50/50); 
purity: 97 %. 
 
N1-[3,3-Diphenylpropanoyl]-N2-[3-(1H-imidazol-4-yl)propyl]guanidine [63]  
Stirred for 10 h; yield: 92 %; colorless sticky oil; C22H25N5O · 2 TFA (603.9); IR (neat) 3083, 
1599, 1508, 1390, 1221, 1158, 1100, 820 cm-1; 1H-NMR (CD3OD), δ (ppm): 7.40 (s, 1H, Im-
2-H), 7.10-7.35 (m, 10H, Ph-H), 4.65 (t, J = 7.7 Hz, 1H, Ph2CH), 3.26 (t, J = 6.5 Hz, 2H, 
CH2NH), 3.06 (d, J = 7.7 Hz, 2H, CH2CO), 2.59 (m, 2H, Im-4-CH2), 1.82 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CD3OD), δ (ppm): 183.5 (quart, CO), 161.7 (quart, C=NH), 145.0 
(quart, Ph-C-1), 134.6 (quart, Im-C-4), 134.2 (+, Im-C-2), 128.4, 128.0, 126.0 (+, Ph-C), 47.4 
(+, Ph2CH), 46.5 (-, COCH2), 40.0 (-, NHCH2), 29.1 (-, Im-4-CH2CH2), 22.9 (-, Im-4-CH2); 
MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 376.2 ([M + H]+); HRMS [FAB 
(CH2Cl2/MeOH)]: m/z, calculated for [C21H23N5O + H]+  376.2132, found: 376.2137;  
Analytical HPLC: Rt 16.51 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 
64/36); purity: 100 %. 
 
N1-(2,2-Diphenylacetyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine [64]  
Stirred for 10 h; yield: 92 %; colorless sticky oil; C21H23N5O · 2 TFA (589.8); IR (neat) 1663, 
1495, 1184, 1128, 1029, 798, 720, 698, 628 cm-1; 1H-NMR (CD3OD), δ (ppm): 8.74 (s, 1H, 
Im-2-H), 7.86 (s, 1H, Im-5-H), 7.40-7.10 (m, 10H, Ph-H), 5.27 (s, 1H, Ph2CH), 3.35 (t, J = 
6.7 Hz, 2H, CH2NH), 2.80 (t, J = 7.6 Hz, 2H, Im-4-CH2), 2.01 (m, 2H, Im-4-CH2CH2); 13C-
NMR (CD3OD), δ (ppm): 176.1 (quart, CO), 155.4 (quart, C=NH), 139.0 (quart, Ph-C-1), 
134.8 (quart, Im-C-4), 134.2 (+, Im-C-2), 129.9, 129.7, 128.7 (+, Ph-C), 117.1 (+, Im-C-5), 
59.4 (+, Ph2CH), 41.6 (-, CH2NH2), 27.8 (-, Im-4-CH2CH2) 22.5 (-, Im-4-CH2); MS (ESI, 
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CH2Cl2/MeOH + 10 mM NH4OAc): 362 ([M + H]+); HRMS [EI-MS]: m/z, calculated for 
[C21H23N5O] 361.1903, found: 361.1903;  
Analytical HPLC: Rt 14.72 min (Column B; 0 min: 0.05% TFA/CH3CN 90/10, 20 min: 
75/25); purity: 100%. 
 
N1-[3,3-Bis(4-fluorophenyl)propanoyl]- N2-[3-(1H-imidazol-4-yl)propyl]guanidine [65] 
Stirred for 10 h; yield: 85 %; colorless sticky oil; C22H23F2N5O (639.8); IR (neat) 2922, 1587, 
1505, 1377, 1220, 1157, 823, 749 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.42 (s, 1H, Im-2-H), 
7.12-7.22 (m, 4H, Ar-H), 6.86-6.97 (m, 4H, Ar-H), 6.73 (s, 1H, Im-5-H), 4.62 (t, J = 7.9 Hz, 
1H, Ar2CH), 3.28 (t, J = 6.7 Hz, 2H, NHCH2), 2.98 (d, J = 7.9 Hz, 2H, CH2CO), 2.58 (m, 
2H, Im-4-CH2), 1.83 (m, 2H, Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 183.2 (quart, 
CO), 161.2 (quart, d, J = 244.2 Hz, 2C, CF), 161.9 (quart, C=NH), 140.0 (quart, Ar-C-1), 
134.6 (quart, Im-C-4), 134.1 (+, Im-C-2), 129.1 (+, d, J = 8.0 Hz, 4C, Ar-C-2,6), 117.1 (+, 
Im-C-5), 115.2 (+, d, J = 21.1 Hz, 4C, Ar-C-3,5), 46.8 (-, CH2CO), 45.9 (+, Ar2CH), 39.9 (-, 
CH2NH), 29.3 (-, Im-4-CH2CH2), 22.9 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc): 412 ([M + H]+); HRMS [EI-MS]: m/z, calculated for (C22H23F2N5O) 411.1871, 
found: 411.1866;  
Analytical HPLC: Rt 19.50 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 
64/36); purity: 95 %. 
 
N1-[3-(4-Fluorophenyl)-3-phenylpropanoyl]-N2-[3-(1H-imidazol-4-yl)propyl]guanidine 
[66] 
Stirred for 10 h; yield: 91 %; colorless sticky oil; C22H24FN5O (621.8); IR (neat) 2941, 1601, 
1508, 1390, 1220, 1158, 819 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.41 (s, 1H, Im-2-H), 7.10-
7.30 (m, 7H, Ar-H), 6.87-6.97 (m, 2H, Ar-H), 6.72 (s, 1H, Im-5-H), 4.64 (t, J = 7.9 Hz, 1H, 
Ar2CH), 3.28 (t, J = 6.5 Hz, 2H, CH2NH), 3.03 (d, J = 7.9 Hz, 2H, CH2CO), 2.60 (m, 2H, 
Im-4-CH2), 1.83 (m, 2H, Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 183.3 (quart, CO), 
161.2 (quart, d, J = 243.8 Hz, Ar-CF), 161.8 (quart, C=NH), 144.8 (quart, Ph-C-1), 140.6 
(quart, d, J = 3.3 Hz, Ar-C-1), 134.8 (quart, Im-C-4), 134.1 (+, Im-C-2), 129.2 (+, d, J = 8.0 
Hz, 2C, Ar-C-2,6), 128.4 (+, 2C, Ph-C-2,6), 127.8 (+, 2C, Ph-C-3,5), 126.1 (+, Ph-C-4), 
118.0 (+, Im-C-5),  115.1 (+, d, J = 21.1 Hz, 2C, Ar-C-3,5), 46.6 (-, Ar2CH), 45.6 (+, 
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COCH2), 39.9 (-, NHCH2), 29.3 (-, Im-4-CH2CH2), 22.9 (-, Im-4-CH2); MS (ESI, 
CH2Cl2/MeOH + 10 mM NH4OAc): 394.3 ([M + H]+); HRMS [EI-MS]: m/z, calculated for 
[C22H24FN5O] 393.1965, found: 393.1964;  
Analytical HPLC: Rt 18.18 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 
64/36); purity: 85 %. 
 
N1-[3-(3,4-Difluorophenyl)-3-phenylpropanoyl]-N2-[3-(1H-imidazol-4-yl)propyl]-
guanidine [67] 
Stirred for 10 h; yield: 91 %; colorless sticky oil; C22H23F2N5O · 2 TFA (639.8); IR (neat) 
3124, 1586, 1507, 1380, 1221, 1134, 783 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.50 (s, 1H, Im-
2-H), 7.11-7.27 (m, 3H, Ar-H), 6.78-7.06 (m, 5H, Ar-H), 6.76 (s, 1H, Im-5-H), 4.64 (t, J = 
7.9 Hz, 1H, Ar2CH), 3.33 (t, J = 6.7 Hz, 2H, NHCH2), 3.03 (d, J = 7.9 Hz, 2H, CH2CO), 2.65 
(m, 2H, Im-4-CH2), 1.86 (m, 2H, Im-4-CH2CH2); 13C-NMR (CDCl3), δ (ppm): 183.1 (quart, 
CO), 162.9 (quart, d, J = 246.8 Hz, 3-CF), 161.6 (quart, d, J = 245.3 Hz, 4-CF), 161.8 (quart, 
C=NH), 144.6 (quart, Ph-C-1), 140.0 (quart, d, J = 3.3 Hz, Ar-C-1), 139.8 (quart, Im-C-4), 
134.1 (+, Im-C-2), 129.9 (+, Ph-C-4), 129.3, 129.4 (+, 2C, Ph-C-3,5), 123.5 (+, d, J = 3.3 Hz, 
Ar-C-6), 118.1 (+, Im-C-5), 115.4, 115.1 (+, 2C, Ph-C-2,6), 114.7 (+, d, J = 21.3 Hz, Ar-C-
5), 113.0 (+, d, J = 21.1 Hz, Ar-C-2), 46.6 (+, Ar2CHCO), 45.9 (-, COCH2), 39.9 (-, NHCH2), 
29.3 (-, Im-4-CH2CH2), 22.9 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 
412 ([M + H]+); HRMS [EI-MS]: m/z, calculated for  [C22H23F2N5O] 411.1871, found: 
411.1866;  
Analytical HPLC: Rt 18.59 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 
68/32); purity: 97 %. 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[3-phenyl-3-(pyridin-2-yl)propanoyl]guanidine [70]  
Stirred for 10 h; Yield: 85 %; colorless sticky oil; C21H24N6O · 3 TFA (719.0); IR (neat) 
1664, 1180, 1125, 831, 798, 719, 700 cm-1; 1H-NMR (CD3OD),  δ (ppm): 8.80 (m, 1H, Pyr-6-
H),  8.57 (m, 1H, Pyr-4-H), 7.99 (m, 1H, Pyr-5-H), 7.58 (d, J = 8.3 Hz, 1H, Pyr-3-H), 7.46 
(m, 1H, Ph-H), 7.21-7.39 (m, 6H, Ph-H and Im-2-H), 4.84 (t overlap with H2O, 1H, Ar2CH), 
3.61 (dd, J1 = 8.8 Hz J2 = 16.7 Hz, 1H, CH2CO), 3.40-3.31 (m, 3H, CH2CO and NHCH2), 
2.80 (t, J = 7.8 Hz, 2H, Im-4-CH2), 1.99  (m, 2H, Im-4-CH2CH2); 13C-NMR (CD3OD), δ 
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(ppm): 175.1 (quart, CO), 161.7 (quart, Py-C-2), 155.1 (quart, C=NH), 147.4 (+, Pyr-C-6), 
142.0 (quart, Ph-C-1), 141.8 (+, Im-C-2), 134.9 (+, Pyr-C-4), 134.5 (quart, Im-C-4), 130.1, 
129.0, 128.6 (+, Ph-C), 125.6 (+, Pyr-C-3), 124.4 (+, Pyr-C-5), 117.1 (+, Im-C-5), 48.1 (+, 
COCH2CH), 42.2 (-, COCH2), 41.5 (-, NHCH2), 27.8 (-, Im-4-CH2CH2), 22.5 (-, Im-4-CH2); 
MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 377 ([M + H]+) ; HRMS [EI-MS]: m/z, 
calculated for (C21H24N6O) 376.2012, found: 376.2002;  
Analytical HPLC: Rt 14.27 min (Column B; 0 min: 0.05% TFA/CH3CN 90/10, 20 min: 
80/20); purity: 86 %. 
 
N1-[3-(4-Fluorophenyl)-3-(pyridin-2-yl)propanoyl]-N2-[3-(1H-imidazol-4-yl)propyl]-
guanidine [71] 
Stirred for 10 h; yield: 79 %; colorless sticky oil; C21H23FN6O · 3 TFA (737.0); IR (neat) 
1663, 1510, 1181, 1125, 831, 787, 719 cm-1; 1H-NMR (CD3OD),  δ (ppm): 8.78 (s, 1H, Im-2-
H), 8.71 (d, J = 5.2 Hz,1H, Pyr-4-H),  8.57 (m, 1H, Pyr-H), 8.38 (t, J = 7.8 Hz, 1H, Pyr-C), 
8.00 (d, J = 8.2 Hz, 1H, Pyr-H ),  7.78 (t, J = 6.7 Hz, 1H, Ph-H), 7.50-7.40 (m, 2H, Ph-H and 
Im-H), 7.09 (t, J = 7.8 Hz, 2H, Ph-H), 4.84 (t overlap with H2O, 1H, Ar2CH), 3.68 (dd, J1 = 
9.0 Hz, J2 = 17.3 Hz, 1H, one of CH2CO), 3.43 (dd, J1 = 6.6 Hz, J2 = 17.3 Hz, 1H, one of 
CH2CO), 3.35-3.30 (m, 2H, NHCH2), 2.82 (t, J = 7.5 Hz, 2H, Im-4-CH2), 2.00 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CD3OD), δ (ppm): 174.4 (quart, CO), 163.7 (quart, d, J = 246.1 Hz, 
CF), 159.8 (quart, Py-C-2), 155.1 (quart, C=NH), 146.2 (+, Py-C-6), 144.5 (+, Im-C-2), 136.3 
(quart, Ar-C-1), 134.9 (+, Pyr-C-4), 134.2 (quart, Im-C-4), 131.1 (+, d, J = 8.2 Hz, 2C, Ar-C-
2/-6), 126.6 (+, Pyr-C-3), 125.9 (+, Pyr-C-5), 117.1 (+, d, J = 21.1 Hz, 2C, Ar-C-3/-5), 117.0 
(+, Im-C-5), 45.9 (+, COCH2CH), 41.8 (-, COCH2), 41.6 (-, NHCH2), 28.0 (-, Im-4-CH2CH2), 
22.4 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 395 ([M + H]+);  
HRMS [EI-MS]: m/z, calculated for (M+·,) 394.1917, found 394.1917;  
Analytical HPLC: Rt 17.51 min (Column B; 0 min: 0.05% TFA/CH3CN 90/10, 20 min: 
80/20); purity: 90 %. 
 
N1-[3-(1H-Imidazol-4-yl)propyl-N2-[3-phenyl-3-(thiazol-2-yl)propanoyl]guanidine [72]  
 
Stirred for 10 h; Yield: 85 %; colorless sticky oil; C19H22N6OS · 2 TFA (610.8); IR (neat) 
1663, 1179, 1128, 832, 798, 720, 702 cm-1; 1H-NMR (CD3OD),  δ (ppm): 8.81 (s, 1H, Im-H-
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2), 7.70 (d,  J = 3.3 Hz, 1H, Thiaz-4-H), 7.49 (d, J = 3.3 Hz, 1H, Thiaz-5-H), 7.35-7.15 (m, 
6H, Ph-H and Im-5-H), 5.04 (t, J = 7.7 Hz, 1H, COCH2CH), 3.59 (dd, J1 = 8.2 Hz, J2 = 16.5 
Hz, 1H, one of COCH2), 3.38 (m, 3H, CH2NH and one of COCH2 ), 2.84 (t, J = 7.7 Hz, Im-
CH2), 2.00 (m, 2H, Im-CH2CH2); 13C-NMR (CD3OD), δ (ppm): 174.8 (quart, CO), 174.4 
(quart, Thiaz-C-2), 155.5 (quart, C=NH), 142.7 (+, Thiaz-C-4), 142.2 (quart, Ph-C-1), 134.8 
(+, Im-C-2), 134.2 (quart, Im-C-4), 130.0, 129.8, 129.3, 128.9 (+, Ph-C), 121.2 (+, Thiaz-C-
5), 117.0 (+, Im-C-5), 45.2 (+, CHCH2CO), 43.4 (-, CH2CO), 41.5 (-, CH2NH), 27.9 (-, 
ImCH2CH2), 22.5 (-, Im-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 383 ([M + 
H]+); HRMS [EI-MS]: m/z, calculated for (C19H22N6OS) 382.1576, found 382.1576;  
Analytical HPLC: Rt 10.91 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 
70/30); purity: 95 %. 
 
N1-[3-(3,4-Difluorophenyl)-3-(thiazol-2-yl)propanoyl]-N2-[3-(1H-imidazol-4-yl)propyl]-
guanidine [73]  
Stirred for 10 h; yield: 86 %; colorless sticky oil; C19H20F2N6OS · 2 TFA (646.8); IR (neat) 
1664, 1518, 1181, 1129, 798, 720 cm-1; 1H-NMR (CD3OD),  δ (ppm): 8.80 (s, 1H, Im-2-H), 
7.73 (d,  J = 3.3 Hz, 1H, Thiaz-4-H), 7.48 (d, J = 3.3 Hz, 1H, Thiaz-5-H), 7.35 (s, 1H, Im-5-
H), 7.35-7.15 (m, 3H, ArC), 5.02 (ddq, J = 8.2 and 6.6 Hz, 1H, CHCH2CO), 3.59 (dd, J1 = 
8.2 Hz, J2 = 16.5 Hz, 1H, one of CH2CO), 3.38 (t, J = 6.8 Hz, CH2NH), 3.27 (dd, J1 = 6.6 Hz, 
J2 = 16.5 Hz, 1H, one of COCH2), 2.84 (t, J = 7.7 Hz, Im-4-CH2), 2.03 (m, Im-4-CH2CH2); 
13C-NMR (CD3OD), δ (ppm): 174.5 (quart, Thiaz-C-2), 173.1 (quart, CO ), 155.1 (quart, 
C=NH),  151.3 (quart, dd, J1 = 12.5 Hz, J2 = 247.6 Hz, CF), 150.8 (quart, dd, J1 = 12.6 Hz, J2 
= 247.1 Hz, CF), 143.1 (+, Thiaz-C-4), 139.6 (quart, Ar-C-1), 134.8 (+, Im-C-2), 134.2 
(quart, Im-C-4), 125.7 (+, Ar-C-6), 121.3 (+, Thiaz-C-5), 118.7 (+, d, J = 17.2 Hz, Ar-C-5), 
118.2 (+, d, J = 17.2, Hz, Ar-C-2), 117.1 (+, Im-C-5), 44.8 (+, CHCH2CO), 43.3 (-, CH2CO), 
41.5 (-, CH2NH), 27.9 (-, Im-4-CH2CH2), 22.5 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 
mM NH4OAc): 419 ([M + H]+); HRMS [EI-MS]: m/z, calculated for (C19H20F2N6OS) 
418.1387, found 418.1387;  
Analytical HPLC: Rt 12.62 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 
62/38); purity: 100%. 
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N1-[3-(Benzyl-1H-imidazol-2-yl)-3-(3,4-difluorophenyl)propanoyl]-N2-[3-(1H-imidazol-
4-yl)propyl]guanidine [74]  
Stirred for 10 h; yield: 87 %; colorless sticky oil; C26H27F2N7O · 2 TFA (719.8); IR (neat) 
1661, 1519, 1180, 1122, 829, 797, 719 cm-1; 1H-NMR (CD3OD), δ (ppm): 8.79 (s, 1H, Im-2-
H), 7.65 (dd, J1 = 1.9  Hz, J2 = 5.8 Hz, Benzyl-Im-4-H and -5-H), 7.35 (s, 1H, Im-5-H), 7.33-
7.24 (m, 3H, Ar-H), 7.20-7.00 (m, 4H, Ph-H), 6.90 (m, 1H, Ph-H), 5.51 (s, 2H, PhCH2), 5.13 
(t overlap with H2O, 1H, CHCH2CO), 3.62 (AMX, J1 = 9.6 Hz, J2 = 17.6 Hz, CH2CO), 3.45-
3.32 (AMX and m overlap, 3H, CH2CO and CH2NH), 2.83 (t, J = 7.8 Hz, 2H, Im-4-CH2), 
2.03 (m, 2H, Im-4-CH2CH2); 13C-NMR (CD3OD), δ (ppm): 173.5 (quart, CO), 163.0 (quart, 
C=NH), 154.9 (quart, C=NH), (quart, Benzyl-Im-C-2), 151.5 (quart, dd, J1 = 12.9 Hz, J2 = 
248.9 Hz, CF), 151.3  (quart, dd, J1 = 12.6 Hz, J2 = 248.9 Hz, CF), 148.1 (quart, Benzyl-Im-
C-2), 135.1 (quart, Im-C-4), 134.9 (+, Im-C-2), 134.4 (quart, Ar-C-1), 134.3 (quart, Ph-C-1), 
130.2, 129.9, 128.6 (+, Ph-C), 125.5 (+, Ar-C-6), 124.8 (+, Benzyl-Im-C-4), 120.6 (+, 
Benzyl-Im-C-5), 119.2 (+, d, J = 17.7 Hz, Ar-C-5), 118.4 (+, d, J = 18.7 Hz, Ar-C-2), 117.1 
(+, Im-C-5), 52.4 (-, PhCH2), 41.6 (-, COCH2), 41.5 (-, NHCH2), 37.6 (+, CHCH2CO), 27.9 (-
, Im-4-CH2CH2), 22.4 (-, Im-4-CH2);  MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 419 ([M 
+ H]+; HRMS (EI-MS): m/z calculated for [C26H27F2N7O], 491.2245, found 491.2234; 
Analytical HPLC: Rt 13.78 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 
70/30); purity: 98 %. 
N1-[3-(3,4-Difluorophenyl)-3-(1H-imidazol-2-yl)propanoyl]-N2-[3-(1H-imidazol-4-yl)-
propyl]guanidine [75]  
Stirred for 10 h; yield: 88 %; colorless sticky oil; C19H21F2N7O · 3 TFA (744.0); IR (neat) 
1659, 1624, 1520, 1182, 1129, 832, 797, 720 cm-1; 1H-NMR (CD3OD), δ (ppm): 8.79 (s, 1H, 
1H-Im-2-H), 7.94 (s, 2H, 2H-Im-3-H and -4-H), 7.47 (s, 1H, 1H-Im-5-H), 7.41-7.10 (m, 4H, 
Ar-H and NH), 5.03 (t overlap with H2O, 1H, CHCH2CO), 3.61 (dd, J1 = 8.2 Hz, J2 = 17.2 
Hz, CH2CO), 3.44 (dd, J1 = 6.9 Hz, J2 = 17.2 Hz, COCH2), 3.30 (m, 2H, CH2NH), 2.81 (t, J 
= 7.8 Hz, 2H, 1H-Im-4-CH2), 2.01 (m, 2H, 1H-Im-4-CH2CH2). 13C-NMR (CDCl3), δ (ppm): 
173.4 (quart, CO), 155.0 (quart, C=NH), 151.8 (quart, dd, J1 = 12.5 Hz, J2 = 249.0 Hz, CF), 
151.4 (quart, dd, J1 = 12.6 Hz, J2 = 248.9 Hz, CF), 148.8 (quart, 2H-Im-C-2), 135.5 (quart, 
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Ar-C-1), 134.9 (+, 1H-Im-C-2), 134.2 (quart, 1H-Im-C-4 ), 125.6 (+, Ar-C-6), 120.6 (+, 2H-
Im-C-5), 120.4 (+, 2H-Im-C-4), 119.4 (+, d, J = 17.7 Hz, Ar-C-5), 118.3 (+, d, J = 18.1 Hz, 
Ar-C-2), 117.1 (+, 1H-Im-C-5), 41.6 (-, CH2CO), 40.4 (-, CH2NH), 39.1 (+, CHCH2CO), 
27.8 (-, 1H-Im-4-CH2CH2), 22.5 (-, 1H-Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc): 402 ([M + H]+); HRMS: FAB-MS: m/z for ([C19H21F2N7O + H]+) calcd. 402.1854, 
found 402.1842; 
Analytical HPLC: Rt 9.12 min (Column B; 0 min: 0.05% TFA/CH3CN 90/10, 20 min: 75/25); 
purity: 80 %. 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N’-[3-(thiophen-2-yl)butanoyl]guanidine [79] 
Stirred for 10 h; yield: 92 %; colorless sticky oil; C15H21N5OS · 2 TFA (547.8); IR (neat) 
2873, 1663, 1433, 1180, 1127, 832, 798, 720 cm-1; 1H-NMR (CD3OD),  δ (ppm): 8.84 (s, 1H, 
Im-2-H), 7.48 (s, 1H, Im-5-H), 7.30 (m, 1H, Thio-H), 6.93 (m, 2H, Thio-H), 3.60 (m, 1H, 
COCH2CH), 3.32 (m, 2H, NHCH2), 2.92 (m, 4H, Im-4-CH2 and one of COCH2 ), 2.00 (m, 
2H, Im-4-CH2CH2), 1.42 (d, J = 7.0 Hz, 3H, CH3); 13C-NMR (CD3OD), δ (ppm): 175.6 
(quart, CO), 155.2 (quart, C=NH), 150.0 (+, Thio-C-2), 134.9 (+, Im-C-2), 134.3 (quart, Im-
C-4), 127.7 (+, Thio-C-5), 126.3, 124.4 (+, Thio-C-3,4), 117.1 (+, Im-C-5), 47.0 (-, 
CHCH2CO), 41.6 (-, CH2NH), 32.9 (+, CHCH2CO), 27.9 (-, Im-4-CH2CH2), 23.2 (+, CH3), 
22.5 (-, Im-4-CH2); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): m/z 320 ([M + H]+);  
HRMS: EI-MS: m/z for (C15H21N5OS) calcd. 319.1467, found 319.1469;  
Analytical HPLC: Rt 9.03 min (Column B; 0 min: 0.05% TFA/CH3CN 80/20, 20 min: 70/30); 
purity: 95 %. 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[3-(pyridin-2-yl)butanoyl]guanidine [80]  
Stirred for 10 h; yield: 89 %; colorless sticky oil; C16H22N6O · 2 TFA (657.0); IR (neat) 3138, 
1665, 1434, 1181, 1129, 833, 798, 720 cm-1; 1H-NMR (CD3OD), δ (ppm): 8.79 (s, 1H, Im-2-
H), 8.57 (d, J = 8.3 Hz, 1H, Pyr-6-H),  8.09 (dt, J1 = 1.7 Hz, J2 = 7.8 Hz, 1H, Pyr-4-H), 7.67 
(d, J = 8.0 Hz, 1H, Pyr-3-H), 7.53 (ddd, J1 = 1.0 Hz, J2 = 5.3 Hz, J3 = 6.4 Hz, 1H, Pyr-5-H), 
7.53 (s, 1H, Im-5-H), 3.60 (m, 1H, Ar2CH), 3.35 (m, 2H, CH2NH), 3.09 (dd, J1 = 8.3 Hz, J2 = 
16.6 Hz, 1H, CH2CO), 2.92 (dd, J1 = 6.2 Hz, J2 = 16.6 Hz, 1H, CH2CO), 2.82 (t, J = 7.6 Hz, 
2H, Im-4-CH2), 2.01  (m, 2H, Im-4-CH2CH2), 1.40 (d, J = 7.0 Hz, 3H, CH3CH); 13C-NMR 
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(CD3OD), δ (ppm): 175.4 (quart, CO), 163.7 (quart, Py-C-2), 155.2 (quart, C=NH), 146.7 (+, 
Pyr-C-6), 142.5 (+, Pyr-C-4), 134.9 (+, Im-C-2), 134.3 (+, Im-C-4), 125.4 (+, Pyr-C-3), 124.8 
(+, Pyr-C-5), 117.1 (+, Im-C-5), 43.4 (-, COCH2CH), 41.5 (-, CH2NH), 37.4 (+, COCH2CH), 
27.9 (-, Im-4-CH2CH2), 22.5 (-, Im-4-CH2), 20.7 (+, CH3); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc): 315 ([M + H]+);  
HRMS: EI-MS: m/z for (C16H22N6O) calcd. 314.1855, found 314.1863;  
Analytical HPLC: Rt 13.00 min (Column B; 0 min: 0.05% TFA/CH3CN 98/2, 20 min: 85/15); 
purity: 95 %. 
 
N1-[3-(1H-Imidazol-4-yl)propyl)-N2-[3-(thiazol-2-yl)butanoyl]guanidine [81]  
Stirred for 10 h; yield: 84 %; colorless sticky oil; C14H20N6OS · 2 TFA (548.8); IR (neat) 
3131, 1663, 1431, 1180, 1128, 832, 798, 720 cm-1; 1H-NMR (CD3OD),  δ (ppm): 8.84 (s, 1H, 
Im-2-H), 7.70 (d,  J = 3.3 Hz, 1H, Thiaz-4-H), 7.49 (d, J = 3.3 Hz, 1H, Thiaz-5-H), 7.28 (s, 
1H, Im-H-5), 3.90 (m, 1H, CHCH2CO), ), 3.38 (m, 2H, CH2NH), 3.12 (dd, J1 = 8.2 Hz, J2 = 
16.5 Hz, 1H, one of COCH2), 2.92 (m, 3H, Im-4-CH2 and one of COCH2 ), 2.00 (m, 2H, Im-
4-CH2CH2), 1.42 (d, J = 7.0 Hz, 3H, CH3); 13C-NMR (CD3OD), δ (ppm): 176.4 (quart, CO), 
175.1 (quart, Thiaz-C-2), 155.2 (quart, C=NH), 142.7 (+, Thiaz-C-4), 134.9 (+, Im-C-2), 
134.3 (quart, Im-C-4), 120.2 (+, Thiaz-C-5), 117.1 (+, Im-C-5), 44.3 (-, CHCH2CO), 41.6 (-, 
CH2NH), 35.1 (+, CHCH2CO), 27.9 (-, Im-4-CH2CH2), 22.5 (-, Im-4-CH2), 21.7 (+, CH3); 
MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 321.5 ([M + H]+); HRMS: FAB-MS: m/z for 
([C14H20N6OS + H]+) calcd. 321.1498, found 321.1508;  
Analytical HPLC: Rt 11.95 min (Column B; 0 min: 0.05% TFA/CH3CN 97/3, 20 min: 65/35); 
purity: 100 %. 
 
3.5.2. Pharmacological methods 
Data handling and pharmacological parameters: Data presented as mean ± SEM or SE or 
with 95% confidence limits (cl) unless otherwise indicated. Agonist potencies are given in 
percent or are expressed as pEC50 values (negative decadic logarithm of the molar 
concentration of the agonist producing 50% of the maximal response) and were corrected 
according to the long term mean value of the reference agonist histamine in our laboratory 
 94
Synthesis and Pharmacological Activity of NG-Acylated Imidazolylpropylguanidines 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 
(guinea pig atrium (H2): pEC50 = 6.00 for histamine; guinea pig ileum (H1): pEC50 = 6.70 for 
histamine). Maximal responses are expressed as Emax values (percentage of the maximal 
response to a reference compound). Antagonist affinities are expressed as either an apparent 
pA2 or a full pA2 value. The apparent pA2 value was calculated from the following equation: 
pA2 = −log c(B) + log(r − 1), where c(B) is the molar concentration of antagonist and r the 
ratio of agonist EC50 measured in the presence and absence of antagonist.45 The full pA2 value 
was determined according to the method of Arunlakshana and Schild46 using antagonist 
concentrations over 1-2 log units. Noncompetitive antagonists are characterized by estimation 
of a pD'2 value according to the equation: pD'2 = −log c(B) + log(100/Emax − 1).47 Where 
appropriate, differences between means were determined by Student's t-test, after checking 
the homogeneity of the variances; P values < 0.05 were considered to indicate a significant 
difference between the mean values being compared. 
Histamine H1 receptor assay on the isolated guinea pig ileum: Guinea pigs of either sex 
(250-500 g) were stunned by a blow on the neck and exsanguinated. The ileum was rapidly 
removed, rinsed and cut into segments of 1.5-2 cm length. The tissues were mounted 
isotonically (preload of 5 mN) in a jacketed 20-mL organ bath that was filled with Tyrode's 
solution of the following composition [mM]: NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 1.0, 
NaH2PO4 0.4, NaHCO3 11.9, and glucose 5.0. The solution additionally contained atropine to 
block cholinergic M receptors at a concentration not affecting H1 receptors (0.1 μM). The 
solution was aerated with 95% O2-5% CO2 and warmed to a constant temperature of 37 °C. 
During an equilibration period of 80 min, the tissues were stimulated three times with 
histamine (1 μM, then 10 μM) followed by washout. Antagonists: Up to four cumulative 
concentration-response curves were determined on each tissue: a first to histamine (0.01-30 
μM), and the 2nd – 4th to histamine in the presence of increasing concentrations of antagonist 
(incubation time 10–15 min). pEC50 differences were not corrected since four successive 
curves for histamine were superimposable (n > 10). 
Histamine H2 receptor assay on isolated guinea pig right atrium (spontaneously 
beating): Hearts were rapidly removed from guinea pigs used for studies on the ileum (see 
above). The right atrium was quickly dissected and set up isometrically in Krebs-Henseleit 
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solution under a diastolic resting force of 5 mN in a jacketed 20 mL-organ bath of 32.5 °C as 
previously described.6 The bath fluid (composition [mM]: NaCl 118.1, KCl 4.7, CaCl2 1.8, 
MgSO4 1.64, KH2PO4 1.2, NaHCO3 25.0, glucose 5.0, sodium pyruvate 2.0) was gassed with 
95% O2-5% CO2 and additionally contained (RS)-propranolol (0.3 μM) and mepyramine (1 
μM). Experiments were started after 30 min of continuous washing and an additional 
equilibration period of 15 min. Antagonists: Two successive concentration-frequency curves 
to histamine (0.1-30 μM) were established, the first in the absence and the second in the 
presence of the compound under study (incubation time 30 min). pEC50 differences were not 
corrected since two successive curves for histamine were virtually superimposable (n > 10). 
Agonists: Two successive concentration-frequency curves were established, the first to 
histamine (0.1-30 μM) and the second for the agonist under study in the absence or presence 
of cimetidine (30 μM, 30 min incubation time). Furthermore, the sensitivity to 30 μM 
cimetidine was routinely checked at the end of each H2 agonist concentration-effect curve 
established in the absence of an H2 receptor antagonist, and a significant reduction of 
frequency was always observed after 15–30 min. 
Calcium assays with U-373 MG cells 
 
Cells and culture conditions: The human U-373 MG (HTB 17) glioblastoma/astrocytoma 
cell line was obtained from the American Type Culture Collection (Rockville, MD, USA). 
Cell banking and quality control were performed according to the "seed stock concept". Cells 
were grown in Eagle´s minimum essential medium containing L-glutamine, 2.2 g/l NaHCO3, 
110 mg/l sodium pyruvate (Sigma, Deisenhofen, FRG), and 10% FCS (GIBCO, Eggenstein, 
FRG The cells were cultured in a water-saturated atmosphere of 95% air and 5% carbon 
dioxide at 37 °C in 75-cm² culture flasks (Costar, Tecnomara, Fernwald, FRG) and were 
serially passaged following trypsinisation using trypsin (0.05%) / EDTA (0.02%) (Roche 
Diagnostics, Mannheim, GER). 
 
Preparation of the cells: Adherently growing U-373 MG cells were trypsinized and 
transferred from a 75-cm2 flask to 175-cm2 flask (Nunclon, 178883, Nunc, Wiesbaden, and 
Germany) 5-6 days before the experiment. At approx. 80% confluence cells were trypsinized, 
the suspension (2-4·105 cells per ml), was centrifuged for 10 min at 200 g and room 
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temperature. After resuspension in 10 ml of loading buffer (25 mM HEPES (Sigma, 
Deisenhofen, GER), 120 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 10 mM 
glucose), pH 7.4, cell number was determined with a hemocytometer (Neubauer, improved), 
and the cells were adjusted to a density of 1.3·106 per ml by addition of an appropriate 
volume of loading buffer. 
 
Loading of the cells with Ca2+ indicator Fura-2/AM: To three volumes of the prepared cell 
suspension, one volume of loading dispersion was added, before the cells were incubated in 
the dark at room temperature for 30 min. The loading dispersion was freshly made by mixing 
10 ml of loading buffer, containing 2 % bovine serum albumin (BSA), with 50 μl of Pluronic-
F-127 (Molecular Probes, Eugene, Oregon, USA) (20 % in DMSO), and 40 μl of Fura-2/AM 
(Molecular Probes, Eugene, Oregon, USA) (1 mM in anhydrous DMSO).  
Cells were centrifuged (200 g, 7 min), resuspended in fresh loading buffer and allowed to 
stand for another 30 min at room temperature in the dark. After two washing/centrifugation 
cycles (loading buffer, 200 g, 7 min) and adjustment of the cell number to a value of 106 /ml, 
cells were incubated for at least 15 min at 20 °C in the dark.  
 
Fluorimetric determination of intracellular [Ca2+]: 1 ml-aliquots of loading buffer were 
filled into disposable acrylic cuvettes (Sarstedt, No. 67.755, Nuembrecht, GER), which were 
thermostatted at 30 ° C in an incubator hood (Infors AG, Bottmingen, CH). Immediately after 
addition of 1 ml of the Fura-2/AM loaded cell suspension and a magnetic stirrer, the cuvette 
was placed into the thermostatted (25 °C) stirred cell holder of a LS 50 B Luminescence 
Spectrometer (Perkin Elmer, Ueberlingen, GER), equipped with a fast filter accessory. 
Fluorescence signals were registered (instrument settings: excitation 340/380 nm, emission 
510 nm, slits 10 nm, resolution 0.1, stirrer low) for 300 s after addition of 10 μl of 6 mM 
histamine dihydrochloride dissolved in millipore water.  
 
Calculation of Ca2+ concentrations: Calcium concentrations were calculated from dual 
wavelength fluorescence intensities according to the Grynkiewicz equation:  
[ ]Ca K R RR R SFBd2+ = ⋅ − − ⋅( )( )minmax       
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were Kd (224 nM) is the dissociation constant of the Fura-2-Ca2+-complex, R is the 
experimental fluorescence ratio value (F340 / F380), Rmin and Rmax are the fluorescence value 
ratios (F340 / F380) under Ca2+-free and Ca2+-saturation conditions, respectively, and SFB is the 
ratio of fluorescence intensities for Ca2+-free/Ca2+-bound indicator, measured at 380 nm. Rmin, 
Rmax and SFB were determined by calibration experiments, performed in every test series. 
To measure Rmax, 10 μl of an aqueous solution of 2 % digitonin (Sigma, Deisenhofen, GER), 
were pipetted into the cuvette, wheras Rmin was determined after subsequent addition of 50 μl 
of a 0.6 M EGTA solution (in 1 M Tris/HCl, pH 8.7). 
 
Determination of histamine H1 receptor antagonists on U-373 MG cells:48  
To determine the histamine H1 receptor antagonism on U-373 MG cells the inhibition of the 
(submaximal) increase in [Ca2+]i elicited by 30 μM histamine was measured. Prior to 
stimulation with histamine the cells were incubated with the putative antagonists for 15 min 
in the dark with stirring. The inhibition (%) was calculated as follows: 
 
Inhibition [%] = ( 100 -  ) ·   100 
[Ca 2+ ] i -increase (control) [µM] 
[Ca 2+ ] i -increase (antagonist + 30 µM hist.) [µM] 
 
At least seven concentrations of the antagonists were used and at least two independent 
experiments were carried out on different days. The mean values of the resulting inhibition 
curves were used to calculate IC50 and pKB values, respectively.  
 
Calculation of IC50 values: IC50- values were calculated from at least two antagonist 
concentrations [B], inhibiting the agonist-stimulated increase in intracellular [Ca2+] between 
20 and 80 %. The mean percentual inhibition values P with SEM < 10 %, determined from at 
least 3 independent experiments, performed on different days, were logit transformed, 
according to the equation  
logit (P) =  log 
P
100 -  P
      
and IC50 values (logit P = 0) were determined from the plot logit (P) versus log [B] with the 
slope n according to 
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log P
100 -  P
 =  n log [B] -  n log IC50⋅ ⋅       
by linear regression with Fig. P (Biosoft, Cambridge, UK). 
 
Steady-sstate GTPase activity assay and receptor ligand binding assay on guinea pig 
and human histamine H2 receptor GsαS fusion proteins: These investigations were 
performed according to the procedure described by Kelley et al.24 
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 Chapter 4 
Synthesis and Pharmacological Activity of N-Acyl-N’-[3-(2-amino-4-
methylthiazol-5-yl)propyl]guanidines: Towards Improved H2 
Receptor Selectivity 
 
 
Only such substances can be anchored at any particular part of the organism, as fit into the 
molecules of the recipient complex like a piece of mosaic finds its place in the pattern.  
                                                                                                                             Paul Ehrlich, 1956 
 
4.1. Introduction  
The clinical use of compounds active on the histamine H2 receptor (H2R) is mainly restricted to 
antagonists, which are useful in the treatment of peptic ulcers. However, some efforts have been 
made with histamine H2R agonists in the treatment of patients suffering from congestive heart 
failure.1,2 Histamine H2 receptor agonists can be divided in two structural classes of compounds: 
histamine analogues and dimaprit3,4 (containing amine), and impromidine analogues (containing 
guanidine)5,6 including arpromidine and related imidazolylpropylguanidines7. Histamine and 
dimaprit both show moderate histamine H2R agonistic activity at the guinea pig right atrium, 
however, the H1-receptor agonistic potency of dimaprit on the isolated guinea pig ileum (H1) 
proved to be less than 0.0001% of that of histamine.8  
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Fig. 4.1. Structure of some histamine H2 receptor agonists. 
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Analogues of impromidine as described by Sterk5 and Buschauer7 are potent histamine H2R 
agonists, and some of them show considerable H1- and H3-receptor antagonistic properties9. 
 
Histamine, impromidine and all its analogues contain a 4-(ω-aminoalkyl)imidazole fragment. The 
imidazole moiety is supposed to trigger the histamine H2 receptor via a l,3-prototropic shift10 
(Fig. 4.2) involving one proton from a proton donating group at the histamine H2 receptor and the 
Ntele proton of the imidazole nucleus. Amino acids Asp-186 and Tyr-182 in transmembrane 
domain 5 are considered to be involved in this process (see receptor models in Chapter 4.1). The 
mechanism for dimaprit is less clear. 
NN
NH3+
HB
H A NN
NH3+
HB
H Aπτ
 
Fig. 4.2. Interaction of the histamine monocation with the H2 receptor (1,3-prototropic shift) 
 
The structure-activity relationship studies on the H2 receptor agonism of dimaprit have revealed 
that the dimethylamino group has the same function as the amino group of histamine, while the 
isothiourea group of dimaprit and the imidazole group of histamine are regarded as bioisosteric 
groups3.  
N
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H H
N
H
H
Site II
Site III
Site I
Fig. 4.3a. Interaction of dimaprit with 
the histamine H2 receptor (S-fit)
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H
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S
NN
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H H
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Fig. 4.3b. Interaction of dimaprit with 
the histamine H2 receptor (N-fit)  
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Green et al.11 suggested the formation of a hydrogen bond between a proton of the histamine H2 
receptor and the sulphur atom of dimaprit in the so-called S-fit (Fig. 4.3a) and the formation of a 
second hydrogen bond between a proton of one of the nitrogen atoms of the isothiourea group 
and another site of the same receptor. As with histamine two protons are involved, one from the 
receptor and one from the agonist, however, in contrast to histamine a tautomeric proton shift is 
impossible in the same region of the active site of the receptor. Durant et al3 considered a second 
possibility for the interaction of dimaprit with the histamine H2 receptor, so-called N-fit, placing 
the two nitrogen atoms of the isothiourea moiety of dimaprit in the same position as the two 
imidazole nitrogen atoms of histamine. As can be seen in Fig. 4.3b, this mechanism supposes an 
interaction between the receptor proton (site III) and a nitrogen atom of the isothiourea group and 
a proton of the second nitrogen atom of this same group and site II of the receptor, thus leaving 
the possibility for a 1,3-prototropic shift as proposed for the mechanism of histamine. However, 
quantum chemical calculations suggest that the S-fit, which includes the interaction of the NH-
group and the S-atom of the isothiourea moity with the H2 receptor, is favourable. Donné-Op den 
Kelder et al.12 performed fit procedures on both the N- and S-fit of dimaprit, showing that the 
conformation of the N-fit is not likely to be the "active" conformation. 
On the basis of that, Impicciatore et al.13 first recognized the possibility of H2R agonistic activity 
of 2-amino-5-(2-aminoethyl)thiazole, being a rigid analogue of dimaprit. Several substituted 2-
aminothiazoles have indeed been shown to be active at the histamine H2 receptor; amthamine14,15 
3 (Fig 4.1) is the most potent H2 agonist in this series. These compounds show moderate to strong 
H2 receptor agonistic activity compared to histamine. Moreover, these thiazole analogues of 
histamine have very less effects on H1 and H3 receptors.  
 
Realizing that 4-methyl-2-aminothiazoles are capable of stimulating the H2 receptor, a series of 
impromidine and arpromidine analogues, such as 7a16, was synthesized by replacing the 3-[(1H-
imidazolyl-4-yl)propyl] group with a 3-(4-methyl-2-aminothiazol-5-yl)propyl moiety. Such 
compounds are reported to be selective agonists for the H2 receptor, in particular versus the H3 
receptor17, i. e. the imidazoles and the aminothiazoles may be considered bioisosteres at 
histamine H2 but not at H3 receptors.  
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The strongly basic guanidino group (pKa value about 13), which is supposed to interact with Asp-
98 in transmembrane domain 3, is essential for the agonistic activity of impromidine and 
analogues, but it is also the main reason for very low oral bioavailability, non-H2R-mediated 
effects and lack of penetration across the blood-brain barrier18. A major advancement was 
achieved by replacing the guanidino group by an acylguanidine moiety (see Chapter 3) resulting 
in potent H2R agonists with reduced basicity and improved pharmacokinetic properties. 
Therefore, we decided to synthesise a series of N-acyl-N’-[3-(2-amino-4-methylthiazol-5-
yl)propyl]guanidines. According to this concept the title compounds should combine advantages 
of the acylguanidines with improved H2R selectivity, in particular the histamine H3 receptor 
antagonistic activity was expected to be considerably reduced.   
 
4.2. Chemistry  
 
The 2-[3-(2-amino-4-methylthiazol-5-yl)propyl]isoindoline-1,3-dione (97) (Scheme 4.1) was 
synthesized according to Eriks19-22 from the chloroketone 94 via phthalimide protection, 
regioselective bromination, and ring closure of 3-bromo-6-(phthalimido)hexan-2-one (96) with 
thiourea as presented in Scheme 1. Subsequently, the 2-amino group was Boc-protected and, 
finally, the phthalimide was deprotected by hydroginolysis. 
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Reagents: (i) K2CO3, phthalimide, DMF, 80 °C, 24 h, 88 %; (ii) Br2, CCl4, rt, 1h, 90 %; (iii) thiourea, DMF, 100 °C, 3 h, 49%; 
(iv) (Boc)2O, Et3N, DMAP, CHCl3, rt, 6 h, 86 %; (v) NH2NH2 .H2O, EtOH, rt, 16 h, 82 %.
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Scheme 4.1: Synthesis of Boc-protected homoamthamine 
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The guanidino group was attached to the propyl chain by treating the amine 99 with di-Cbz-
triflate-protected guanidine (23, Chapter 3, Scheme 3.5), followed by deprotection of the Cbz-
groups by hydrogenolysis (Scheme 4.2).  
 
Reagents: (i) 23, Et3N, CHCl3, rt, 93 %; (ii) H2 / Pd-C, MeOH : THF (1:1), rt, 4 h
N
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Me
BocHN
NH2 N
S
Me
BocHN
N
H
NHCbz
NCbz
N
S
Me
BocHN
N
H
NH2
NR
(ii)
99 100 101': R = H
101'': R = Cbz
TfHN NHCbz
NCbz23
(i)
 
Scheme 4.2: Introduction of the guanidino group 
 
The acylation of compound 101´ was very interesting. Under similar reaction condition as 
described for acylation of imidazolylpropylguanidine (Chapter 3), 101´ gave the diacylated 
product 102 instead of the monoacylated one (102). But with the mixture of mono Cbz protected 
(101´´) and deprotected guanidines (101´), two products were obtained as shown in Scheme 4.3.  
Reagents: (i) EDC, HOBt, DMF, DIEA, 40-53%.
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a: R1 = R2 = Ph
b: R1 = CH3, R2 = Ph
c: R1 = CH3, R2 = c-Hex  
Scheme 4.3: Coupling of protected guanidine with acids 
 
The two products were separated by column chromatography. Subsequently, the Cbz-substituted 
acylguanidines (102a-c) were hydrogenolyzed to deprotect the Cbz group and then treated with 
50 % TFA to remove the Boc protecting group (Scheme 4.4). 
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Reagents: (i) H2/Pd-Cs, MeOH, rt, 8-12 h; (ii) 20 % TFA, CH2Cl2, rt, 90-96 %.
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Scheme 4.4: Deprotection of Cbz and Boc groups 
 Table 4.1: Yields, formulas and analytical data of compounds 104a-c 
No. R1 R2 Yield 
(%)a
Formulab HRMS: m/z 
Found 
(calcd.)c
Rtd 
104a Ph Ph 83 C23H27N5OS (2 TFA) 421.1935 
(421.1936) 
13.50 
 
104b CH3 Ph 92 C18H25N5OS (2 TFA) 359.1778 
(359.1779) 
11.75 
 
104c CH3 c-Hex 92 C18H31N5OS (2 TFA) 365.2250 
(365.2249) 
13.62 
 
a After preparative HPLC; b isolated as trifluoroacetic acid salt; c Techniques for HRMS is described in experimental 
section of respective compounds; d retention time in minutes; the solvent system is presented in experimental section.  
 
On the other hand, the Boc-protected di-acylated products (103a-c) were deprotected to the corre-
sponding aminothiazoles 105a-c by treating with 50 % TFA for short time (2-3 h) and isolated by 
preparative HPLC (Scheme 5). However, stirring the reaction for a longer period of time (e.g. 
overnight) or storage of 105a-c · 2 TFA for a few days, led to slow decomposition of the 
corresponding monoacylated products 104a-c (analyzed by HPLC). 
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Scheme 5.5: Deprotection of Boc group 
 
 
4.3. Pharmacological Results and Discussion 
As for the imidazolylpropylguanidines in section 3.3 (Chapter 3), synthesized compounds were 
tested for histamine H2R activity on the isolated spontaneously beating guinea pig right atrium 
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(positive chronotropic response) and were also investigated for H1 antagonism on the isolated 
guinea pig ileum and on U-373 MG human cells. The results are summarized in Table 4.3. 
Moreover, the compounds were investigated for activity in the GTPase assay using guinea pig 
and human H2R expressing Sf9 insect cells (co-operation with Prof. Seifert, Institute of 
Pharmacy, University of Regensburg) in Table 4.4. The compounds were investigated for 
receptor specificity on H3 receptor antagonism on the isolated guinea pig ileum. The results are 
summarized in Table 4.5. 
 
Table 4.3: Histamine H2 receptor agonism on guinea pig atrium, H1 receptor antagonism on 
guinea pig ileum and on U-373MG cells (Ca2+-assay) 
 
 Histamine H2 receptor agonism Histamine H1 receptor antagonism 
 Guinea pig atrium Guinea pig ileum U-373MG cells 
(Ca2+-assay) 
No. pEC50a 
 ± SEMi
Rel. 
potb
Emax 
(%)c
Nd PA2a,c ± SEM 
[or pD’2a,c ± SEM]e
Nd IC50 [µM]h
HIS 6.00 ± 0.10 100 100 ± 2 >50 6.70 ±   - 
63 7.22 ± 0.09 1650 85 ± 3 5 5.93 ± 0.05f 
[5.00 ± 0.09] 
10 
18 
- 
78 7.45 ± 0.07 2710 99 ± 2 4 6.31 ± 0.06 2 19.5 
88 6.81 ± 0.07 641 101 ± 3 3 5.43 ± 0.009 5 0.95 
104a 7.14 ± 0.11 1370 71 ± 4  4 5.64 ± 0.05f 
[5.48 ± 0.12] 
8 
8 
13 
104b 7.18 ± 0.17 1520 89 ± 3  4 5.48 ± 0.10g 6 18 
104c 7.03 ± 0.06 1070 74 ± 8  3 6.36 ± 0.04g 11 10 
a  Explanation of abbreviations see appendix; b Potency relative to histamine = 100 %, c efficacy, maximal response ( 
%), relative to the maximal increase in heart rate induced by the reference compound histamine.d Number of 
experiments; e pD’2 values given in brackets for compounds producing a significant, concentration-dependent 
reduction of histamine’s maximal response; f non-surmountable; g competitive/non-surmountable;  h IC50 values for 
the inhibition of the histamine (30 µM) induced increase in intracellular calcium; mean of at least 3 independent 
experiments; SEM < 10 %; i pEC50 was calculated from the mean shift ΔpEC50 of the agonist curve relative to the 
histamine reference curve by the equation: pEC50 = 6.00 + ΔpEC50. The SEM given for pEC50 is the SEM calculated 
for ΔpEC50; 
 
 
On replacement of the 3-(imidazol-4-yl)propyl moiety of acyl guanidines (63, 78 and 88) by 3-(2-
amino-5-methylthiazol-4-yl)propyl (in 104a-c respectively), the synthesized compounds are 
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found to be partial agonists (intrinsic activities 70 – 90 %) on spontaneously beating guinea pig 
right atrium (H2 receptor). On the guinea pig ileum as well as on human U373 cells all tested 
compounds proved to be devoid of histamine H1 receptor agonistic activity and to have only weak 
H1R antagonistic activity. 
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Fig. 4.4: Comparison of potency (pEC50 values) on guinea pig right atrium of imidazolyl (in 
dark) and 2-amino-4-methyl-thiazolyl (in light) guanidines (from Table 4.3) 
 
Histamine H2R agonism on the isolated guinea pig right atrium  
As shown in Fig. 4.4, in case of the diphenylpropanoylguanidines the compound with 
imidazolylpropyl moiety and the corresponding aminothiazolylpropyl analogue are about 
equipotent on the guinea pig atrium (63 vs. 104a; difference in pEC50 = 0.08), whereas for the 
two 3-phenylbutanoylguanidines there is a small difference (78 vs. 104b: ΔpEC50 = 0.27). 
Comparing the 3-cyclohexylbutanoylguanidines 88 and 104c, the aminothiazole 104c was found 
to be slightly more active than the corresponding imidazole 88. However, the intrinsic activities 
(Emax) of the aminothiazoles 104a-c were by 10 - 30 % lower than those of the corresponding 
imidazoles (Table 4.3). 
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Species selectivity - agonism on guinea pig and human H2R-Gsα fusion proteins  
The synthesized compounds were also tested for potency and efficacy on hH2R-Gsαs and gpH2R-
Gsαs fusion proteins expressed in Sf9 cells (investigations on cell membrane preparations 
according to the procedure reported by Kelley et al.)23. The results are summarized in Table 4.4. 
Compared to imidazolylpropylguanidines (63, 78 and 88), the corresponding aminothiazolyl-
propyl analogues (104a-c) are found to have little less efficacy at both hH2R-Gsαs and gpH2R-Gsαs 
(in Table 4.4), but the difference of efficacy between hH2R-Gsαs and gpH2R-Gsαs is about the 
same (0.15- 0.25 logarithm units).  
 
Table 4.4: Agonistic activity on the human and guinea pig histamine H2 receptor  
(GTPase assay*; gpH2R-GsαS fusion proteins and hH2R-GsαS fusion proteins)  
 
  hH2R-GsαS gpH2R-GsαS
No Efficacy pEC50 Rel. Pot. Efficacy pEC50 Rel. Pot. 
EC50 hH2R-GsαS
EC50 gpH2R-GsαS
HIS 1,00 5.90 100 1,00 5.92 100 1,05 
63 0.69 7.11 1600 0.93 8.22 19000 12.1 
104a 0.61 6.93 1071 0.86 7.59 4677 4.37 
78 0.87 7.17 1880 1.03 7.92 10300 5.58 
104b 0.82 7.32 2630 0.98 7.65 5370 2.04 
88 0.87 7.64 5480 1.11 8.04 2920 2.68 
104c 0.56 8.04 13804 0.81 8.15 16982 1.23 
* GTP hydrolysis was determined according to the procedure described by Kelley et al. using cell membrane 
preparations of Sf9 cells expressing the respective H2R GsαS fusion proteins. For details see ref.23  and footnote to 
Table 3.3 in Chapter 3. 
 
The order of potency (pEC50) for the 2-amino-4-methylthiazolyl series (104a-c) on gpH2R-Gsαs 
assay was in agreement with the atrium values. For both series of agonists, thiazoles and 
imidazoles, the potency is higher at gpH2R than at hH2R. But in case of imidazolyl series (63, 78 
and 88), the ratios of EC50 values between hH2R-Gsαs and gpH2R-Gsαs are 12.1, 5.6 and 2.7, 
whereas for 2-amino-4-methyl-thiazolyl series (104a-c) the ratios are 4.4, 2.1 and 1.2 
respectively. This result indicates a tendency towards higher activity of 3-(2-amino-4-methyl-
thiazolylpropyl)guanidines compared to the corresponding imidazoles at the human H2 receptor. 
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If we compare the pEC50 values of imidazolyl analogues (63, 78 and 88) and 2-amino-4-methyl-
thiazolyl series (104a-c) for hH2R-Gsαs (graphical presentation in Fig. 5.5), the 3-
cyclohexylbutanoylguanidine is more favoured by human H2 receptor compared to guinea pig. 
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Fig. 4.5: H2R agonistic potencies (pEC50 values) of imidazolylpropyl (A) and 2-amino-4-methyl-
thiazolylpropyl (B) guanidines on guinea pig and human H2R-Gsα fusion proteins (from Table 
4.4) 
 
Histamine H3R antagonism on the guinea pig ileum: receptor selectivity 
The first identified histamine H3 receptor antagonists were mono-substituted imidazoles. 
Meanwhile numerous imidazole-type H3R antagonists are described.24 
Imidazolylpropylguanidine-type histamine H2R agonists such as arpromidine or impromidine are 
also known to be H3R antagonists. Therefore, a selection of the synthesized H2R agonists was 
investigated for activity at H3 receptors. The field stimulated guinea pig ileum longitudinal 
muscle was used as a model (data see Table 5.5).a   
As expected the imidazolylpropylguanidine-type H2R agonists (61, 63, 71, 78, 88), proved to be 
moderate to potent H3R antagonists on the guinea pig ileum. The maximal response of the H3R 
agonist (R)-α-methylhistamine was not significantly affected. The lowest pA2 value was found 
for “oxo-impromidine” (61), whereas compound 78 (pA2 8.33) was the most potent H3R 
antagonist in this series. However, the aminothiazole analogues 104a-c were inactive at the 
                                                 
a Prior to these investigations the compounds were tested for antagonistic activity on muscarinic M3 receptors (guinea 
pig ileum; see experimental section). All test compounds proved to be only very weak M3 antagonists (pA2 < 6). In 
order to avoid measurement artefacts the investigations for H3R antagonism were generally performed with 
antagonist concentrations at least half an order of magnitude below the KB value for MB 3R antagonism.  
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concentrations tested, confirming the working hypothesis that the aminothiazole and the 
imidazole moiety are bioisoteric groups at H2R but not at H3R. By this approach the histamine 
H2R selectivity (vs. H3R) can be considerably increased. 
 
Table 5.5: H3R antagonistic activity of selected compounds  
(guinea pig ileum: field stimulated longitudinal muscle with adhering myenteric plexus) 
No Na c(antagonist) 
[nM] 
pA2 ± SEMb Emax ± SEMc 
[%] 
Emax ± SEMd 
[%] 
Ne
61 4 1000 6.86 ± 0.06 106 ± 15 110 ± 1 3 
63 4 100 7.81 ± 0.09 93 ± 10 91 ± 8 7 
71 4 100 7.90 ± 0.05 95 ± 15 93 ± 10 4 
78 4 100 8.33 ± 0.08 75 ± 7 84 ± 6 4 
88 4 100 7.64 ± 0.11 72 ± 7 87 ± 8 6 
104a 3 500 [−0.18 ± 0.07] 79 ± 5 85 ± 9 4 
104b 3 500 [0.06 ± 0.12] 85 ± 1 85 ± 9 4 
104c 3 500 [0.14 ± 0.02] 88 ± 7 85 ± 9 4 
a Number of experiments (tissues from 2 – 4 animals).  b Corrected ΔpEC50 values given in brackets for compounds 
producing no relevant shift by the concentration tested. For these compounds, pA2 was < 6.3.  c Emax of (R)-α-
methylhistamine in the presence of the compound.  d Emax of (R)-α-methylhistamine in untreated control tissues 
(second concentration-effect curve).  e Number of untreated control tissues (from 2 – 4 animals). 
 
As expected the imidazolylpropylguanidine-type H2R agonists (61, 63, 71, 78, 88), proved to be 
moderate to potent H3R antagonists on the guinea pig ileum. The maximal response of the H3R 
agonist (R)-α-methylhistamine was not significantly affected. The lowest pA2 value was found 
for “oxo-impromidine” (61), whereas compound 78 (pA2 8.33) was the most potent H3R 
antagonist in this series. However, the aminothiazole analogues 104a-c were inactive at the 
concentrations tested, confirming the working hypothesis that the aminothiazole and the 
imidazole moiety are bioisoteric groups at H2R but not at H3R. By this approach the histamine 
H2R selectivity (vs. H3R) can be considerably increased. 
 
4.4. Conclusion 
 
The bioisosteric replacement of the imidazolyl moiety in NG-acylated guanidine-type histamine 
H2 receptor agonists by a 2-amino-4-methylthiazol-5-yl group resulted in about the same H2R 
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agonistic potency in the isolated guinea pig right atrium as well as in GTPase assays performed 
with both guinea pig and human H2R-GsαS fusion proteins. However, the maximal response 
induced by the thiazoles was reduced, i. e. these compounds were partial agonists in the used 
pharmacological models. Interestingly, in the GTPase assay the thiazolyl analogue with 
cyclohexylbutanoyl substituent was favoured compared to the corresponding phenylbutanoyl-
guanidine on the human H2R. This could provide a hint that a certain degree of selectivity for the 
human H2R may be achieved by structural variation of both the acyl and the heterocyclylpropyl 
group. Moreover, the aminothiazoles proved to be devoid of H3R antagonistic activity. Thus, the 
selectivity for H2R versus H3R can be considerably improved. 
 
 
4.5. Experimental section 
 
4.5.1. Chemistry: 
 
General procedures 
For detailed description of the general procedures and equipments, see section 3.6.1 of Chapter 
3. 
 
2-(5-Oxohexyl)isoindoline-1,3-dione [95]25  
A mixture of phthalimide (6.3 g, 0.043 mol), 6-chloro-2-hexanone (11.5 g, 0.086 mol), potassium 
carbonate (9.0 g, 0.064 mol) and N,N-dimethylformamide (100 mL) was heated to 80°C for 24 h. 
After cooling to room temperature, the mixture was added to ice cold water and extracted with 
chloroform. The organic solvent was removed under reduced pressure to get a viscous reaction 
mixture. Column chromatography of the residue gave a solid.  
Yield 88 %; colorless crystalline solid; C14H15NO3 (245.3); mp 57°C; IR (neat): 1768, 1706, 
1437, 1392, 1357, 1257, 1163, 1122, 1045, 890, 793, 720 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.66-
7.90 (m, 4H, Phth-H), 3.70 (t, J = 6.3 Hz, 2H, COCH2), 2.52 (t, J = 6.8 Hz, 2H, Phth-CH2), 2.14 
(s, 3H, CH3CO), 1.48-1.80 (m, 4H, MeCOCH2CH2CH2); 13C-NMR (CDCl3), δ (ppm): 208.3 
(quart, CH3CO), 168.4 (quart, C(O)N), 133.9 (+, Phth-CH), 132.1 (quart, Phth-C), 123.2 (+, Phth-
CH), 42.8, 37.5 (-, CH2), 29.9 (+, CH3), 27.9, 20.7 (-, CH2); EI-MS, m/z (rel. intensity, %): 245 
([M]+·, 17), 202 ([M-CH3CO]+, 12), 188 ([M-CH3COCH2]+,66), 174 ([Phth-CH2CH2]+, 23), 160 
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([Phth-CH2]+, 100), 148 (6), 133 (10), 130 (18), 104 (3), 77 (20), 43 (51): Anal. (C14H15NO3) C, 
H, N.  
 
2-(4-Bromo-5-oxohexyl)isoindoline-1,3-dione [96]25  
Bromine (14.5 g (0.09 mole) was cautiously added to a solution of 6-phthalimidohexane-2-one 
(95) (23.0 g, 0.09 mol) in carbontetrachloride (150 mL) with vigorous stirring at room 
temperature. After decoloration of the reaction mixture the stirring was continued at room 
temperature for 2 h. Subsequently, chloroform (100 mL) and water (300 mL) were added and the 
mixture was stirred for 30 minutes. The water phase was removed and the organic phase was 
washed with water until neutralized. The organic phase was subsequently dried on anhydrous 
sodium sulphate, filtered and vacuum concentrated. The residue (viscous oil) was used without 
any purification for the preparation of 2-amino-4-methyl-5-(3-phthalimidopropyl)thiazole (97). 
 
Yield 92 %; colorless viscous oil; C14H14BrNO3 (324.2); 1H-NMR (CDCl3), δ (ppm): 7.60-7.95 
(m, 4H, Phth-H), 4.36 (t, J = 7.2 Hz, 1H, CHBr), 3.46-3.90 (m, 2H, CH2N), 2.36 (s, 3H, 
CH3CO), 1.74-2.22 (m, 4H, CHBrCH2CH2). 
 
2-[3-(2-Amino-4-methylthiazol-5-yl)propyl]isoindoline-1,3-dione [97]25 
To a solution of crude 2-(4-bromo-5-oxohexyl)isoindoline-1,3-dione (96) (20.0 g, 0.06 mol) in 
anhydrous DMF (50 mL) a solution of thiourea (4.5 g, 0.06 mol) in 50 mL of dry DMF was 
added with stirring. After the exothermic reaction (the temperature may rise to 100°C), the 
mixture is heated at 100°C for 3h. After cooling the reaction mixture is high vacuum 
concentrated, then to the residue an ethylacetate/methanol mixture (1:1, v/v) is added. After 
stirring for 30 minutes the precipitate is filtered off, washed subsequently with ethyl acetate and 
diethyl ether and thereafter dried in vacuo. 
 
Yield 49 %; colorless solid; C15H15N3O2S (301.4); mp 242 oC; IR (neat): 1769, 1711, 1623, 1464, 
1438, 1398, 1337, 1293, 1270, 1120, 1067, 1039, 872, 719 cm-1; 1H-NMR (DMSO-d6), δ (ppm): 
9.23 (broad s, 2H, NH2), 7.88 (s, 4H, Ar-H), 3.64 (t, J = 6.6 Hz, 2H, Thiaz-CH2), 2.70 (t, J = 8.1 
Hz, 2H, PhthN-CH2), 2.15 (s, 3H, Thiaz-4-CH3), 1.62-2.04 (m, 2H, Thiaz-CH2CH2); 13C-NMR 
(CDCl3), δ (ppm): 167.9 (quart, CO), 167.5 (quart, Thiaz-C-2), 134.2 (+, Phth-C), 131.6 (quart, 
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Phth-C), 130.8 (quart, Thiaz-C-4), 122.8 (+, Phth-C), 116.7 (quart, Thiaz-C-5), 36.5 (-, PhthN-C), 
28.6 (-, Thiaz-C), 22.3 (-, Thiaz-CH2CH2), 11.2 (+, Thiaz-4-CH3); EI-MS m/z, 301  ([M]+·, 24), 
169 ([C7H11N3S]+, 21), 160 (8), 141 (15), 127 ([C5H7N2S]+, 100), 100 (19), 77 (8), 28 (37); Anal. 
(C15H15N3O2S) C, H, N. 
 
tert-Butyl 4-methyl-5-[3-(1,3-dioxoisoindolin-2-yl)propyl]thiazol-2-ylcarbamate [98] 
2-[3-(2-Amino-4-methylthiazol-5-yl)propyl]isoindoline-1,3-dione (97) (6 g, 20 mmol) was 
dissolved in CHCl3 (50 mL), di-tert-butyl dicarbonate (4.8 g, 22 mmol, 1.1 eqiuv.), triethylamine 
(3.4 mL, 24 mmol, 1.2 equiv) and 4-dimethylaminopyridine (DMAP, 10 mg) were added, and the 
mixture was stirred for 6h at room temperature. Subsequently, the mixture was diluted with 
dichloromethane (100 mL), washed with 0.1N HCl, brine, and then water and dried over MgSO4. 
The solvent was removed under reduced pressure and the residue was purified by column 
chromatography to give a foam-like solid. 
 
Yield 86 %; colorless foam-like solid; C20H23N3O4S (401.5); mp 71 oC; IR (neat): 1771, 1708, 
1553, 1437, 1394, 1368, 1296, 1244, 1153, 1069, 1038, 870, 791, 716 cm-1; 1H-NMR (CDCl3), δ 
(ppm): 7.89-7.79 (m, 2H, Phth-H), 7.77-7.66 (m, 2H, Phth-H), 3.75 (t, J = 6.9 Hz, 2H, Thiaz-
CH2), 2.72 (t, J = 7.8 Hz, 2H, Phth-NCH2), 2.24 (s, 3H, Thiaz-4-CH3), 1.99 (m, 2H, Thiaz-
CH2CH2), 1.53 (s, 9H, C(CH3)3); 13C-NMR (CDCl3), δ (ppm): 168.2 (quart, Phth-CO), 158.5 
(quart, Thia-C-2), 152.4 (quart, tBuO-CO), 140.2 (quart, Thiaz-C-4), 134.0 (+, Phth-C), 132.0 
(quart, Phth-C), 123.2 (+, Phth-C), 122.9 (quart, Thiaz-C-5), 82.7 (quart, C(CH3)3), 37.4 (-, Phth-
CH2), 30.0 (-, Thiaz-5-CH2), 28.2 {+, C(CH3)3}, 23.5 (-, Thiaz-5-CH2CH2), 14.0 (+, Thiaz-4-
CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 402 ([M+H]+); Anal. (C20H23N3O4S) C, H, 
N. 
 
tert-Butyl 5-(3-aminopropyl)-4-methylthiazol-2-ylcarbamate [99]  
To a suspension of 98 (6.7 g, 16.7 mmol) in ethanol (60 mL) was added hydrazine monohydrated 
(4.0 mL, 83.5 mmol). After 30 min of stirring at room temperature, the solid was dissolved and 
the solution was further stirred overnight at same temperature. After the mixture was cooled in 
ice bath the precipitated was removed by filtration and the filtrate was concentrated to dryness. 
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The residue was purified by column chromatography on silica by using chloroform and methanol 
with 1 % of triethylamine. 
Yield 82 %; grey colored sticky oil; C12H21N3O2S (271.4); IR (neat): 1713, 1555, 1452, 1367, 
1297, 1244, 1154, 1068, 871, 764, 690 cm-1; 1H-NMR (CDCl3), δ (ppm): 5.9 (br, NH2), 2.80 (t, J 
= 7.1 Hz, 2H, CH2NH2), 2.77-2.63 (m, 2H, Thiaz-5-CH2), 2.26 (s, 3H, Thiaz-4-CH3), 1.82 (m, 
2H, Thiaz-5-CH2CH2), 1.51 (s, 9H, C(CH3)3; 13C-NMR (CDCl3) δ: 157.9 (quart, Thia-C-2), 
153.0 (quart, Boc-CO), 141.5 (quart, Thia-C-4), 123.5 (quart, Thia-C-5), 81.9 {quart, C(CH3)3}, 
40.9 (-, CH2NH2), 34.3 (-, Thiaz-5-CH2), 28.2 {+, C(CH3)3}, 23.3 (-, Thiaz-5-CH2CH2), 14.4 (+, 
Thiaz-4-CH3);  MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 215 ([(M-C4H8) + H]+), 272 
([M+H]+), 543 ([2M + H]+). 
 
tert-Butyl 5-[3-[N2,N3-bis(benzyloxycarbonyl)guanidino]propyl]-4-methylthiazol-2-ylcarba-
mate [100] 
The amine 99 (3.98 g, 14.7 mmol) was dissolved in 40 mL of CHCl3 and added to a solution of 
N1,N2-bis(benzyloxycarbonyl)-N3-trifluoromethanesulphonylguanidine (23, 6.14 g, 13.4 mmol) 
and triethylamine (1.49 g, 14.74 mmol) in CHCl3 (40 mL) and the mixture was allowed to stir at 
rt until the triprotected guanidine 23 was consumed (4 h) as evidenced by TLC. After the reaction 
was complete, the mixture was diluted with CHCl3 (100 mL) and washed with 2 M sodium 
bisulphate, saturated sodium bicarbonate, and brine. The organic extract was then dried over 
sodium sulphate and filtered, and the solvent was removed under reduced pressure. The crude 
product was purified by flash column chromatography to afford a colorless solid. 
Yield 93 %; colorless solid; C29H35N5O6S (581.7); mp 110°C; IR (in CH2Cl2): 1726, 1638, 1572, 
1427, 1382, 1302, 1263, 1203, 1156, 1044, 731, 698 cm-1; 1H-NMR (CDCl3), δ (ppm): 11.74 (br., 
1H, NH), 8.36 (t, J = 5.3 Hz, 1H, CH2NH), 7.43-7.23 (m, 10H, Ph-H), 5.17 (s, 2H, Ph-CH2O), 
5.12 (s, 2H, Ph-CH2O), 3.47 (m, 2H, CH2NH), 2.70 (t, J = 7.4 Hz, 2H, Thiaz-5-CH2), 2.23 (s, 
3H, Thiaz-4-CH3), 1.88 (m, 2H, Thiaz-5-CH2CH2), 1.52 {s, 9H, C(CH3)3}; 13C-NMR (CDCl3), δ 
(ppm): 163.6 (quart, Thiaz-C-2), 157.9 (quart, PhCH2O-CO), 153.8 (quart, tBuO-CO), 152.6 
(quart, PhCH2O-CO), 141.5 (quart, Thiaz-C-4), 136.7 (quart, Ph-C-1), 134.5 (quart, Ph-C-1), 
128.8, 128.6, 128.5, 128.4, 128.1, 127.9 (+, Ph-C), 122.9 (quart, Thia-C-5), 82.4 {quart, 
C(CH3)3}, 68.1, 67.1 (-, PhCH2), 40.1 (-, CH2NH), 30.6 (-, Thiaz-5-CH2), 28.2 {+, C(CH3)3}, 
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23.2 (-, Thiaz-5-CH2CH2), 14.3 (+, Thiaz-4-CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 
582 ([M+H]+), 1163 ([2M+H]+), 1185 ([2M+Na]+); Anal. (C29H35N5O6S) C, H, N. 
 
tert-Butyl 5-(3-guanidinopropyl)-4-methylthiazol-2-ylcarbamate [101’] 
To a solution of 100 (10 mmol) in a mixture of 150 mL THF and MeOH (1:1) was added 0.5 g of 
Pd/C (10 %) and then the mixture was stirred under H2 (filled with balloon) overnight. The 
catalyst was removed by filtration through celite and washed with MeOH. The solvent was 
evaporated in vacuo to obtain a foam-like solid. However, when the reaction mixture was stirred 
for only 6h, there was a partial deprotection and the remaoval of solvent after filtration gave a 
mixture of 101’ and 101’’ (40:60).  
 
Yield 96 %; colorless solid; C13H23N5O2S (313.4); mp 147 oC; IR (neat): 1622, 1555, 1451, 1366, 
1294, 1246, 1154, 1053, 869, 784, 689 cm-1; 1H-NMR (CD3OD), δ (ppm): 3.19 (t, J = 6.8 Hz, 
2H, CH2NH), 2.69 (t, J = 7.4 Hz, 2H, Thiaz-CH2), 2.11 (s, 3H, Thiaz-4-CH3), 1.83 (m, 2H, 
CH2CH2CH2NH), 1.49 (s, 9H, C(CH3)3); 13C-NMR (CD3OD), δ (ppm): 163.7 (quart, Thiaz-C-2), 
158.8 (quart, tBuO-CO), 158.2 (quart, C=NH), 142.3 (quart, Thiaz-C-4), 122.5 (quart, Thiaz-C-
5), 80.7 (quart, Boc-C), 41.4 (-, CH2NH), 31.6 (-, Thiaz-5-CH2), 28.8 {+, C(CH3)3}, 23.9 (-, 
Thiaz-5-CH2CH2), 14.4 (+, Thiaz-4-CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 314 
([M+H]+). 
 
General procedure for the preparation of the acylguanidines 102a-c and 103a-c 
To a solution of 3,3-diphenylpropanoic acid, (R,S)-3-phenylbutanoic acid or (R,S)-3-
cyclohexylbutanoic acid  (1 equivalent), EDC (1 equivalent) and HOBt (1 equivalent)  in CH2Cl2 
(3 mL) under argon, was added DIEA (1 mmol) and stirred for 10 min. To this mixture a solution 
of 1 mmol of 101’ and 101’’ (used as mixture of both, ratio = 40:60) in CH2Cl2 (2 mL) was added 
dropwise, and stirred overnight (12-16 h) at rt. After removing the solvent, the residue was 
dissolved in EtOAc, 5 mL of water was added, the organic layer was separated, and the aqueous 
phase extracted with EtOAc. After drying over anhydrous sodium sulphate, the solvent was 
removed in vacuo and the residue was purified to give monoacylated (102a-c) and diacylated 
(103a-c) products.  
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tert-Butyl 5-[3-[N2-benzyloxycarbonyl-N3-(3,3-diphenylpropanoyl)guanidino]propyl]-4-
methylthiazol-2-ylcarbamate [102a]
Stirring for 12h; yield 48 %; colorless sticky liquid; C36H41N5O5S (655.8); IR (neat): 1714, 1643, 
1560, 1451, 1368, 1300, 1245 cm-1; 1H-NMR (CD3OD), δ (ppm): 12.32 (s. br, 1H, NH), 8.94 (m, 
1H, NHCH2), 7.43-7.09 (m, 15H, Ph-H), 5.14 (s, 2H, OCH2Ph), 4.57 (t, J = 8.0 Hz, 1H, Ph2CH), 
3.40 (m, 2H, CH2NH), 3.14 (d, J = 7.9 Hz, 2H, COCH2), 2.63 (t, J = 7.6 Hz, 2H, Thiaz-5-CH2), 
2.18 (s, 3H, Thiaz-4-CH3), 1.90 (m, 2H, Thiaz-5-CH2CH2), 1.51 {s, 9H, (CH3)3 of Boc}; 13C-
NMR (CD3OD), δ (ppm): 173.0 (quart, COCH2), 163.7 (quart, Thiaz-C-2), 158.2 (quart, 
C(=O)OBn), 156.2 (quart, C(=O)O-tBu), 152.2 (quart, C(=N)), 144.5 (quart, Thiaz-C-4), 142.6, 
136.6 (quart, Ph-C-1), 128.7, 128.4, 128.1, 127.9, 127.8, 127.5, 126.8, 126.3, 126.1, 125.8 (+, C 
of Ph), 123.1 (quart, Thiaz-C-5), 82.9 (quart, C of Boc), 67.3 (-, CH2Ph), 46.5 (+, Ph2C), 44.1 (-, 
COCH2), 39.8 (-, CH2NH), 30.3 (-, Thiaz-5-CH2), 28.2 {+, (CH3)3 of Boc}, 23.1 (-, Thiaz-5-
CH2CH2), 13.9 (+, Thiaz-4-CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 656 ([M + H]+), 
556 {[(M-Boc) + H]+}. 
 
tert-Butyl 5-[3-[N2,N3-bis(3,3-diphenylpropanoyl)guanidino]propyl]-4-methylthiazol-2-yl-
carbamate [103a] 
Yield 30 %; colorless sticky liquid; C43H47N5O4S (729.9); IR (neat): 1714, 1618, 1556, 1493, 
1450, 1368, 1301, 1264, 1246 cm-1; 1H-NMR (CDCl3), δ (ppm): 13.09 (s. br, 1H, NH), 8.91 (m, 
1H, NHCH2), 7.31-7.10 (m, 20H, Ph-H), 4.60 (t, J = 7.9 Hz, 1H, Ph2CH), 4.52 (t, J = 7.9 Hz, 1H, 
Ph2CH), 3.34 (m, 2H, CH2NH), 3.09 (m, 4H, COCH2), 2.61 (t, J = 7.4 Hz, 2H, Thiaz-5-CH2), 
2.19 (s, 3H, Thiaz-4-CH3), 1.79 (m, 2H, Thiaz-5-CH2CH2), 1.51{s, 9H, (CH3)3 of Boc}; 13C-
NMR (CD3OD), δ (ppm): 173.4 (quart, COCH2), 158.2 (quart, Thiaz-2-C), 155.4 (quart, 
C(=O)O-tBu), 152.3 {quart, C(=N)}, 144.5 (quart, Thiaz-C-4), 142.7, 133.3 (quart, Ph-C-1), 
128.9, 128.7, 128.4, 127.9, 127.8, 127.5, 126.8, 126.3, 126.1 (+, C of Ph), 123.1 (quart, Thiaz-5-
C), 82.7 (quart, C of Boc), 47.6, 46.5 (+, Ph2CH), 47.2, 44.0 (-, COCH2), 40.0 (-, CH2NH), 30.4 
(-, Thiaz-5-CH2), 28.2 {+, (CH3)3 of Boc}, 23.1 (-, Thiaz-5-CH2CH2), 14.2 (+, Thiaz-4-CH3); MS 
(ESI, MeOH + 10 mM NH4OAc): 730 ([M + H]+), 752 ([M + Na]+). 
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tert-Butyl 5-[3-[N2-benzyloxycarbonyl-N3-(3-phenylbutanoyl)guanidino]propyl]-4-methyl-
thiazol-2-ylcarbamate [102b] 
Stirring for 15h; yield 52 %; colorless liquid; C31H39N5O5S (593.7); IR (in CH2Cl2): 1715, 1642, 
1558, 1495, 1452, 1368, 1299, 1243, 1155, 1123, 1068, 803, 734, 698 cm-1; 1H-NMR (CDCl3), δ 
(ppm): 12.21 (br. S, 1H, NH), 9.03 (br. s, 1H, NH), 7.45-7.12 (m, 10H, Ph-H), 5.13 (s, 2H, 
OCH2Ph), 3.52-3.15 {m, 3H, CH2NH &  CH(CH3)Ph}, 2.82-2.52 (m, 4H, COCH2 & Thiaz-5-
CH2), 2.20 (s, 3H, Thiaz-4-CH3), 1.95-1.74 (m, 2H, Thiaz-5-CH2CH2), 1.52 {s, 9H, CH(CH3)3}, 
1.33 {d, J = 6.9 Hz, 3H, Ph(CH3)CH}; 13C-NMR (CDCl3), δ (ppm): 174.2 (quart, CO), 163.7 
(quart, CO), 157.9 (quart, Thiaz-C-2), 156.3 (quart, Boc-CO), 152.4 (quart, Thiaz-C-4), 144.6, 
136.8 (quart, Ph-C-1), 128.7, 128.5, 128.4, 128.3, 128.1, 127.9, 126.8, 126.7, 126.6, 125.9 (+, Ph-
C), 123.0 (quart, Thiaz-C-5), 82.7 (quart, Me3C), 67.2 (-, CH2Ph), 46.4 (-, COCH2), 39.9 (-, 
CH2NH), 36.3 {+, Ph(CH3)CH}, 30.4 (-, Thiaz-5-CH2), 28.2 {+, C(CH3)}, 23.2 (-, Thiaz-5-
CH2CH2), 14.2 {+, Ph(CH3)CH}, 14.17 (+, Thiaz-4-CH3); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc): 594 ([M + H]+), 494{[(M-Boc) + H]+}. 
 
tert-Butyl 5-[3-[N2,N3-bis(3-phenylbutanoyl)guanidino]propyl]-4-methylthiazol-2-ylcarba-
mate [103b] 
Yield 32 %; colorless liquid; C33H43N5O4S (605.8); IR (CH2Cl2): 1714, 1616, 1556, 1451, 1366, 
1301, 1245, 1154, 1069, 762, 734, 698 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.33-7.11 (m, 10H, Ph-
H), 3.46-3.20 (m, 4H, CH3CH & CH2NH), 2.51-2.75 (m, 6H, COCH2 & Thiaz-5-CH2), 2.23 (s, 
3H, Thiaz-4-CH3), 1.85 (m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, Boc-CH3), 1.30 (d, J = 6.9 Hz, 
3H, COCHCH3), 1.27 (d, J = 6.9 Hz, 3H, COCHCH3); 13C-NMR (CD3OD), δ (ppm): 186.7 
(quart, COCH2), 174.1 (quart, COCH2), 157.9 (quart, Thiaz-2-C), 155.4 (quart, Boc-CO), 152.6 
(quart, C=NH), 146.9, 144.7 (quart, Ph-C-1), 141.5 (quart, Thiaz-C-4), 133.2, 133.1, 128.8, 
128.6, 128.5, 128.3, 128.1, 126.8, 125.9 (+, Ph-C), 122.9 (quart, Thiaz-C-5), 82.3 (quart, Boc-C), 
49.5, 46.4 (-, COCH2CH), 40.0 (-, CH2NH), 36.9, 36.3 (+, COCH2CH), 30.5 (-, Thiaz-5-CH2), 
28.2 (+, Boc-CH3), 23.2 (-, Thiaz-5-CH2CH2), 22.2, 21.9 (+, CHCH3), 14.3 (+, Thiaz-4-CH3); 
MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 606 ([M + H]+), 506 {[(M-Boc) + H]+}. 
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tert-Butyl 5-[3-[N2-benzyloxycarbonyl-N3-(3-cyclohexylbutanoyl)guanidino]propyl]-4-
methylthiazol-2-ylcarbamate [102c] 
Stirring for 16h; yield 46 %; colorless sticky liquid; C31H45N5O5S (599.8); 1H-NMR (CDCl3), δ 
(ppm): 12.21 (br, NH), 9.17 (br. t, J = 5.3 Hz, 1H, NHCH2), 7.45-7.20 (m, 5H, Ph-H), 5.15 (s, 
2H, PhCH2), 3.47 (m, 2H, NHCH2), 2.70 (t, J = 7.5 Hz, 2H, Thiaz-5-CH2), 2.45 (m 1H, one of 
COCH2), 2.21 (s, 3H, Thiaz-4-CH3), 2.11 {m, 2H, one of COCH2 & CH(c-Hex)}, 2.01-1.59 (m, 
c-Hex), 1.52 (s, 9H, Boc), 1.42-0.71 (m, c-Hex), 0.92 (d, J = 6.9 Hz, 3H, COCH2CHCH3); 13C-
NMR (CD3OD), δ (ppm): 179.2 (quart, C=N), 175.4 (quart, COCH2), 163.8 (quart, C(=O)), 158.3 
(quart, Thiaz-C-2), 156.5 (quart, Boc-CO), 152.5 (quart, Thiaz-C-4), 136.7 (quart, Ph-C-1), 
128.4, 128.1, 127.9 (+, Ph-H), 82.5 (quart, Boc-C), 67.2 (-, PhCH2O), 42.8 (-, COCH2), 42.5 (+, 
Cy-C-1), 39.9 (-, CH2NH), 35.3 (+, COCH2CH), 30.5, 30.3, 29.7 (-, Thiaz-5-CH2CH2, c-Hex-
CH2), 28.9 (+, Boc CH3), 26.7, 26.6 (-, c-Hex-CH2), 16.5 (+, c-Hex-CHCH3), 14.1 (+, Thiaz-4-
CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 600.3 ([M + H]+), 500{[(M-Boc) + H]+}, 
1199 ([2M + H]+) 
 
tert-Butyl 5-[3-[N2,N3-bis(3-cyclohexylbutanoyl)guanidino]propyl]-4-methylthiazol-2-yl-
carbamate [103c] 
Yield 28 %; colorless sticky liquid; C33H55N5O4S (617.9); ; 1H-NMR (CD3OD), δ (ppm): 12.21 
(br, NH), 9.17 (br. m, 1H, NHCH2), 3.46 (m, 2H, CH2NH), 2.69 (t, J = 7.4 Hz, 2H, Thiaz-5-
CH2), 2.45 (d, J = 4.9 Hz, 2H, COCH2), 2.39 (d, J = 4.9 Hz, 2H, COCH2), 2.16 (s, 3H, Thiaz-4-
CH3), 2.15-1.50 (m, H), 1.54 {s, 9H, (CH3)3 of Boc}, 1.30-1.00 (m, H), 0.93 (d, J = 6.8 Hz, 6H, 
COCH2CHCH3), 13C-NMR (CD3OD), δ (ppm): 188.9 (quart, CH2CO), 179.8 (quart, CH2CO), 
176.0 {quart, C(=N)}, 158.9 (quart, Thiaz-C-2), 155.6 (quart, Boc-CO), 152.5 (quart, Thiaz-C-4), 
122.7 (quart, Thiaz-C-5), 82.5 (quart, Boc-C), 42.8 (-, COCH2), 42.5 (+, Cy-C-1), 39.9 (-, 
CH2NH), 35.3 (+, COCH2CH), 30.5, 30.3, 29.7 (-, Thiaz-5-CH2CH2, c-Hex-CH2), 28.9 (+, Boc-
CH3), 26.7, 26.6 (-, c-Hex-CH2), 16.5 (+, c-HexCHCH3), 14.1 (+, Thiaz-4-CH3); MS (ESI, 
CH2Cl2/MeOH + 10 mM NH4OAc): 618 ([M + H]+). 
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General procedure for the preparation of the N2-monoacylated 3-(2-amino-4-methylthiazol-
5-yl)propylguanidines 104a-c 
To a solution of corresponding Boc- and Cbz-compound (102a-c) (1 mmol) in 5 mL MeOH was 
added 20 mg of Pd/C (10 %) and then the mixture was stirred under H2 (baloon) overnight. The 
catalyst was filtered off through celite, washed with MeOH, and then the solvent was removed in 
vacuo. To the residue 5 mL of 50 % TFA in CH2Cl2 was added and stirred at rt till the Boc group 
was completely removed (3 - 4 h). The solvent was then removed in vacuo and the residue was 
purified by preparative HPLC (Instrumental setup described at General condition in section 3.6.1. 
of Chapter 3). 
 
N1-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N2-(3,3-diphenylpropanoyl)guanidine [104a] 
Reaction time: 3 h; yield 88 %; colorless sticky liquid; C23H27N5OS (421.5); IR (neat) 1639, 
1596, 1493, 1433, 1392, 1200, 1131, 827, 799, 754, 720, 706, 626 cm-1; 1H-NMR (CD3OD), δ 
(ppm): 7.34-7.11 (m, 10H, Ph-H), 4.59 (t, J = 8.0 Hz, 1H, Ph2CH), 3.28 (m, 4H, COCH2 & 
CH2NH), 2.65 (t, J = 7.6 Hz, 2H, Thiaz-5-CH2), 2.17 (s, 3H, Thiaz-4-CH3), 1.85 (m, 2H, Thiaz-
5-CH2CH2); 13C-NMR (CD3OD), δ (ppm): 175.5 (quart, COCH2), 170.4 (quart, Thiaz-C-2), 
155.1 {quart, C(=N)}, 144.5 (quart, Ph-C-1), 132.6 (quart, Thiaz-C-4), 129.7, 128.8, 127.8 (+, C 
of Ph), 118.4 (quart, Thiaz-C-5), 48.1 (+, Ph2C), 43.8 (-, COCH2), 41.5 (-, CH2NH), 29.6 (-, 
Thiaz-5-CH2), 23.5 (-, Thiaz-5-CH2CH2), 11.4 (+, Thiaz-4-CH3); MS (ESI, CH2Cl2/MeOH + 10 
mM NH4OAc): 422 ([M + H]+). 
Analytical HPLC: Rt 13.5 min (Column B; 0 min: 97/3, 24 min: 85/15); purity: 95 %. 
 
N1-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N2-(3-phenylbutanoyl)guanidine [104b] 
Reaction time: 2.5 h; yield 92 %; colorless sticky liquid; C18H25N5OS (359.5); IR (in CH2Cl2) 
1664, 1600, 1432, 1180, 1130, 1024, 832, 798, 762, 720, 700 cm-1; 1H-NMR (CD3OD), δ (ppm): 
7.33-7.13 (m, 5H, Ph-H), 4.15 {m, 1H, Ph(CH3)CH}, 3.34 (m, 2H, CH2NH), 2.76 (dd, J1 = 3.3 
Hz, J2 = 15.4 Hz, 2H, COCH2), 2.67 (t, J = 7.5 Hz, 2H, Thiaz-5-CH2), 2.15 (s, 3H, Thiaz-4-CH3), 
1.88 (m, 2H, Thiaz-5-CH2CH2), 1.31 {d, J = 7.1 Hz, 3H, Ph(CH3)CH}; 13C-NMR (CD3OD), δ 
(ppm): 176.1 (quart, CO), 170.3 (quart, Thiaz-1-C), 155.1 {quart, C(=NH)}, 146.4 (quart, Thiaz-
4-C), 132.6 (quart, Ph-1-C), 129.6, 127.9, 127.7 (+, Ph-C), 118.3 (quart, Thiaz-C-5), 46.1 (-, 
COCH2), 41.5 (-, CH2NH), 37.6 {+, CH(CH3)Ph}, 29.6 (-, Thiaz-5-CH2), 23.5 (-, Thiaz-5-
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CH2CH2), 22.3 (+, Thiaz-4-CH3), 11.4 {+, CH(CH3)Ph}; MS (ESI, H2O/AcCN + 0.0059% TFA): 
360 ([M + H]+);  
Analytical HPLC: Rt 11.75 min (Column B; 0 min: 97/3, 24 min: 85/15); purity: >90 %. 
 
N1-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N2-(3-cyclohexylbutanoyl)guanidine [104c] 
Reaction time: 3 h; yield 92 %; colorless sticky liquid; C18H31N5OS (365.5); IR (neat): 1788, 
1663, 1433, 1179, 1130, 835, 798, 720 cm-1; 1H-NMR (CDCl3), δ (ppm): 3.53 (t, J = 6.9 Hz, 2H, 
CH2NH2), 2.72 (t, J = 7.5 Hz, 2H,  Thiaz-5-CH2), 2.57 (dd, J1 = 5.2 Hz, J2 = 14.8 Hz, 1H, one of 
COCH2), 2.23 (dd, J1 = 5.2 Hz, J2 = 14.8 Hz, 1H, one of COCH2), 2.16 (s, 3H, Thiaz-4-CH3), 
2.10-1.58 {m, 8H, CH2 of c-Hex & CH(c-Hex)}, 1.40-0.96 (m, 6H, CH2 of c-Hex), 0.92 (d, J = 
6.9 Hz, 3H, COCH2CHCH3); 13C-NMR (CD3OD), δ (ppm): 177.5 (quart, COCH2), 170.4 (quart, 
Thiaz-C-2), 155.3 {quart, C(=N)}, 132.6 (quart, Thiaz-C-4), 118.4 (quart, Thiaz-C-5), 43.9 
(+,Cy-C-1), 42.7 (-, COCH2), 41.6 (-, CH2NH), 36.4 (+, c-HexCHCH3), 31.5 (-, Thiaz-5-CH2), 
30.0 (-, Thiaz-5-CH2CH2), 29.7 (-, CH2 of c-Hex), 27.8, 27.7, 23.6 (-, CH2 of c-Hex), 16.6 (+, c-
HexCHCH3), 11.4 (+, Thiaz-4-CH3); MS (ESI, CH2Cl2/MeOH + 10 mM NH4OAc): 366 ([M + 
H]+). 
Analytical HPLC: Rt 13.60 min (Column B; 0 min: 97/3, 24 min: 85/15); purity: 90 %. 
 
General procedure for the preparation of the diacylated guanidines 105a-c 
1 mmol of the Boc-proteceted diacylated guanidines (103a-c) in 5 mL of 50 % TFA in CH2Cl2 
was stirred at rt till the starting material completely disappeared (< 3 h). The solvent was then 
removed in vacuo and the residue was purified by preparative HPLC. 
 
N1-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N1,N2-bis(3-phenylbutanoyl)guanidine [105b] 
Reaction time: 2.5 h; yield 73 %; colorless sticky oil; C28H35N5O2S (505.7); IR (neat) 1685, 1619, 
1493, 1366, 1199, 1134, 1050, 1024, 1005, 823, 799, 761, 720, 699 cm-1; 1H-NMR (DMSO-d6), δ 
(ppm): 10.86 (br, NH), 9.44 (br, NH), 9.25 (br, 2H, NH2), 7.69-7.10 (m, 10H, Ph-H), 3.40-3.05 
(m, 4H, CH3CH & CH2NH), 2.90-2.40 (m, 6H, COCH2 & Thiaz-5-CH2), 2.12-1.98 (m, 3H, 
Thiaz-4-CH3), 1.81-1.61 (m, 2H, Thiaz-5-CH2CH2), 1.30-1.10 (m, 6H, COCHCH3);  13C-NMR 
(DMSO-d6), δ (ppm): 173.8 (quart, COCH2), 167.8 (quart, COCH2), 159.1 (quart, Thiaz-C-2), 
153.8 (quart, C=NH), 146.4, 145.1 (quart, Ph-C-1), 141.5 (quart, Thiaz-C-4), 133.2, 133.1, 128.8, 
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128.6, 128.5, 128.3, 128.1, 126.8, 125.9 (+, Ph-C), 116.5 (quart, Thiaz-C-5), 44.8, 41.9 (-, 
COCH2CH), 39.6 (-, CH2NH), 36.2, 35.6 (+, COCH2CH), 28.9 (-, Thiaz-5-CH2), 22.0 (-, Thiaz-
5-CH2CH2), 22.2, 21.9 (+, CHCH3), 11.1 (+, Thiaz-4-CH3); MS (ESI, CH2Cl2/MeOH + 10 mM 
NH4OAc): 506 ([M + H]+);  
However, this compounds are not stable enough, decomposed slowly even storing at -27°C for 
few days. 
 
N1-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N2,N3-bis(3-cyclohexylbutanoyl)guanidine 
[105c] 
Reaction time: 2.5 h; yield 65 %; colorless sticky liquid; C28H47N5O2S (517.8); IR (neat) 1668, 
1597, 1384, 1198, 1181, 1134, 1026, 720 cm-1; 1H-NMR (CD3OD), δ (ppm): 12.21 (br, NH), 
9.17 (br. m, 1H, NHCH2), 3.41 (m, 2H, CH2NH), 2.53-2.29 (m, 4H), 2.22-0.52 (m, 41H); 13C-
NMR (CD3OD), δ (ppm): 188.9 (quart, C(=O)CH2), 179.8 (quart, COCH2), 176.0 (quart, C(=N)), 
158.9 (quart, Thiaz-C-2), 152.5 (quart, Thiaz-C-4), 122.7 (quart, Thiaz-C-5), 42.8 (-, COCH2), 
42.5 (+, Cy-C-1), 39.9 (-, CH2NH), 35.3 (+, COCH2CH), 30.5, 30.3, 29.7 (-, Thiaz-5-CH2CH2, c-
Hex-CH2), 26.7, 26.6 (-,c-Hex-CH2), 16.5 (+, c-HexCHCH3), 14.1 (+, Thiaz-4-CH3); MS (ESI, 
CH2Cl2/MeOH + 10 mM NH4OAc): 518 ([M + H]+). 
However, this compounds are not stable enough, decomposed slowly even storing at -27°C for 
few days. 
 
4.5.2. Pharmacological Methods 
Data handling and pharmacological parameters, histamine H1 receptor assay on the isolated 
guinea pig ileum, histamine H2 receptor assay on isolated guinea pig right atrium (spontaneously 
beating), calcium cssays with U-373 MG cells, and steady-state GTPase activity assay was 
performed similar method as described in section 3.6.2 in Chapter 3. 
 
Acetylcholine M3 receptor assay on the isolated guinea pig ileum. Guinea pigs of either sex 
were stunned by a blow on the head and exsanguinated. The ileum was removed, and whole 
segments (1.5-2 cm) were mounted isotonically (preload 0.5 g) at 37 °C in Tyrode's solution,26 
aerated with 95% O2-5% CO2, in the continuous presence of 1–3 μM mepyramine, a 
concentration not affecting M3 receptors. During an equilibration period of ca. 80 min, the organs 
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were stimulated three times with carbachol (1 and 10 μM) followed by washout. Each preparation 
was used to establish a cumulative concentration-effect curve for carbachol (0.003-10 μM) 
followed by up to three curves for carbachol in the presence of increasing concentrations of 
antagonist (incubation time 10-15 min). The pEC50 difference was not corrected since four 
successive curves for carbachol were superimposable (n > 10). 
 
Histamine H3 receptor assay on electrically stimulated guinea pig ileum longitudinal muscle 
with adhering myenteric plexus. Strips of guinea pig ileal longitudinal muscle, with adhering 
myenteric plexus of approximately 2 cm length and proximal to the ileocaecal junction, were 
prepared as previously described.27,28 The strips were mounted isometrically under an initial 
tension of approximately 7.5 mN in a jacketed 20-mL organ bath of filled with modified Krebs-
Henseleit solution of the following composition [mM]: NaCl 117.9, KCl 5.6, CaCl2 2.5, MgSO4 
1.2, NaH2PO4 1.3, NaHCO3 25.0, glucose 5.5, and choline chloride 0.001. The solution was 
aerated with 95% O2-5% CO2 and warmed to a constant temperature of 37 °C. After an 
equilibration period of 1 h with washings every 15 min, the preparations were stimulated for 30 
min with rectangular pulses of 15 V and 0.5 ms at a frequency of 0.1 Hz. Viability of the muscle 
strips was monitored by addition of the histamine H3 receptor agonist (R)-α-methylhistamine 
(100 nM). The agonist caused a relaxation of the twitch response of more than 50% up to 100%. 
After washout, reequilibration and 30 min field-stimulation, a cumulative concentration-response 
curve to (R)-α-methylhistamine (1-1000 nM) was constructed. Subsequently, the preparations 
were washed intensively and reequilibrated for 20-30 min. During the incubation period of the 
antagonist under study, the strips were stimulated continuously for 30 min. Finally, a second 
concentration-response curve to (R)- -methylhistamine was obtained. The rightward 
displacement of the curve to the histamine H3 receptor agonist evoked by the antagonist under 
study was corrected with the mean shift monitored by daily control preparations in the absence of 
antagonist. New antagonists were tested at concentrations that did not block ileal cholinergic M3 
receptors. Mepyramine (1–3 μM) and cimetidine (30 μM) were present throughout the 
experiments to block H1 and H2 receptors, respectively. 
 
 125
Chapter 4 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 
 
4.6. References  
 
(1) Felix, S. B.; Buschauer, A.; Baumann, G. Therapeutic value of H2-receptor stimulation in 
congestive heart failure. Hemodynamic effects of BU-E-76, BU-E-75 and arpromidine 
(BU-E-50) in comparison to impromidine. Agents Actions Suppl. 1991, 33, 257-269. 
(2) Baumann, G.; Buschauer, A.; Felix, S. B. Hemodynamic profile of arpromidine and its F2-
substituted derivatives in comparison to impromidine in congestive heart failure. Agents 
Actions Special Conference Issue: Birkhäuser Verlag, Basel, Switzerland, 1992, pp C329-
332. 
(3) Durant, G. J.; Ganellin, C. R.; Parsons, M. E. Dimaprit, (S-[3-(N,N-
dimethylamino)propyl]isothiourea). A highly specific histamine H2-receptor agonist. Part 
2. Structure-activity considerations. Agents Actions 1977, 7, 39-43. 
(4) Parsons, M. E.; Owen, D. A.; Ganellin, C. R.; Durant, G. J. Dimaprit -(S-[3-(N,N-
dimethylamino)prophyl]isothiourea) - a highly specific histamine H2 -receptor agonist. 
Part 1. Pharmacology. Agents Actions 1977, 7, 31-37. 
(5) Sterk, G. J.; Koper, J.; Van der Goot, H.; Timmerman, H. Studies on histaminergic 
compounds VIII. A new series of compounds showing H1-antagonistic and H2-agonistic 
properties; synthesis, in vitro pharmacology, and structure-activity relationships. Eur. J. 
Med. Chem. 1987, 22, 491-498. 
(6) Durant, G. J.; Duncan, W. A.; Ganellin, C. R.; Parsons, M. E.; Blakemore, R. C. et al. 
Impromidine (SK&F 92676) is a very potent and specific agonist for histamine H2 
receptors. Nature 1978, 276, 403-405. 
(7) Buschauer, A. Synthesis and in vitro pharmacology of arpromidine and related 
phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J. Med. 
Chem. 1989, 32, 1963-1970. 
(8) Cooper, D. G.; Young, R. C.; Durant, G. J.; Ganellin, C. R. Histamine Receptors. 
Comprehensive Medicinal Chemistry; Emmett, J. C., Ed.; Pergamon Press: Oxford, 1990, 
357. 
(9) Arrang, J. M.; Garbarg, M.; Schwartz, J. C. Auto-inhibition of brain histamine release 
mediated by a novel class (H3) of histamine receptor. Nature 1983, 302, 832-837. 
(10) Weinstein, H.; Chou, D.; Johnson, C. L.; Kang, S.; Green, J. P. Tautomerism and the 
receptor action of histamine: a mechanistic model. Mol. Pharmacol. 1976, 12, 738-745. 
(11) Green, J. P.; Johnson, C. L.; Weinstein, H. Histamine as a neurotransmitter. In 
Psychopharmacology, A Generation of Progress, Lipton, M. A.; Di Mascio, A.; Killam, 
K. F.; Eds, Raven Press: New York, 1978, 319-322. 
(12) Donné-Op den Kelder, G. M.; Haaksma, E. E. J.; Timmerman, H. Theoretical 
Considerations concerning the H2-receptor. Trends in Medicinal Chemistry '88; Van der 
Goot, H.; Domhy, G.; Pallos, L.; Timmerman, H., Eds.; Elsevier: Amsterdam, 1989, 365-
392. 
 126
N-Acyl-N’-[3-(2-amino-4-methylthiazol-5-yl)propyl]guanidines: Towards Improved H2 Receptor Selectivity 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
(13) Impicciatore, M.; Morini, G.; Chiavarini, M.; Barocelli, E.; Bordi, F. et al. Are histamine 
receptors involved in the stimulant activities of thiazolylethylamines supposed as cyclic 
models of dimaprit? Agents Actions 1987, 20, 262-264. 
(14) Eriks, J. C.; van der Goot, H.; Sterk, G. J.; Timmerman, H. Histamine H2 receptor 
agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships 
of substituted 4- and 5-(2-aminoethyl)thiazoles. J. Med. Chem. 1992, 35, 3239-3246. 
(15) Eriks, J. C.; van der Goot, H.; Timmerman, H. New activation model for the histamine H2 
receptor, explaining the activity of the different classes of histamine H2 receptor agonists. 
Mol. Pharmacol. 1993, 44, 886-894. 
(16) Eriks, J. C.; Sterk, G. J.; van der Aar, E. M.; van Acker, S. A.; van der Goot, H. et al. 4- or 
5- (omega-aminoalkyl) thiazoles and derivatives; new selective H2-receptor agonists. 
Agents Actions Suppl. 1991, 33, 301-314. 
(17) Baumann, G.; Permanetter, B.; Wirtzfeld, A. Possible value of H2-receptor agonists for 
treatment of catecholamine-insensitive congestive heart failure. Pharmacol. Ther. 1984, 
24, 165-177. 
(18) Kelley, M. T.; Burckstummer, T.; Wenzel-Seifert, K.; Dove, S.; Buschauer, A. et al. 
Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type 
agonists. Mol. Pharmacol. 2001, 60, 1210-1225. 
(19) Eriks, J. C.; Sterk, G. J.; Van der Goot, H.; Timmerman, H. Preparation of substituted 
thiazole derivative as drugs; (Cedona Pharmaceuticals B. V., Neth.). Application: WO, 
1991; pp 54. 
(20) Eriks, J. C.; Sterk, G. J.; Van der Goot, H.; Timmerman, H. Preparation of 2-amino-5-(ω-
aminoalkyl)thiazole derivatives; (Cedona Pharmaceuticals B. V., Neth.). Application: 
WO, 1991, pp 18. 
(21) Eriks, J. C.; Sterk, G. J.; van der Goot, H.; Timmerman, H. Process for preparing 
substituted or unsubstituted 4(5)-(ω-aminoalkyl) imidazoles,. PCT Int. Appl. 1989, WO 89 
00,019, 5 April, N. Appl. 88/00.998, 18 April 1988. 
(22) Eriks, J. C.; Sterk, G. J.; van der Goot, H.; Timmerman, H. New thiazole derivatives for 
treatment of congestive heart failure and certain allergic affections. N. L. Appl. 1990, 
90/000.132, Jan. 19. 
(23) Kelley, M. T.; Burckstummer, T.; Wenzel-Seifert, K.; Dove, S.; Buschauer, A. et al. 
Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type 
agonists. Mol. Pharmacol. 2001, 60, 1210-1225. 
(24) Stark, H.; Kathmann, M.; Schlicker, E.; Schunack, W.; Schlegel, B. et al. Medicinal 
chemical and pharmacological aspects of imidazole-containing histamine H3 receptor 
antagonists. Mini-Rev. Med. Chem. 2004, 4, 965-977. 
(25) Eriks, J. Ch.; Sterk, G. -J.; van der Goot, H.; Timmerman, H. Process for preparing 
substituted or unsubstituted 4(5)-(ω-aminoalkyl) imidazoles. PCT Int. Appl. 1989, WO 89 
00, 019, 5 April, N Appl. 88/00.998, 18 April 1988. 
(26) Pertz, H.; Elz, S. In-vitro pharmacology of sarpogrelate and the enantiomers of its major 
metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-
induced depression of 5-HT contractions in rat tail artery. J. Pharm. Pharmacol. 1995, 47, 
310-316. 
(27) Buchheit, K. H.; Engel, G.; Mutschler, E.; Richardson, B. Study of the contractile effect 
of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig 
ileum. Evidence for two distinct release mechanisms. Naunyn-Schmiedebergs Arch. 
Pharmacol. 1985, 329, 36-41. 
 127
Chapter 4 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
(28) Sasse, A.; Kiec-Kononowicz, K.; Stark, H.; Motyl, M.; Reidemeister, S. et al. 
Development of chiral N-alkylcarbamates as new leads for potent and selective H3-
receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo 
activity. J. Med. Chem. 1999, 42, 593-600. 
 
 
 128
 Chapter 5 
Synthesis and Pharmacological Activity of Chiral NG-Acylated 
Heteroarylpropylguanidines 
 
 
It is a capital mistake to theorize before one has data. Insensibly one begins to twist facts 
to suit theories instead of theories to suit facts.                                               Conan Doyle 
 
5.1. Introduction  
Information on the stereochemical features of the ligands is necessary with respect to the 
potential therapeutic use as well as for theoretical considerations, e. g. for molecular 
modelling and for the development of a three-dimensional model of the receptor. 
Arpromidine (5d) and related imidazolylpropylguanidines, the most potent histamine H2 
receptor agonists described in literature,1 are promising new cardiovascular agents which 
may be useful for the treatment of severe congestive heart failure.2 The pharmacological 
investigation of stereoisomers, e.g. of the 3,4-difluorinated (5e) and 3,4-dichlorinated 
(5g) analogues, revealed that the (S)-configured compounds are more active enantiomers 
with eudismic ratios of up to 403,4. According to a model for the interaction of agonists 
with the histamine H2 receptor, supported by site-directed mutagenesis and molecular 
modelling investigations, the guanidino group is supposed to interact with Asp-98 in 
transmembrane domain 3 (TM3), the imidazole ring is assumed to interact with Asp-186 
and Tyr-182 in TM5 and the (S)-configured phenyl(pyridyl)alkyl group is probably 
oriented towards amino acids in TMs 6 and 7. As the strongly basic guanidino group is 
the main reason for very low oral bioavailability, non-H2R-mediated effects and lack of 
penetration across the blood-brain barrier the diarylalkyl group was replaced by diaryl-, 
monoaryl- or cyclohexylalkanoyl residues, i. e. the strong basicity was reduced by 4-5 
orders of magnitude (Chapters 3 and 4). A diaryl group is not required: compounds such 
as the acylated guanidines 78 and 80 (Fig. 5.1) proved to be potent histamine H2 receptor 
agonists which possess up to 30 times higher potency than the natural ligand and have 
more favourable pharmacokinetic properties than the corresponding alkylated guanidines. 
Moreover, the replacement of imidazolyl ring with a 2-amino-4-methylthiazol-5-yl group 
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(e.g. see compound 104b in Fig. 5.1) resulted in increased selectivity for histamine H2 
over H3 receptors.  
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Fig. 5.1: Structure of some histamine H2 receptor agonists 
 
Enantiomers of the aforementioned acylguanidines are required to compare the stereo-
chemical requirements with those of the arpromidine series and to further improve the 
receptor model. In this chapter the synthesis of the enantiomers of 78 as well as the 
corresponding pyridine (80) and aminothiazole analogues (104b) via asymmetric 
synthesis of 3-arylbutanoic acid is described.  
 
5.2. Chemistry 
For the synthesis of the target molecules according to the method reported in the previous 
Chapters 3 and 4, the enantiomers of the chiral acids were required. The building block 
(R)-3-phenylbutanoic acid ((R)-109) was synthesized from the achiral precursor, methyl 
(E)-but-2-enoate (106), via asymmetric addition of phenylboronic acid (107) as reported 
by Hayashi et al.5,6, using a catalytic amount of rhodium catalyst and (S)-binap ligand, 
followed by hydrolysis of the methyl ester (R)-108. As the enantiomeric excess (ee) of 
this reaction did not exceed about 80 %, the acid was recrystallized to obtain a pure 
enantiomer (99 % ee) which was hydrolysed to give the pertinent acid (R)-109 (Scheme 
5.1).  
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H3C
COOMe
H3C
(R)
H3C
(i) (ii) OH
OO
OMe
106
Reagents: (i) [Rh(acac)(C2H4)2] / (S)-binap, dioxane / H2O (10/1), 100 oC, 16 h; (ii) LiOH, THF, rt.
B(OH)2
107 (R)-108 (R)-109
 
Scheme 5.1: Synthesis of (R)-3-phenylbutanoic acid ((R)-109) 
 
 
H3C
O
OMe
108A B
 
Fig 5.2: UV detection and optical rotation (CD) signal at 240 nm for the chiral separation 
of the 3-phenylbutanoic acid methyl ester, racemic (A) and (R)-108 (B), by HPLC on a 
Chiralcel OD column. Injection volume: 50 µL; analyte concentration: 0.5 mg/mL; 
mobile phase: n-hexane-isopropanol (99:1); temperature: 22 °C; flow: 0.5 mL/min. 
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Scheme 5.2: Synthesis of (S)-3-phenylbutanoic acid ((S)-109) 
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Fig 5.3: Representative electropherogram of the chiral separation of acids, racemate, (R)- 
and (S)-109 by capillary electrophoresis using (2-hydroxypropyl)-β-CD as chiral selector. 
Analyte concentration: 500 µM; capillary temperature 30 °C; running buffer 30 mM (2-
hydroxypropyl)-β-CD in 5 M urea and 125 mM sodium phosphate buffer pH 6.00; UV-
detection: 210 nm. 
 
(S)-3-Phenylbutanoic acid was prepared according to the same procedure except for using 
(R)-binap instead of (S)-binap as the chiral ligand (Scheme 5.2). The methyl esters (R)- 
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and (S)-108 could be separated by chiral HPLC (see Fig. 5.2). The enantiomeric purities 
of the acids (R)- and (S)-109 were determined by means of capillary electrophoresis 
using (2-hydroxypropyl-)-β-cyclodextrin as chiral selector (Fig. 5.3). 
 
 
For the synthesis of chiral 2-pyridyl analogues according to the Hayashi et al.5,6, 2-
pyridylboronic acid was required. As this compound is not commercially available and a 
procedure for the synthesis is not described, we thought of preparing 3-phenyl-3-(2-
pyridyl)propanoic acid by conjugate addition of phenylboronic acid (107) with t-butyl 3-
pyridin-2-ylpropenoate (112). The acrylate 112 (Scheme 5.3) was prepared from the 
corresponding aldehyde (110) via Witting-Horner reaction, which gave mainly the trans 
form. To block the lone pair of the pyridine-N in acrylate 112, the compound was con-
verted to its N-oxide (113) by using m-chloroperoxybenzoic acid (m-CPBA). 
 
N
OC(CH3)3
O
N
OC(CH3)3
O
N CHO
O
(i)
(ii)
Reagents: (i) n-BuLi, THF, rt; (ii) m-CPBA, CH2Cl2, rt
110 112 113
(EtO)2P
O
OC(CH3)3
O 111
 
 
Scheme 5.3: Synthesis of 2-pyridyl and 2-pyridyl-N-oxide acrylate  
 
The conjugate addition reaction of phenylboronic acid with the tertiary butyl ester of 3-
pyridin-2-ylacrylic acid (112) in presence of [Rh(acac)(C2H4)2] catalyst and (S)-binap 
was unsuccessful (Scheme 5.4). Replacing the catalyst with [Rh(COD)(OH)]2 led to a 
little advance of reaction. As it was conceivable that the nucleophilic pyridine caused the 
problem, we used the N-oxide 113. However, the conjugate addition reaction of 113 at 
the same reaction condition was not satisfactory (Scheme 5.5).  
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Scheme 5.4: Conjugate addition of phenylboronic acid to t-butyl 3-pyridin-2-
ylpropenoate 
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Scheme 5.5: Conjugate addition using the pyridine-N-oxide 113 as starting material 
 
In search for a better synthetic route an enzyme-catalysed reaction described in the 
literature was selected as the most promising alternative: the lipase catalysed 
enantioselective acetylation of  racemic 1-(2-pyridyl)ethanol (116) with vinyl acetate is 
reported to give the (R)-configured ester, (R)-118, with high yield and excellent 
enantiomeric excess7 (Scheme 5.6). Accordingly, we prepared the racemic alcohol (116), 
converted it to (R)-118 with high yield, and separated (S)-1-(2-pyridyl)ethanol ((S)-117).       
                                                                                                                                                                              
N
CH3
OH
N
CH3
OH
N
CH3
OAc
(ii)
N CHO
(i)
110 117 (R)-118
91%
47 % yield
99 % ee
46 % yield
97 % ee
(S)-117
 
Reagents: (i) MeMgBr, Et2O, 0°C, 2h; (ii) Lipase, Vinyl acetate, iso-Pr2O, Molecular sieves 4A, 
4h. 
Scheme 5.6: Enantioselective acylation of 1-(2-pyridyl) ethanol using vinyl acetate 
Candida antarctica lipase (CAL). 
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117
∗ CH3
OH
(S)-117 
Fig 5.4: UV detection and optical rotation signal at 245 nm for the chiral separation of 
the 1-(2-pyridyl)ethanol racemic and (R)- and (S)- 117 on a Chiralcel OD column. 
Injection volume: 40 µL; analyte concentration: 0.5 mg/mL; mobile phase: n-heptane-
isopropanol (99:1); temperature: 22°C; flow: 0.5 mL/min. 
 
The acetyl protected compound (R)-118 was then hydrolyzed to alcohol (R)-117 by 
treating with 1N NaOH solution. All attempts to stereoselectively displace the OH group 
of the chiral secondary alcohol (R)-117 by a CH-acidic compound [HC(COOEt)3] under 
Mitsunobu conditions8,9 (DEAD, PMe3) failed (Scheme 5.7).  
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N (R)
CH3
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CH3
O
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(R)-119
N
CH3
OAc
(R)-118
1N NaOH
MeOH/H2O
rt, 3h (R)-117
 
Scheme 5.7: Stereoselective Mitsunobu reaction to synthesize (R)-119 was unsuccessful 
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So, the alcohol functionality of (R)-1-pyridin-2-ylethanol was first converted to the 
methanesulfonate10 (R)-120 (Scheme 5.8) to make a better leaving group and then treated 
with the sodium salt of dimethyl malonate [CH2(COOMe)2] to give dimethyl (R)-(1-
pyridin-2-ylethyl)malonate11 (R)-121 stereospecifically. Subsequent saponification and 
decarboxylation yielded (R)-3-phenyl-3-pyridin-2ylpropanoic acid ((R)-122). 
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N
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N
CH3
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98 %
(ii) (iii)
89 %
(iv)
85 %
95 % ee
(R)-117 (R)-120 (R)-121 (R)-122  
Reagents: (i) MsCl, Et3N, DMAP, CH2Cl2, rt; (ii) DMM, NaH, DMSO, rt, 12h; (iii) a. NaOH, 
reflux, 12h; b. HCl, reflux, 12h. 
 
Scheme 5.8: Synthesis of (R)-3-phenyl-3-pyridin-2-ylpropanoic acid via SN2 displace-
ment of (R)-1-pyridin-2-ylethyl methanesulfonate.  
 
Similarly, the (S)-enantiomer (S)-122 was prepared from (S)-117 via synthesis of the 
mesyl (Ms) ester, SN2 displacement with H2C(COOMe)2, hydrolysis of the methyl ester 
groups and decarboxylation (Scheme 5.9). 
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86 %
(iv)
88 %
(S)-117 (S)-120 (S)-121 (S)-122  
Reagents: (i) MsCl, Et3N, DMAP, CH2Cl2, rt; (ii) DMM, NaH, DMSO, rt, 12h; (iii) a. NaOH, 
reflux, 12h; b. HCl, reflux, 12h. 
 
Scheme 5.9: Synthesis of (S)-3-phenyl-3-pyridin-2-ylpropanoic acid via SN2 displace-
ment of (S)-1-pyridin-2-ylethyl methanesulfonate.  
 
Unfortunately, the HPLC and CE methods which were successfully used to separate the 
stereoisomers of 3-phenylbutanoic acid and its methyl ester (see above) were not appli-
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cable to compound 122. However, the circular dichroism spectra confirm that the optical 
antipodes of 3-pyridin-2-ylbutanoic acid, (R)- and (S)-122, were obtained (Fig. 5.5). 
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Fig 5.5: Circular dichroism spectra of the two enantiomers of the carboxylic acid 122.  
A: spectrum from 200 to 330 nm wavelength; B (magnification): 240 - 300 nm. The 
analytes were dissolved in methanol. The analyte concentrations were 10 mM. 
 
The coupling of the chiral acids (R)-109, (S)-109, (R)-122 and (S)-122 with the 
imidazolylpropylguanidine building block 27 according to the general procedure 
described in  Chapter 3 followed by detritylation with TFA gave the corresponding 
chiral NG-acylated products (Scheme 5.10). 
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Scheme 5.10: Coupling of chiral acids with imidazolylpropylguanidin 
 
 137
Chapter 5 
 
The enantiomeric purities of (R)- and (S)-125, 98.3 and 95.5 %, respectively, were 
determined by capillary electrophoresis (Fig. 5.6).  
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Fig 5.6: Representative electropherogram of the chiral separation of acids, racemate (78), 
(R)- and (S)-125 using (2-hydroxypropyl)-β-CD as chiral selector. Analyte concentration: 
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500 µM; capillary temperature 30 °C; running buffer 30 mM/l (2-hydroxypropyl)-β-CD 
in 5M urea and 125 mM sodium phosphate buffer pH 2.50; UV-detection: 210 nm. 
 
The corresponding 2-aminothiazole analogue was prepared from the building blocks 101 
and 101’, and the chiral acids (R)-109 and (S)-109 according to the general coupling 
procedure described in Chapter 4, followed by cleavage of the Boc protecting group 
(Scheme 5.11). 
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Scheme 5.11: Coupling of chiral acids with 3-(2-amino-4-methylthiazol-5-yl)propyl-
guanidine  
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Fig. 5.7: Representative analytical HPLC chromatograms of (S)-125 (Rt: 11.05 min; 
UV detection at 210 nm) and (R)-125 (Rt: 11.05 min; UV detection at 254 nm). 
Detailed description is given in experimental section. 
 
The purity of the synthesised compounds was checked by HPLC analysis as shown for 
(R)- and (S)-125 in Fig. 5.7.   
  
Table 5.1: Analytical data of the chiral NG-acylated heteroarylpropylguanidines 125, 126 
and 129 
 
 a  Purified by preparative HPLC; b techniques for determination of ee is given in Fig. 5.6 and experimental 
section c isolated as trifluoroacetic acid salt; dTechniques for HRMS is described in experimental section of 
respective compounds; e  retention time in minutes; the solvent system (0.05 % TFA / acetonitrile; gradient) 
Enantiomera % eeb, Formulac 
 
HRMSd  
m/z found 
(calculated) 
Rt (min)e
(R)-125 98.3 C17H23N5O (2 TFA) 313.1906 
(313.1902) 
11.0 
(S)-125 95.5 C17H23N5O (2 TFA) 313.1905 
(313.1902) 
11.0 
(R)-126 n.d. C16H22N6O (3 TFA) 314.1863 
(314.1855) 
9.4 
(S)-126 n.d. C16H22N6O (3 TFA) 314.1863 
(314.1855) 
9.4 
(R)-129 98.3 C18H25N5OS (2 TFA) 359.1778 
(359.1779) 
11.7 
(S)-129 95.5 C18H25N5OS (2 TFA) 359.1780 
(359.1779) 
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is presented in experimental section and the experimental setup is in the experimental section; 
representative chromatogram in Fig. 5.7; nd = not determined.                                  
 
 
5.3. Pharmacological Results and Discussion 
 
The synthesised compounds were tested for histamine H2 receptor (H2R) agonistic 
activity on the isolated spontaneously beating guinea pig right atrium (positive 
chronotropic response). Most of the acylguanidines were also investigated for H1 
antagonism on the isolated guinea pig ileum and on U-373 MG human cells. The results 
are summarized in Table 5.2. Moreover, the agonistic activity was studied in the GTPase 
assay using guinea pig and human H2R GsαS fusion protein expressing Sf9 insect cells 
(see Table 5.3). 
 
Table 5.2: Histamine H2 receptor agonism on guinea pig right atrium, H1 receptor 
antagonism on guinea pig ileum and on U-373 MG human cells (Ca2+-assay) 
 
Histamine H1 receptor antagonism 
Histamine H2 receptor agonism 
on the isolated guinea pig right atrium 
 
guinea pig ileum 
U-373 
MG cells 
 
 
 
 
No. 
pEC50a,f ± 
SEMf
relative  
potencyb
Emax  
( %)c
Nd PA2a,c,g ± SEM Nd IC50 [µM]e
1, HIS 6.00 ± 0.10 100 100 ± 2 >50    
78h 7.45 ± 0.07 2710 99 ± 2 4 6.31 ± 0.06 2 19.5 
(R)-125 7.47 ± 0.08 2930 
(108 % relative
to 78) 
102 ± 2 3 5.59 ± 0.04 14 32 
(S)-125 6.90 ± 0.12 800 
(30 % relative 
to 78) 
93 ± 1 3 5.85 ± 0.03 16 37 
gpH2R: (R)-125 : (S)-125 = 3.5 : 1 gpH1R: (R)-125 : (S)-125 = 1 : 1.8
80i  7.29 ± 0.06 1940 98 ± 2 3 n.d.  49 
(R)-126 7.15 ± 0.12 1400 101 ± 3 3 n.d. - 35 
(S)-126 7.15 ± 0.07 1400 101 ± 1 3 n.d. - 66 
104bj 7.18 ± 0.17 1520 89 ± 3  4 5.48 ± 0.10 6 18 
(R)-129 6.68 ± 0.10 730 
(48 % rel. to 
(±)-129) 
73 ± 4 3 n.d. - 17 
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(S)-129 7.27 ± 0.11 1840 
(120 % rel. to 
(±)-129) 
87 ± 3 4 n.d. - 25 
gpH2R: (R)-129 : (S)-129 = 1 : 2.5  
a Explanation of abbreviations see appendix; b Potency relative to histamine = 100 %, c efficacy, maximal 
response ( %), relative to the maximal increase in heart rate induced by the reference compound histamine; d 
Number of experiments; e IC50 values for the inhibition of the histamine (30 µM) induced increase in 
intracellular calcium; mean of at least 3 independent experiments; SEM < 10 %; f pEC50 was calculated from the 
mean shift ΔpEC50 of the agonist curve relative to the histamine reference curve by the equation: pEC50 = 6.00 + 
ΔpEC50. The SEM given for pEC50 is the SEM calculated for ΔpEC50; g Antagonist (pA2); n.d. = not determined; h 
racemic 78 (see Chapter 3) corresponds to (±)-125; i racemic 80 (see Chapter 3) corresponds to (±)-126; j 
racemic 104b (see Chapter 4) corresponds to (±)-129. 
 
On the spontaneously beating right atrium (R)-3-phenylbutanoylguandine (R)-125 was 
found to be slightly more active (108 %) than the corresponding racemate (compd. 78 
(see Chapter 3) corresponds to (±)-125), whereas (S)-125 was only 30 % as potent as 78, 
i.e. the (R)-enantiomer is the eutomer with an eudismic ratio of  3.5. (R)-125 was found 
to be full agonist whereas the intrinsic activity of (S)-125 was slightly reduced (partial 
agonist with i. a. = 0.93) (Table 5.2). On the guinea pig ileum there was only a very low 
difference in antagonistic activities in favour of the (S)-enantiomer.  
No difference in agonistic activity on the atrium was found for the enantiomeric 3-
pyridin-2-ylpropanoylguanidines. In this case, the chiral separation of the acylguanidines 
by means of capillary electrophoresis or HPLC was unsuccessful. As racemisation during 
the coupling reaction cannot be precluded there is still some doubt concerning the 
enantiomeric purities of (R)- and (S)-126. Further analytical investigations are required 
for clarification. 
Compared to (R)-125 the situation was other way round for the corresponding 2-amino-
thiazole analogues (graphical presentation in Fig. 5.7): (S)-129, was found to be more 
active than (R)-129 by a factor of 2.5. This may be interpreted as a hint to a different 
binding mode of thiazoles and corresponding imidazoles. As the difference in 
stereoselection is rather small, overestimation of these results should be prevented, 
however, the result is in accordance with the data from the GTPase assay (see Table 5.3).  
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Fig. 5.7: H2R agonistic 
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The pharmacological data obtained from the guinea pig right atrium (Table 5.2) was 
supported by the results obtained from GTPase assay on guinea pig H2R-Gsα fusion 
proteins; here also the (R)-125 was found to be 3.2 times more potent than corresponding 
(S)-enantiomer. Moreover, similar to the results from guinea pig right atrium, the (S)-
configured 2-aminothiazole analogue (S)-129 was 2 times more active than its optical 
antipode. The efficacy was also higher for the (S)-enantiomer. By analogy with the 
results from the guinea pig right atrium no significant difference was found for (R)- vs. 
(S)-126 (R. Seifert, personal communication, data not shown). On the human H2R-Gsαs 
neither enantiomeric pair produced significantly different agonistic effects. 
 
Table 5.3: Activity on the human and guinea pig receptor (GTPase assay* on human and 
guinea pig H2R-Gsα fusion proteins)  
 
  hH2R-GsαS gpH2R-GsαS EC50 hH2R-GsαS
EC50 gpH2R-GsαS
No. Efficacy pEC50 Rel. 
Pot. 
Efficacy pEC50 Rel. 
Pot. 
 
HISa 1.00 5.90 100 1.00 5.92 100 1.05 
5da 0.79 ± 0.07 6.72 659 1.02 ± 0.04 7.15 1600 2.71 
78b 0.87 ± 0.01 7.17 1880 1.03 ± 0.06 7.92 10300 5.58 
(R)-125 1.07 ± 0.17 7.10 1575 1.19 ± 0.17 7.62 5000 3.33 
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(S)-125 1.01 ± 0.16 6.92 1050 1.01 ± 0.10 7.12 1600 1.6 
104bc 0.82 7.32 2630 0.98 7.65 5370 2.04 
(R)-129  0.64 7.27 2333 0.86 7.81 8000 3.6 
(S)-129 0.87 7.27 2333 1.00 8.12 15000 6.75 
a data from ref.16  b from Table 3.3 in Chapter 3; c from Table 4.4 in Chapter 4. 
* Potencies and efficacies of ligands at hH2R-Gs S and gpH2R-Gs S were determined in the GTPase assay. GTP 
hydrolysis was determined as described in literature. Reaction mixtures contained membranes of Sf9 cells 
expressing fusion proteins and agonists at concentrations from 1 nM to 1 mM as appropriate to generate 
saturated concentration/response curves. Curves were analyzed by nonlinear regression. Typical basal GTPase 
activities ranged between ~1 and 2 pmol/mg/min, and typical GTPase activities stimulated by HIS (100 µM) 
ranged between ~4 and 8 pmol/mg/min. To calculate agonist efficacies, the maximum stimulatory effect of HIS 
was set at 1.00, and the stimulatory effects of other agonists were referred to this value. Data shown are the 
means ± SD of four to six experiments performed in duplicate. The relative potency (Rel. Pot.) of HIS was set at 
100, and the potencies of other agonists were referred to this value to facilitate comparison of agonist potencies. 
Efficacies and potencies, respectively, of ligands at hH2R-Gs S were compared with the corresponding 
parameters at gpH2R-Gs S using the t test. 
 
 
5.4. Conclusion 
Previously, in the arpromidine series of H2R agonists eudismic ratios up to 40 were found 
in favour of the (S)-enantiomer. In the new series of acylguanidine-type histamine H2 
receptor agonists described in this thesis N1-[3-(1H-imidazol-4-yl)propyl]-N2-(3-phenyl-
butanoyl)guanidine was discovered as a potent H2 histaminergic agent and a promising 
candidate for further structural optimisation. Analogues having a heterocyclyl instead of 
the phenyl rings were equipotent. Moreover, replacement of the imidazolyl ring with a 
bioisosteric 2-amino-4-methylthiazol-5-yl group resulted about the same H2R agonistic 
potency. Due to the chirality of the aforementioned acylguanidines special attention had 
to be paid to the stereoselective synthesis and pharmacological investigation of a few 
representative enantiomeric H2R agonists. The pertinent intermediate, 3-phenylbutanoic 
acid, was prepared via enantioselective addition of phenylboronic acid to (E)-butenoic 
acid ester. The pyridyl analogue was accessible by enantioselective enzymatic prepar-
ation of 1-pyridin-2-ylethyl acetate followed by conversion of the enantiopure alcohol to 
the required building block. Finally, the chiral acids were coupled to imidazolylpropyl-
guanidine. With the exception of the pyridyl analogue, the enantiomeric purity of the syn-
thesised acylguanidines could be determined by CE. The enantiomeric excess were in the 
range of 95-99 %, which were considered to be sufficient for pharmacological 
investigations.  
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Compared to the arpromidine series the acylguanidine-type H2R agonists showed rather 
low eudismic ratios in the range of 2 - 3.5. The data from the guinea pig atrium were 
consistent with those determined in the GTPase assay using H2R-Gsαs fusion proteins. 
Interestingly, the preferred stereoisomers were conversely configured in case of the 
imidazolyl compound (R > S) and its aminothiazolyl analogue (S > R), respectively. This 
information is of particular interest with respect to the further refinement of receptor 
models, as the binding mode of imidazoles and aminothiazoles appears to be different. 
Although the alternate exchange of both heterocyclic rings was tolerated without note-
worthy changes in H2R agonistic activity, the concept of bioisosterism may be 
questioned. Additional enantiomeric pairs are required to study this phenomenon in more 
detail. As suggested by molecular modelling the replacement of the methyl group in the 
3-phenylbutanoyl portion of the molecule, especially the variation of substituent size and 
functionality, will be useful to interpret the H2R binding on the molecular level and to 
identify potential interaction sites of the acyl group. 
 
 
5.5. Experimental Section 
5.5.1. Chemistry 
General procedure 
For detailed description of the general procedures and equipments, and preparative and 
analytical HPLC, see section 3.6.1 of Chapter 3.  
The chiral HPLC and CD spectra referred to this chapter consisted of a L-6000A pump 
(MERCK-HITACHI), a CD 1595 (Jasco) detector, a Chiralcel OD column. Injection 
volume was 40-50 µL, analyte concentration was 0.5 mg/mL; mobile phase was either n-
heptane-isopropanol or n-hexane-isopropanol (99:1) as mentioned later; temperature: 
22°C; Flow: 0.5 mL/min. 
 
Circular dichroism spectrometry 
Circular dichroism measurements were made with a Model J-710 CD Spectropolarimeter 
from Jasco (Groß-Umstadt, Germany) using a 5 mm quartz cell at room temperature. In 
order to avoid errors due to racemization, the sample solutions were prepared by dilution 
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of methanolic stock solutions (analyte concentration: about 10 mM) immediately before 
recording the spectra.  
 
Capillary electrophoresis 
Electrophoretic experiments were performed with a Biofocus 3000 capillary 
electrophoresis system (Bio-Rad, Munich, Germany). Chiral separations were carried out 
in a 75 (effective length 70.4 cm)×50 µm I.D. fused-silica capillary (Microquarz, 
Gesellschaft für Quarzglaskomponenten, Munich, Germany). The voltage (positive 
mode) was set at 20 kV, resulting in a field strength of 266.7 V/cm. In order to obtain 
reproducible operating conditions with respect to the capillary surface, before 
hydrodynamical injection of the samples at a constant pressure–time integral of 20 p.s.i.·s 
(1 p.s.i.=6894.76 Pa), the capillary was flushed with 0.1 M NaOH for 5 min, with water 
for 2 min and finally with running buffer for 10 min. The UV detector was set to 210 nm.  
For the preparation of the running buffers 125 mM NaH2PO4·H2O and 5 M urea were 
dissolved in water, and the pH was adjusted by adding appropriate amounts of 85% 
H3PO4 and NaOH (conc.), respectively. The CDs were dissolved in these sodium 
phosphate buffers. CD concentrations were calculated as c*=n(CD)/v(solvent) (mM). The 
high urea concentration was necessary to increase the water solubility of the CDs, in 
particular of β-CD. Urea slowly decomposes in water to CO2 and NH3. To preclude 
changes of the buffer pH, the buffers were made freshly every few days. To reach the 
required high concentrations of α- and β-CD in the sodium phosphate buffers, the 
solutions were sonicated and subsequently carefully heated on a water bath. For 
dissolving γ-CD at the required high concentrations, sonication alone was sufficient. 
Because of the high viscosity of the running buffers, these solutions were used without 
final filtration. 
 
General procedure for the preparation of (R)- and (S)-methyl 3-phenylbutanoate 
[(R)-and (S)-108] 6 
Rh(I) catalysed conjugate 1,4-addition of phenylboronic acid to methyl alkenoates: 
Rhodium complex (0.03 mmol), ligand (0.045 mmol), and arylboronic acid (2 mmol) 
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were added to the flask containing a magnetic stirring bar, a septum inlet, and a reflux 
condenser. The flask was charged with 1,4-dioxane (6 mL) and water (1 mL). After being 
stirred for 30 min, the pertinent α,β-unsaturated ester (1.0 mmol) was added. The mixture 
was then stirred for 16 h (temperature see below). The product was extracted with 
benzene, washed with brine, and dried over anhydrous magnesium sulfate. 
Chromatography over silica gel gave the desired product. 
 
(R)-Methyl 3-phenylbutanoate [(R)-108]5 
At 100 °C; yield 80 %; 88 % ee (HPLC, OD-H: hexane/2-propanol; colourless oil; 
C11H14O2 (178.2); [α]20D -18.9° (c 0.72, CHCl3) {lit.12 [α]33D -29.4° (c 1.02, CHCl3)}; IR 
(neat): 3062, 3029, 2965, 1738, 1604 cm-1; 1H-NMR (CDCl3), δ (ppm): 7.78 (m, 5H, Ar-
H), 3.71 (s, 3H, OCH3), 3.38 (m, 1H, CHCH3), 2.66 (dd, J = 6.9 Hz, J2 = 15.1 Hz, 1H, 
one H of CH2CHCH3), 2.58 (dd, J = 8.2 Hz, J2 = 15.1 Hz, 1H, one H of CH2CHCH3), 
1.40 (d, J = 7.0 Hz, 3H, CHCH3); 13C-NMR (CDCl3),  δ (ppm): 172.7 (quart, C=O), 
145.5 (quart, Ph-C-1), 128.3, 126.5, 126.2 (+, Ph-C), 51.3 (+, COCH3), 42.5 (-, CH2CO); 
36.3 (+, CHCH3), 21.6 (+, CHCH3); MS (ESI, ), 201 [M + Na]+ 
 
(S)-Methyl 3-phenylbutanoate [(S)-108]5 
At 100 °C; yield 82 %; 86 % ee (HPLC, OD-H: hexane/2-propanol; colourless oil; 
C11H14O2 (178.2); [α]20D +19.5° (c, 0.70, CHCl3); IR, NMR and MS data is the same as 
for (R)-108. 
 
Preparation of (R)- and (S)-3-phenylbutanoic acid [(R)- and (S)-109] 
General procedure for the hydrolysis of the methyl esters (R)- and (S)-108: To a solution 
of ester (0.178 g, 1.0 mmol) in THF (8 ml) was added 1N LiOH aqueous solution (1.5 
mL). After being stirred at room temperature for 6 h, the solution was acidified to pH 2 
with 1N aqueous HCl. It was diluted with EtOAc. The organic layer was separated, and 
the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers 
were washed with brine, dried over Na2SO4 and evaporated. To increase the enantiomeric 
excess the acids were recrystallized from a mixture of EtOAc and n-hexane.   
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(R)-3-Phenylbutanoic acid [(R)-109] 
Yield 89 %; 98 % ee (CE); colourless oil; C10H12O2 (164.2); [α]20D -42.5° (c 0.77, 
benzene) {Lit.13 [α] D -45.8° (c 0.77, benzene)} ; IR (neat): 3400-2500, 1705 cm-1; 1H-
NMR (CDCl3), δ (ppm): 7.19-7.32 (m, 5H, Ph-H), 3.27 (ABq, J1 = 6.8, 8.3 Hz, J2 = 15.6 
Hz 1H, Ph-CHCH3), 2.67 (AB, J1 = 6.8 Hz, J2 = 15.6 Hz, 1H, one H of CH2CO), 2.58 
(AB, J1 = 8.3 Hz, J2 = 15.6 Hz, 1H, one H of CH2CO), 1.32 (d, J = 6.8 Hz, 3H, Ph-
CHCH3); 13C-NMR (CDCl3), δ (ppm): 178.3 (quart, CO), 145.4 (quart, Ph-C-1), 128.5, 
127.7, 126.5 (+, Ph-C), 42.5 (+, Ph-CHCH3), 36.1 (-, CH2CO), 21.8 (+, CH3); EI-MS: m/z 
(rel. intensity, %):  164 (M+·, 4), 147 ([M – OH]+, 6), 110 ([M – CO2H]+, 100). 
 
(S)-3-Phenylbutanoic acid [(S)-109]  
Yield 86 %; 95 % ee (CE); colourless oil; C10H12O2 (164.2); [α]20D +46.5° (c 0.77, 
benzene) {Lit.14 [α]20D +50.0° (c 1.12, benzene, 87 % ee)}. The analytical data (IR, NMR 
and MS) is the same as for (R)-109. 
Synthesis of (R)- and (S)-1-pyridin-2-ylethanol [(R)- and (S)-117]7
General procedure for the stereoselective acetylation of (RS)-1-pyridin-2-ylethanol 
(117): A mixture of (RS)-117 (100 mg), lipase {Candida antarctica lipase (CAL)} (30 
mg), and vinyl acetate (0.2 mL) in anhydrous diisopropyl ether (20 mL) was stirred 
vigorously at rt for 4 h in the presence of molecular sieves 4A (100 mg). The reaction 
mixture was filtered through a filtering paper. The filtrate was condensed, and the residue 
was chromatographed on silica gel to give the ester (R)-122 and recovered alcohol (S)-
121. The enantiomeric purities of the products were determined by HPLC using a chiral 
Chiralcel OD column (Fig. 5.4). Physical properties including specific rotation values 
and spectroscopic data for the (R)-acetates and physical data and specific rotation values 
for the recovered (S)-alcohol is as follows: 
(S)-1-Pyridin-2-ylethanol [(S)-117] 
Yield 46 %; colourless oil; C9H11NO2 (165.2); [α]20D -29.0° (c 2.0, CHCl3) {Lit.7 [α]29D -
28.1° (c 2.23, CHCl3)} ; the analytical data (IR, NMR, MS) are all the same as for 
compound 47a (Chapter 3).  
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(R)-1-Pyridin-2-ylethyl acetate [(R)-118]  
Yield 46 %; colourless oil; C9H11NO2 (165.2); [α]20D +94.1° (c 2.1, CHCl3) {Lit.7 [α]28D 
+97.4° (c 2.03, CHCl3)}; 1H-NMR (CDCl3), δ (ppm): 8.59 (m, 1H, Pyr-6-H), 7.69 (m, 
1H, Pyr-4-H), 7.33 (m, 1H, Pyr-5-H), 7.23 (m,1H, Pyr-3-H), 5.91 (q, J = 6.7 Hz, 1H, 
Pyr-2-CHCH3), 2.13 (s, 3H, CH3CO), 1.60 (d, J = 6.7 Hz, 3H, Pyr-2-CHCH3); 13C-NMR 
(CDCl3), δ (ppm): 170.3 (quart, CO), 160.2 (quart, Pyr-C-2), 149.3 (+, Pyr-C-6), 136.8 
(+, Pyr-C-4), 122.7 (+, Pyr-C-5), 120.5 (+, Pyr-C-3), 73.0 (+, Pyr-2-CHCH3), 21.3 (+, 
CH3), 20.6 (+, CH3); CI-MS [NH3], m/z (rel. intensity, %): 166 ([M + H]+); 
 
(R)-1-Pyridin-2-ylethanol [(R)-117] 
Procedure for chemical hydrolysis of (R)-118: To a solution of (R)-118 (3.0 mmol) in 
methanol (40 mL) and water (10 mL), a 1N solution of NaOH (3.0 mL, 3.0 mmol) was 
added. The mixture was stirred at rt 3 h. The solution was extracted with chloroform, 
dried with anhydrous Na2SO4 and evaporated to give the alcohol (R)-117, which was 
purified with column chromatography on silica gel eluting with ethyl acetate. 
Yield 46 %; colourless oil; C9H11NO2 (165.2); [α]20D + 22.4° (c 2.00, CHCl3). The 
analytical data are the same as for 47a (Chapter 3). 
 
Synthesis of (R)- and (S)-1-pyridin-2-ylethyl methanesulfonate [(R)- and (S)-120] 
The procedure for the preparation of methanesulfonates (R)- and (S)-120 is the same as 
that described for the racemic compound in chapter 3 (compound 48a): 
 
(S)-1-Pyridin-2-ylethyl methanesulfonate [(S)-120]: Yield 92 %; colourless oil; 
C8H11NO3S (201.2);  [α]20D -95.3° (c, 1.50, CHCl3) {Lit.15 [α]27D -90.3° (c, 1.63, 
CHCl3)}; the analytical data (IR, NMR, MS) are all the same as for 48a (Chapter 3). 
 
 
(R)-1-Pyridin-2-ylethyl methanesulfonate [(R)-120]: Yield 95 %; colourless oil; 
C8H11NO3S (201.2); [α]20D + 96.8 (c, 1.53, CHCl3); the analytical data (IR, NMR, MS) 
are all the same as for 48a (Chapter 3). 
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Synthesis of (R)- and (S)-dimethyl 2-(1-pyridin-2-ylethyl)malonate [(R)- and (S)-121] 
The procedure for the preparation of (R)- and (S)-121 is the same as that described for the 
racemate in Chapter 3 (compound 49a). 
 
Dimethyl 2-((S)-1-pyridin-2-ylethyl)malonate [(S)-121]: Yield 81 %; colourless oil; 
C12H15NO4 (237.3); [α]20D -27.9° (c, 1.20, CHCl3); the analytical data (IR, NMR, MS) are 
all the same as for 49a in Chapter 3. 
 
 
Dimethyl 2-((R)-1-pyridin-2-ylethyl)malonate [(R)-121]: Yield 83 %; colourless oil; 
C12H15NO4 (237.3); [α]20D +20.12° (c, 1.24, CHCl3) {Lit.11 [α]25D +23.0 ° (c, 1.29, 
CHCl3)}; the analytical data (IR, NMR, MS) are all the same as for 49a in Chapter 3. 
 
Synthesis of (R)- and (S)-3-pyridin-2-ylbutanoic acid [(R)- and (S)-122] 
The procedure for the preparation of (R)- and (S)-122 is the same as that described for the 
racemate 50a in Chapter 3. 
 
(S)-3-Pyridin-2-ylbutanoic acid [(S)-122]: Yield 86 %; colourless oil; C9H11NO2 
(165.2); [α]20D -35.1° (c, 1.02, CHCl3); the analytical data (IR, NMR, MS) are all the 
same as for 50a (Chapter 3). 
 
(R)-3-Pyridin-2-ylbutanoic acid [(R)-122]: Yield 84 %; colourless oil; C9H11NO2 
(165.2); [α]20D +41.6° (c, 1.06, CHCl3); the analytical data (IR, NMR, MS) are all the 
same as for 50a (Chapter 3). 
 
Synthesis of N1-(3-arylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidines (R)- 
and (S)-125 and -126 
The trityl protected acylguanidines (R)-123, (S)-123, (R)-124 and (S)-124 were prepared 
by analogy with the general procedure for the coupling of racemic carboxylic acids with 
3-(1-trityl-1H-imidazol-4-yl)propylguanidine described in Chapter 3 {Compounds (61-
81)a}. The crude products were purified by a chromatotron under ammonia atmosphere 
and then treated with 20 % TFA solution as described in Chapter 3 for the synthesis of 
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compounds 78 and 80. Purification of 125 and 126 was done by preparative HPLC as 
described in Chapter 3. 
 
(R)-N1-[3-(1H-Imidazol-4-yl)propyl)-N2-(3-phenylbutanoyl)guanidine [(R)-125] 
Yield 65 % in two steps; colourless oil; C17H23N5O·2TFA (541.8); 95.5 % ee (CE); [α]20D 
-14.14° (c, 1.57, MeOH); IR (neat): 3207, 2877, 1667, 1570, 1365, 1277, 1119, 728 cm-1; 
1H-NMR (CD3OD), δ (ppm): 8.76 (s, 1H, Im-2-H), 7.34 (s, 1H, Im-5-H), 7.30-7.10 (m, 
5H, Ph-H), 3.32 (m, 3H, Ph-CHCH3 and NHCH2),  2.78 (m, 4H, CH2CO and Im-4-
CH2CH2), 2.00 (m, 2H, Im-CH2), 1.30 (d, J = 7.1 Hz, 3H, Ph-CHCH3); 13C-NMR 
(CD3OD), δ (ppm): 176.1 (quart, CO), 155.2 (quart, C=N), 146.4 (quart, Im-C-4), 134.8 
(+, Im-C-2), 134.2 (quart, Ph-C-1), 129.6, 128.1, 127.6 (+, Ph-C), 117.1 (+, Im-C-5), 46.1 
(-, CH2CO), 41.4 (-, CH2NH), 37.6 (+, Ph-CH), 28.1 (-, Im-4-CH2CH2), 22.5 (+, Im-4-
CH2CH2), 22.3 (+, CH3); MS (ESI, CH3CN + 0.1% TFA): 314 ([M + H]+), 627 ([2M + 
H]+); HRMS: EI-MS: calculated for (C17H23N5O) 313.1903, found 313.1906;  
Analytical HPLC: Rt 11.05 min (Column B; 0 min: 0.05% TFA/CH3CN 97/3, 24 min: 
85/15); purity: 99 %. 
 
(S)-N1-[3-(1H-Imidazol-4-yl)propyl]-N2-(3-phenylbutanoyl)guanidine  [(S)-125] 
Yield 61 % in two steps; colourless oil; C17H23N5O·2TFA (541.8); 98.3 % ee (CE);  
[α]20D -14.71° (c, 1.45, MeOH); the analytical spectra are all the same as those of (R)-
125. 
Analytical HPLC: Rt 11.05 min (Column B; 0 min: 0.05% TFA/CH3CN 97/3, 24 min: 
85/15); purity: 99 %. 
 
(R)-N1-[3-(1H-Imidazol-4-yl)propyl]-N2-(3-pyridin-2-ylbutanoyl)guanidine [(R)-126] 
Yield 55 % for two steps; colourless sticky oil; C16H22N6O·3TFA (656.4); [α]20D +23.0° 
(c, 1.35, MeOH); the analytical spectra are all the same as those of the racemic compound 
80 (Chapter 3). 
Analytical HPLC: Rt 9.39 min (Column B; 0 min: 0.05% TFA/CH3CN 97/3, 20 min: 
85/15); purity: 97 %. 
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(S)-N1-[3-(1H-Imidazol-4-yl)propyl]-N2-(3-pyridin-2-ylbutanoyl)guanidine [(S)-126] 
Yield 53 % for two steps; colourless sticky oil; C16H22N6O·3TFA (656.4); [α]20D -28.6° 
(c, 1.40, MeOH); the analytical spectra are all the same as those of the racemic compound 
80 (Chapter 3). 
Analytical HPLC: Rt 9.39 min (Column B; 0 min: 0.05% TFA/CH3CN 97/3, 20 min: 
85/15); purity: 80 %. 
 
Synthesis of (R)- and (S)-N1-[3-(1-amino-4-methylthiazol-5-yl)propyl]-N2-(3-
phenylbutanoyl)guanidine [(R)-129  and (S)-129] 
The preparation of the intermediates (R)-127/(R)-128 and (S)-127/(S)-128 (structures see 
Scheme 5.11) was performed by analogy with the procedure described for the coupling 
of racemic carboxylic acids with Boc-protected-3-(2-amino-4-methylthiazol-5-
yl)propylguanidine (101) in Chapter 4 {Compounds }: The crude products were purified 
by column chromatography to give the enantiomers of 127 and 128, respectively. The 
products, (R)-127 and (S)-127 was hydrogenated, followed by deprotection of the Boc 
group to give (R)-129 and (S)-129, respectively (cf. racemic compound, Chapter 4). The 
Boc-protected intermediates (R)-128 and (S)-128 were likewise converted to (R)-129 and 
(S)-129, respectively, by treatment with 50 % TFA solution (see Chapter 3) for a longer 
period of time (overnight).  
 
(R)-N1-[3-(1-Amino-4-methylthiazol-5-yl)propyl]-N2-(3-phenylbutanoyl)guanidine 
[(R)-129] 
Yield 62 % overall; colourless sticky oil; C28H35N5O2S.2TFA (733.7); 95.5 % ee (CE); 
[α]20D -11.92° (c, 1.34, MeOH); the analytical spectra are all the same as those of 105b in 
Chapter 4. 
Analytical HPLC: Rt 11.79 min (Column B; 0 min: 97/3, 24 min: 85/15); purity: 85 %. 
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(S)-N1-[3-(1-Amino-4-methylthiazol-5-yl)propyl]-N2-(3-phenylbutanoyl)guanidine 
[(S)-129] 
Yield 59 % overall; colourless sticky oil; C28H35N5O2S.2TFA (733.7); 98.3 % ee (CE);  
[α]20D + 14.27° (c, 1.10, MeOH); the analytical spectra are all the same as those of 105b 
in Chapter 4. 
Analytical HPLC: Rt 11.74 min (Column B; 0 min: 97/3, 24 min: 85/15); purity: 100 %. 
 
5.5.2. Pharmacological methods 
Described in section 3.6.2 in Chapter 3.  
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Since the characterization of the histamine H2 receptor by Black et al, several H2 receptor 
(H2R) antagonist such as cimetidine, ranitidine, famotidine, nizatidine and roxatidine acetate 
have been developed as antiulcer drugs. From the therapeutic point of view the interest in 
drugs acting on histamine H2 receptors is focused on antagonists. Nevertheless, there has 
been increasing evidence that histamine receptor stimulation might be an interesting aspect 
for the development of future drugs as well. The first highly potent H2R agonist 
impromidine resulted from histamine, by replacing the amine functionality with the strongly 
basic guanidine group and combining the structure with the 2-[(5-methyl-1H-imidazole-4-
yl)methylthio]ethyl moiety known from the H2R antagonist cimetidine. Later on, Buschauer 
and co-workers produced arpromidine and analogues by replacing the “cimetidine-like” part 
with lipophilic H2R nonspecific structures. Arpromidine and related imidazolylpropyl-
guanidines with a NG-phenyl(pyridyl)alkyl substituent are the most potent H2R agonists on 
the isolated guinea pig right atrium, a standard model for the pharmacological investigation 
of histamine H2 receptor ligands. However, the arpromidines are less potent or act as partial 
agonists at human (hH2R) compared to guinea pig H2 receptors (gpH2R). The strongly basic 
guanidino group, which is supposed to interact with Asp-98 in transmembrane domain 3 
(TM3) of the H2R, is essential for the agonistic activity but it is also responsible for very 
low oral bioavailability, non-H2R-mediated effects and lack of penetration across the blood-
brain barrier. Therefore, the objective of this work was to design, synthesize and 
characterize histamine H2 receptor agonists, structurally related to arpromidine, but with 
lower basicity in order to achieve more favourable pharmacokinetic properties, in particular, 
oral bioavailability and penetration across the blood-brain barrier. 
The first part of this project was to develop a general synthetic route for the synthesis of NG-
acylated imidazolylpropylguanidines, i. e. a methylene had to be replaced with a carbonyl 
group in the connecting chain between the diaryl and guanidine group. In Chapter 3, the 
development of a very convenient and straight forward synthetic route is described for the 
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synthesis of the central building block, trityl-protected imidazolylpropylguanidine, from the 
commercially available starting material, urocanic acid and guanidine. Then, the NG-
acylated guanidines were synthesised via coupling of this building block with corresponding 
acids, followed by deprotection of resulting products.  
The synthesised compounds were pharmacologically tested on isolated guinea pig tissues 
(ileum: H1R, H3R; right atrium: H2R), on human H1R expressing cells (U373MG) and on 
membrane preparations of guinea pig and human histamine H2 or H4 receptor expressing 
Sf9 cells. The basicity of the acylguanidines is by 4-5 orders of magnitude lower than that 
of the corresponding guanidines. However, alkanoylguanidines and alkylguanidines appear 
to be bioisosteres, and it may be speculated that the acylguanidines are capable of 
interacting with Asp-98 in transmembrane domain 3 of the H2R by a charge-assisted 
hydrogen bond. Compounds having a carbonyl instead of a methylene group adjacent to the 
guanidine are about equipotent as, for instance, demonstrated for the diphenylpropyl versus 
the diphenylpropanoyl and for impromidine versus the oxo-substituted analogue. However, 
a considerable decrease in activity was found when the methylene group in arpromidine was 
converted to a carbonyl group. Surprisingly, compounds with only one phenyl ring are 
equally or even more potent than the diaryl analogues, whereas in the arpromidine series of 
histamine H2R agonists highest potency resides in the 3-phenyl-3-hetarylpropyl-substituted 
imidazolylpropylguanidines. This may be interpreted a first hint to different modes of 
interaction of the affinity-conferring moiety with the H2R protein. On the isolated guinea 
pig right atrium the most active H2R agonist, the 3-phenylbutanoyl substituted guanidine 
was about 30 times more potent than the natural ligand. In terms of agonistic potency on the 
guinea pig atrium the new compounds are inferior to the arpromidines. However, the 
acylated imidazolylpropylguanidines are superior with respect to pharmacokinetic 
properties. A very important finding is that the compounds are absorbed from the 
gastrointestinal tract and are capable of penetrating through the blood-brain barrier (tested 
by HPLC-MS analysis after administration to mice). Centrally active H2R agonists will be 
useful pharmacological tools to study the role histamine H2 receptors in the brain.  
In Chapter 4, a general method is described for the synthesis of N-acyl-N’-[3-(2-amino-4-
methylthiazol-5-yl)propyl]guanidines from a simple starting material. The 3-(2-amino-4-
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methylthiazol-5-yl)propylguanidine side chain was prepared first by following a reported 
method, then the guanidine group was introduced by treating with di-Cbz-triflate-protected 
guanidine with the amine, followed by deprotection of the Cbz-groups with hydrogenolysis. 
Then the N-acyl-N’-[3-(2-amino-4-methylthiazol-5-yl)propyl]guanidines were prepared via 
acylation of Boc-protected-3-(2-amino-4-methylthiazol-5-yl)propylguanidine with the 
corresponding acid, followed by deprotection of the Boc group. 
The bioisosteric replacement of the imidazolyl moiety in NG-acylated guanidine-type 
histamine H2 receptor agonists by a 2-amino-4-methylthiazol-5-yl group resulted in about 
the same H2R agonistic potency on the isolated guinea pig right atrium as well as in GTPase 
assays performed with both guinea pig and human H2R-GsαS fusion proteins. However, the 
maximal response induced by the thiazoles was slightly reduced, i. e. these compounds were 
partial agonists in the used pharmacological models. Interestingly, in the GTPase assay on 
the human H2R the thiazolyl analogue with cyclohexylbutanoyl substituent was favoured 
compared to the corresponding phenylbutanoylguanidine. This may be interpreted a hint 
that a certain degree of selectivity for the human H2R may be achieved by structural 
variation of both the acyl and the heterocyclylpropyl group. Moreover, the aminothiazoles 
proved to be devoid of H3R antagonistic activity. Thus, the selectivity for H2R versus H3R 
can be considerably improved. 
With respect to development of models for the ligand-receptor interactions on the molecular 
level enantiomerically pure agonists of defined 3D structure are valuable tools to explain the 
species dependent potency and to optimise the structure of the substances. In Chapter 5, the 
stereoselective preparation of enantiomers of several chiral new H2R agonists is described. 
For the synthesis of the target molecules according to the method reported in the previous 
chapters, the enantiomers of the chiral acids were required. The building block (R and S)-3-
phenylbutanoic acid was synthesized from the achiral precursor, methyl (E)-but-2-enoate, 
via asymmetric addition of phenylboronic acid as reported by Hayashi et al., using a 
catalytic amount of rhodium catalyst and chiral binap ligand, followed by hydrolysis of the 
methyl ester. The corresponding chiral pyridyl propanoic acids were prepared by the lipase 
catalysed enantioselective acetylation of  racemic 1-(2-pyridyl)ethanol, then protection of 
alcohol with methanesulfonate, followed by SN2 displacement with sodium salt of dimethyl 
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malonate, and finally the decarboxylation of saponified product. Finally, the chiral acids 
were coupled to imidazolylpropylguanidine. With the exception of the pyridyl analogue, the 
enantiomeric purity of the synthesised acylguanidines could be determined by CE. The 
enantiomeric excess was in the range of 95-99 %, which was considered sufficient for 
pharmacological investigations.  
Compared to the arpromidine series the acylguanidine-type H2R agonists showed rather low 
eudismic ratios in the range of 2 - 3.5. The data from the guinea pig atrium were consistent 
with those determined in the GTPase assay using H2R-Gsαs fusion proteins. Interestingly, 
the preferred stereoisomers were conversely configured in case of the imidazolyl compound 
(R > S) and its aminothiazolyl analogue (S > R), respectively. This information is of 
particular interest with respect to the further refinement of receptor models, as the binding 
mode of imidazoles and aminothiazoles appears to be different. Although the alternate 
exchange of both heterocyclic rings was tolerated without noteworthy changes in H2R 
agonistic activity, the concept of bioisosterism may be questioned. Additional enantiomeric 
pairs are required to study this phenomenon in more detail. As suggested by molecular 
modelling the replacement of the methyl group in the 3-phenylbutanoyl portion of the 
molecule, especially the variation of substituent size and functionality, will be useful to 
interprete the H2R binding on the molecular level and to identify potential interaction sites 
of the acyl group. 
 
Meanwhile imidazolylpropylguanidines and corresponding acylated analogues were found 
to be useful building blocks beyond the preparation of H2R agonists, for instance for the 
synthesis of ligands preferentially binding to other histamine receptor subtypes, to 
neuropeptide Y Y1 or Y4 receptors. Thus, there is increasing evidence that in terms of 
medicinal chemistry the imidazolylpropylguanidine moiety and the acylated analogues may 
be considered “privileged structures”. An extremely promising perspective results from very 
recent studies: surprisingly, some of the acylguanidines proved to be rather potent as either 
agonists or inverse agonists at the recently discovered H4R. The elaboration of the structure-
activity relationships based on these results and the design of H4R selective ligands will be 
subject of a new project.  
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1. NMR spectra of 63a:  
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HSQC NMR (CDCl3, 151 MHz) spectra of 63a:  
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2. NMR spectra of 73:  
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HSQC NMR (CDCl3, 151 MHz) spectra of 63a: 
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